A ‘bump-&amp;-hole’ approach for engineering allele-selective inhibition of the BET bromodomains by Runcie, Andrew C.
                                                                          
University of Dundee
DOCTOR OF PHILOSOPHY







Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 24. May. 2021
A ‘bump-&-hole’ approach for  
engineering allele-selective inhibition of 
the BET bromodomains 
Andrew Colin Runcie 
Supervisor: 
Professor Alessio Ciulli 
Thesis submitted for the degree of 
Doctor of Philosophy 
School of Life Sciences 








I would first like to thank my supervisor Prof.  Alessio Ciulli for giving me this 
opportunity.  Thank you for your advice, encouragement and fruitful discussions. 
Thank you for providing me with the resources to pursue my own ideas and fuel my 
growth as a researcher. 
Many thanks to the AC lab members, past and present, for their help and 
guidance. Dr Kwok-Ho Chan for help with protein purification, X-ray crystallography 
and tissue culture. Dr Michael Zengerle and Andrea Test for help with chemistry. Dr 
Morgan Gadd for guidance with crystallography.  
Large parts of this work relied heavily on interdisciplinary nature of the School 
of Life Sciences. Thank you to Lorna Campbell and Sandra O’Neill, from the DDU’s 
David Gray lab, for their assistance. Also from the DDU, Dr Ola Epemolu and Dr Lucy 
Ellis provided DMPK data invaluable to evaluation of our compounds. Thank you to Dr 
Sam Swift and the Light Microscope Facility for their help with fluorescent microscopy. 
In addition, reagents crucial to this research were provided by the Division of Signal 
Transduction Therapy and the Structural Genomics Consortium.  
Thank you to the BBSRC and to the EastBio group for funding and training, and 
specifically to Maria Filippakopoulou, Dr Caroline Pope and Caroline Proctor. As a part 
of the EastBio DTP programme I carried out a 3-month internship at Collagen Solutions 
Plc in Glasgow, and I would like to thank my supervisors Dr Grahame Busby of Collagen 
Solutions and Alex Muhlholzl of Mikota for their support and guidance. Thank you as 
well to my colleagues Leigh Adamson and Steven Lee for their help with training me 
and making me feel at home in a new lab.  
This work also relied on the work of many School of Life Science staff, and 
apologies to those not specifically named. Thank you to the BCDD lab managers Shona 
McInroy and Tracey Norris, and PhD administrative staff Lesley Coats, Gail Guild and 
Nikki Wilson. Many thanks to MRC tissue culture staff, managed by Dr Laura Finn.  
Finally, special thanks to my wife Ketsuda, my family and my friends for their 





I declare that the work described in this thesis was carried out by me under the 
supervision of Professor Alessio Ciulli and, unless otherwise stated, all references cited 
have been consulted by me. To my knowledge, the work of which this thesis is a record 
of is original and has not been submitted for any other degree at this or another 
university. 





The work described in this thesis led to the following publications: 
1. Runcie AC, Chan KH, Zengerle M & Ciulli A. Chemical genetics approaches for
selective intervention in epigenetics. Current Opinion in Chemical Biology 2016, 33, 
186-194.
2. Runcie AC, Zengerle M, Chan KH, Testa A, van Beurden L, Baud MGJ, Epemolu O, Ellis
LCJ, Read KD, Coulthard V, Brien A & Ciulli A. Optimization of a “bump-and-hole” 
approach to allele-selective BET bromodomain inhibition. Chemical Science 2018, 9, 
2452-2468 
3. Testa A, Lucas X, Castro GV, Chan KH, Wright JE, Runcie AC, Gadd MS, Harrison WTA,
Ko EJ, Fletcher D & Ciulli A. 3-Fluoro-4-hydroxyprolines: Synthesis, conformational 
analysis and stereoselective recognition by the VHL E3 ubiquitin ligase for targeted 




Chemical tools can be used to investigate the function of proteins and their 
importance to biological processes and disease. This approach has many advantages 
over classical genetic tools, but requires compounds with high selectivity for their 
targets. When single-target selectivity cannot be achieved through normal means it 
can be engineered through the development of orthogonal protein:ligand pairs, 
wherein target proteins are mutated and an existing ligand is modified to become 
mutant-selective.  
An ideal model for this engineered, allele-specific chemical genetic work is the 
BET family of bromodomains – 8 closely related, and structurally conserved, epigenetic 
acetyl-lysine reader domains that so far has defied single-bromodomain inhibition. The 
Alessio Ciulli lab has previously designed a proof-of-concept ‘bump-&-hole’ system to 
selectively target these bromodomains by mutating a conserved leucine to an alanine 
(L/A mutation) and adding an ethyl bump to an existing inhibitor scaffold (ET 
compound). This system was promising, but required optimisation of the mutation and 
modified compound before it could be used to answer biological questions. 
Here the L/A mutation is replaced with a more conservative leucine/valine (L/V) 
mutation, which is shown to be significantly more functional with regards to acetylated 
chromatin binding and downstream gene expression. Simultaneously, a large number 
of new modifications were incorporated into a library of bumped compounds, which 
were then screened for their selectivity for L/V BET bromodomains (over WT). This 
lead to the selection of ‘9-ME-1’ as the preferred L/V-selective compound.  
This optimised BET bump-&-hole system was validated through a number of 
cellular assays. By repurposing some of these cellular assays the bump-&-hole system 
was then used to answer biological questions – specifically the relative importance of 
different BET bromodomains to BET protein function. These results, in connection to 
recent advances in the literature, provides evidence for a new model of how the BET 
bromodomains work together to drive downstream gene expression. 
Finally, the need to use CRISPR/Cas9 gene-editing technology to generate L/V-
mutant cell-lines was identified, and an attempt was made to knock-in the L/V 
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1.1 – Chemical Genetics: 
 Chemical genetics is the use of biologically active ‘chemical probe’ compounds 
(typically small-molecule inhibitors) to investigate the role, and elucidate the function, 
of genes and their encoded proteins [1-3]. Thus, chemical genetics parallels 
conceptually classical genetics in which genetic tools such as RNA interference (RNAi), 
gene mutations and knock-outs (KOs) are used to study genes and gene products. 
While classical genetics typically interrupts the gene – protein – phenotype system at 
the DNA or RNA level chemical genetics acts through disruption of the protein stage 
(figure 1.1). There is a great deal of overlap between chemical probes and therapeutic 
drugs, with many compounds being used as both. However, the focus of therapeutic 
drugs is to be efficacious in select indications, which means they may not necessarily 
have to be overly selective or even have a fully characterised mode of action. In 
contrast to therapeutic drugs, chemical probes must be thoroughly characterised and 
selective, but there is less need for high quality drug metabolism and pharmacokinetics 
(DMPK) characteristics and safety profiles as they are typically used in vitro [4]. 
 
Figure 1.1. ‘The Central Dogma’ and genetic/chemical tools. 
Protein is crystal structure of BRD4 BD1 (PDB: 3UVW). 
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Chemical and classical genetics can both be performed in a ‘forward’ or 
‘reverse’ manner [3, 5] (figure 1.2). In forward genetics a library of small molecules (or 
random RNAi/mutations) is screened against cell-line(s) of interest. When a molecule 
or mutation is found to elicit a phenotype of interest it undergoes further studies to 
identify the molecule’s target protein, or the gene affected by the mutation. Such 
processes are typically referred to as ‘phenotypic screens’. In reverse genetics a 
specific protein or gene of interest is already identified, and small-molecules or 
mutations are deliberately designed to target it. These chemical or genetic tools are 
then used in a variety of biological contexts to investigate the phenotype induced by 
their disruption of the gene/protein of interest. In practice the forward/reverse 
dichotomy is not always so distinct, and often important gene or protein families will 
be identified first through forward genetics, then for additional tools to be developed 




Figure 1.2. Schematic and comparison between classical & chemical genetics. 
In forward genetics random compounds, mutations or RNAi tools are screened, and the target 
gene/protein of any hits are identified. In reverse genetics a target gene/protein is known, and genetic 
or chemical tools custom designed towards it. Modified from Runcie et al, COCB, 2016 [1]. 
Both classical and chemical genetics have distinct advantages and 
disadvantages, with different techniques being preferable in different contexts [5]. 
Classical tools such as mutations and gene knock-outs can be very specific, only 
affecting the gene within which said alterations are made. Unfortunately such 
modifications are not necessarily tuneable, with 100% of the gene product affected 
(potentially 50% in diploid heterozygous systems), and hence one cannot observe 
dose-response effects and may face complications due to cell death or, in the case of 
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in vivo systems, potentially embryonic lethality following gene deletion. Additionally, 
such effects are uniform, and hence cannot be controlled temporally or spatially.  
Finally, introducing mutations into endogenous genes can be a very complicated affair, 
despite constant advances in gene editing technology. More complicated systems, 
such as the use of inducible systems such as tetracycline-controlled genes [6], can 
allow for some degree of ‘dosage’ and temporal control, although the compounds 
used to regulate expression may alter cell phenotypes themselves by affecting other 
proteins. RNA interference is considered a genetic tool, although faces a very different 
set of challenges [7]. RNAi tools do not require gene editing, and can be used in various 
doses and timings, but suffer from mixed efficacy (not completely removing gene 
products) and tend to cause off-target effects due to low selectivity. The CRISPR/Cas9 
gene-editing system is an increasingly valuable genetic tool, which will be discussed 
fully in chapter 5 of this thesis.  
 Chemical genetics can offer a much greater degree of control than classical 
genetic tools, as doses can be applied at desired time points, and once the probe is 
washed out one may see its effect be reversed. When working with animal models one 
can try to limit the effect of the probe to specific tissues for a more nuanced 
experiment.  Dose-response relationships can be observed, and the probe dose tuned 
to allow for experimentation without killing the cells or animals tested. While many 
genetic tools (gene KO, RNAi) work by removing the entire protein of interest, 
chemical tools will only inhibit specific functions or block individual binding sites. This 
can be very significant when working with multi-domain proteins where one may wish 
only to investigate the role of a specific domain’s function, while not affecting other 
active domains or scaffolding roles. Chemical genetics is generally favourable to 
classical genetics when performing target validation, to determine if a specific protein 
can be inhibited for therapeutic effects. As therapeutics typically take the form of 
small-molecule inhibitors, chemical genetics is a much more accurate representation 
of their potential biological impact.  The main drawback of chemical genetics is the 
need for well characterised and highly-selective inhibitors [1, 4]. While mutations will 
only affect the genes they are integrated into, small-molecules will often inhibit 
multiple structurally-related proteins. This can be very evident when working with 
strongly conserved protein families, which exhibit very high sequence identity and 
32 
 
conservation of the targeted binding site. Moreover, it is also not uncommon for small-
molecules to affect multiple proteins with little genetic similarity and very different 
functions. It is also important to ensure that the chemical tools used are sufficiently 
potent to disturb the function of the protein of interest, and possesses the necessary 
DMPK characteristics to remain active in cellular or physiological contexts.  
 
1.2 – Epigenetics: 
 Epigenetics generally lacks a universal definition, but here will refer to 
reversible and partially heritable chemical modifications made to DNA (that don’t alter 
its sequence) and its associated chromatin components that serve to regulate genetic 
processes. Epigenetics is involved in the regulation of DNA repair, replication and 
recombination and, most importantly for our purposes, gene expression through 
transcription [8, 9]. These chemical modifications are referred to as ‘epigenetic marks’. 
Epigenetics involves the interplay of three types of protein (figure 1.3): 1) writer 
enzymes (e.g. histone acetyltransferases HATs) add epigenetic marks to specific DNA 
or histone regions; 2) eraser enzymes (e.g. histone deacetylases HDACs) remove said 
marks; and 3) reader proteins (e.g. bromodomains BDs) recognise these marks, and in 
turn recruit additional proteins that induce or inhibit various important processes 
regarding DNA [9].  
 
 
Figure 1.3. Epigenetic proteins. 
Writer, reader and eraser proteins add, recognise and remove (respectively) epigenetic marks (yellow) 
from nucleosome (purple DNA & grey histone protein). 
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The main epigenetic modification of DNA itself is cytosine methylation. 
Conversion of cytosine to 5-methylcytosine by DNA methyltransferase (DNMT) 
enzymes is associated with a reduction in gene expression [10, 11]. This gene 
repression is believed to be caused in part by  altering the physical properties of the 
DNA and hindering its binding to transcription complexes, and mainly by the 
recruitment of methyl-CpG binding domain (MBD) proteins, which in return recruit 
histone-modifying epigenetic proteins [10, 11]. In mammals C methylation mainly 
occurs at CpG sites, although can occur at CpApC sites in some progenitor cells. 
Aberrant hypo- or hyper-methylation at CpG sites has been associated with some 
cancers [10, 11]. 
The majority of epigenetic marks occur at the histone level. Inside the cell 
nucleus DNA is packaged into chromatin. Chromatin is, fundamentally, constructed of 
a series of ‘nucleosomes’ - ~146bp of DNA wrapped in a double super-helix around 8 
histone proteins (2 copies each of H2A, H2B, H3 and H4) [12] (figure 1.4A). Each 
histone protein possesses an unstructured N-terminal ‘tail’, of 40–60 amino acids (AA) 
in length, that are accessible for a wide range of covalent and reversible post-
translational modifications (PTMs) [12] (figure 1.4B). The first structure of the 
nucleosome was published in 1997 [13], while the exact manner in which nucleosomes 
and additional scaffolding proteins come together to form higher order structures is 
not fully understood. Areas of the genome packaged into isolated nucleosomes (‘beads 
on a string’) is referred to as euchromatin and is typically more transcriptionally active. 
The recruitment of the H1 histone protein, together with certain epigenetic marks, 
causes nucleosomes to coil into the transcriptionally silent ’30 nm fibre’, or 





Figure 1.4. Nucleosome structure and histone tail modifications 
A) X-ray crystal structure of nucleosome (PDB: 1KX5). B) Amino acid sequence of histone N-terminal tails 
(first 20 residues shown), with common epigenetic marks. DNA and second copy of each histone protein 
omitted for clarity. Colour scheme: green – H2A, yellow – H2B, red – H3, blue – H4.  
The most common, and best understood, histone modifications are acetylation 
and methylation, although phosphorylation, ubiquitination, citrullination, SUMOylation 
and ADP-ribosylation are also known [15]. Histone modifications can directly regulate 
cellular processes, without recognition by reader proteins, by altering the structure of 
chromatin. Histone acetylation and phosphorylation can be seen as neutralising the 
positive charge of histone proteins, reducing their affinity for DNA and producing less 
compact euchromatin. There is evidence that this occurs following acetylation both of 
histone tail residues (such as H4 K16 [16]) and of globular residues (H3 K122 [17]). 
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Ubiquitination and SUMOylation may also induce large conformational changes that 
alter chromatin structure, due to the large size of the added modification [15].  
Lysine acetylation is a major epigenetic mark, installed by HAT enzymes, 
removed by HDACs and read by bromodomains. It is strongly associated with increased 
gene transcription and more open euchromatin, both for the structural reasons 
mentioned above but also due to the recruitment/activation of transcription 
machinery and chromatin remodelling complexes by bromodomain-containing 
proteins [15]. Lysine methylation is another important epigenetic mark. Lysine residues 
can be mono-, di- or tri-methylated, with each mark (as well as unmodified lysine) 
being recognised by different readers [18]. Broadly speaking, di- and tri-methylation 
are associated with reduced gene expression, while mono- and un-methylated lysine 
residues are associated with active expression, but even these trends are not absolute. 
Tri-methylated H3 K4, common at transcription start sites, can be recognised by 3 
different types of reader – PHD (plant homeodomain), CHD (chromodomain) and 
Tudor – which generally leads to the recruitment of pro-transcription writer and eraser 
enzymes. Tri-methylated H3 K9 is strongly associated with heterochromatin and 
permanently silenced genes, and is thought to be recognised by CHD-proteins to 
recruit additional HKMT (histone lysine methyltransferase) writers to maintain 
heterochromatin status during DNA replication. Mono-methylated H3 K4 is found in 
abundance at active transcriptional enhancers, and is strongly associated with active 
gene expression [15, 18].  
As many epigenetic marks have been clearly shown to influence gene 
expression and other processes it has been proposed that there exists a ‘histone-code’, 
wherein the regulation of a given gene may be determined by the exact combination 
of epigenetic marks around it and its promoter [12]. If such a precise code does exist it 
is likely to be highly complex, with each histone tail possessing dozens of potential 
epigenetic marks and an incredible array of conceivable combinations of marks. 
Furthermore, the effects of some marks are heavily context-dependent and influenced 
by inter-modification cross-talk [15]. One study identified ~4000 distinct combinations 
of histone modifications at CD+ T cell promoters. While some patterns could be 
observed in this study the majority of combinations (~3000) occurred at only a single 
promoter [19].  
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1.3 – Chemical Genetics for Epigenetics: 
 The development of chemical probes for epigenetic proteins has had a major 
impact on our understanding of their function and role in disease, although 
unfortunately the majority of epigenetic targets are still essentially unexplored [20]. 
The development of chemical probes has likely suffered somewhat from the reliance 
of epigenetic proteins on PPIs (protein:protein interactions), which are typically 
considered ‘undruggable’ due to their large, shallow and hydrophobic nature [21]. This 
has not been a total block on epigenetic chemical probe development, as the PPIs that 
epigenetic proteins are reliant upon typically involve well-defined and often deep 
binding pockets that have evolved to recognise very specific chemical modifications 
(e.g. acetylated lysine) or enzyme cofactors (e.g. SAM S-adenosyl-l-methionine). 
Additionally, due to the regulatory nature of epigenetics processes the modulation of 
any one gene will likely have many severe downstream impacts, complicating further 
analysis. This may make the need for selectivity even more stringent when working in 
epigenetics. The development of epigenetic chemical probes, either out of unbiased 
phenotypic screens or following genetic target validation, has had the effect of greatly 
increasing the level of research into the relevant target [20].  
 The most established example of epigenetic inhibitor design is that of HDAC 
eraser enzymes.  Following a series of hits in phenotypic screens many HDAC inhibitors 
have now been developed, with 4 approved for use in the clinic for treatment of 
cancers such as lymphoma and multiple myeloma (MM) (scheme 1.1) [22-24]. The use 
of HDAC inhibitors in chemical genetics studies have shown that HDACs affect many 
biological responses. HDAC inhibition has been shown to alter the expression of 2-20% 
of genes, as well as alter chromatin structure, likely through fairly immediate effects 
on histone acetylation levels. Downstream functions include, but are not limited to, 
DNA repair, cell-cycle control, angiogenesis and metastasis [22-24]. The use of HDAC 
inhibitors has been somewhat hindered by the difficulty in developing inhibitors for all 








Scheme 1.1. HDAC inhibitors in clinical use. 
Structures of FDA-approved HDAC inhibitors, alongside commercial and chemical names. FDA approved 
indication in brackets: CTCL – cutaneous T-cell lymphoma, MM – multiple myeloma, PTCL – peripheral T-
cell lymphoma.  
 The development of inhibitors for epigenetic readers has generally lagged 
behind that of writers and erasers, but recent work on BET bromodomains (discussed 
later) has shown that readers are viable therapeutic targets and has helped lead to the 
development of many reader domain inhibitors. This reader inhibitor development has 
been most successful with bromodomains, but there has also been a wealth of methyl-
lysine reader inhibitor design [26, 27]. The Stephen Frye lab has developed several 
inhibitors of malignant brain tumor (MBT) domains, specifically targeting L3MBTL1 and 
L3MBTL3, with the most potent being UNC1215, which has an affinity of 120 nM [28]. 
In addition, several compounds with micromolar affinity for CHD and Tudor domains 
have been published, and several fragments have been identified with affinity for Pygo 









1.4 – Bromodomains: 
 As mentioned previously, bromodomains are the main reader domain for lysine 
acetylation (Kac marks). Originally identified in the Brahma/brm gene of Drosophila in 
1992 [31], 59 human bromodomains have now been identified, located within 43 
proteins (11 proteins contain 2 BDs, 1 protein contains 6 BDs) (figure 1.5A). All 
bromodomains possess a structurally conserved fold comprising of 4 alpha helices (αZ, 
αA, αB, αC) linked by loops named ZA and BC [32] (figure 1.5B). Despite being a PPI 
(typically involving shallow and featureless areas of protein) bromodomains bind Kac-
modified histone tails within a deep hydrophobic pocket, which typically contains a 
conserved asparagine residue that forms important hydrogen bonds to the Kac mark 
and water molecules [32]. This deep hydrophobic pocket has the effect of making 
some bromodomains unusually ‘druggable’ by the standards of PPIs, although there is 
variation within the family [33]. In addition to their Kac binding pocket bromodomains 
possess positively or negatively charged patches on their surface, which may act to 
help recognise more basic/acidic histone tails, or to interact directly with DNA [32, 34].  
Following recognition of acetylated chromatin, bromodomain-containing 
proteins then bring about a number of potential biological activities. These activities 
can be mediated directly by other domains within the proteins [32], with BD-
containing proteins also possessing helicase [35], HAT [36] and HKMT [37] domains, or 
through the recruitment of additional proteins or protein complexes. By recruiting or 
modulating transcription factors and other transcription machinery components BDs 
can, relatively directly, modulate the expression of select genes. Additionally, through 
the recruitment of chromatin remodelling complexes BDs can drive changes to the 
epigenetic labelling of histones and through that the packaging and accessibility of 
chromatin. By switching gene loci between heterochromatin and euchromatin states, 
through histone tail modification and nucleosome addition/removal, these complexes 
can further regulate gene expression as well as other processes such as DNA repair and 
replication. In several proteins BDs are paired with other epigenetic reader domains, 
such as the methyl-lysine recognising PHD domain [38], which may help to provide 
additional specificity with regards to recognition of specific regions of the genome and 





Figure 1.5. Human bromodomains, their structure & their inhibitors 
A) Phylogenetic tree of human bromodomains, modified from Filippakopoulos et al, Cell, 2012 [32]. BDs 
targeted by chemical probe from [39] highlighted. BET subfamily (II) is highlighted in light blue. B) X-ray 
co-crystal structure of BRD4 BD1 bound to H4(1-11) K(5,8)ac (red). PDB: 3UVW. Critical hydrogen bond 
between Kac5 and N140 are shown with black dash. C) Chemical structures of a representative inhibitor 




A number of bromodomain inhibitors have been developed (figure 1.5C) [40, 
41], so far primarily being used as chemical probes to study protein function. To date, 
chemical probes exist for ~31 human bromodomains from all but one main branch of 
the bromodomain family, with selectivity varying from a single bromodomain to entire 
subfamilies [39] (figure 1.5A). In addition, a promiscuous bromodomain inhibitor, 
bromosporine, has been developed with binding observed against >20 human 
bromodomains [42].  
 
1.5 – BET Proteins: 
 Some of the best studied bromodomains are those of the bromodomain and 
extra-terminal domain (BET) subfamily. There are 4 human BET proteins (BRD4, BRD3, 
BRD2 & BRDT), which each possess two tandem bromodomains (BD1 & BD2) (figure 
1.6). The BET BDs are generally understood to recognise acetylated lysine residues in 
histone tails [32]. No single Kac pattern is associated with BET BDs, although H4 di- and 
tetra-acetylation is commonly used for model substrates (histone tail peptides and 
whole nucleosomes). The possibility of the BD1s and BD2s recognising different Kac 
marks has been raised, with the BD1s being suggested to prefer H4 histone tails while 
the BD2s preferring H3 tails [32] or being promiscuous. BET bromodomain prefer to 
bind pairs of nearby Kac marks, with the H4 K(5,8)ac pair (separated by two glycines) 
seemingly being optimal [32]. The BET proteins are known to possess homologues in 
mice [43], drosophila [44] and fungi [45].  
 
Figure 1.6. Domain organisation of human BET proteins.  
BRD4 long and short isoforms shown. Based on Wu & Chiang, JBC, 2007 [46] and Devaiah et al, J. 
Leukoc. Biol., 2016 [47]. 
In addition to the Kac-recognising BDs all four BET proteins possess an extra-
terminal domain (ETD), a helical domain that has not yet been fully characterised. ETDs 
are believed to form PPIs with epigenetic/transcriptional proteins/complexes that the 
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BET proteins direct to certain loci (figure 1.7A). Known ETD binding partners include 
NSD3 [48, 49], JMDJ6, GLTSCR1, CHD4 and ATAD5 [50], as well as a number of viral 
proteins [51]. The recruitment of NSD3, JMDJ6 and GLTSCR1 is believed to contribute 
to up-regulating gene expression, potentially through histone demethylation (NSD3) 
and transcript splicing (JMDJ6). CHD4, meanwhile, is a component of the NuRD 
complex associated with heterochromatin formation and gene silencing, while ATAD5 
may play a role in DNA repair [50]. Viral integrases may hijack the BET ETDs in order to 
ensure that the viral genome is integrated into transcriptionally active gene loci [51]. 
The ETD hence appears to work with the BET BDs in a variety of cellular processes, 
from directing chromatin remodelling and DNA repair complexes to Kac-rich gene loci 
and ensuring splicing of BET-regulated transcripts.  
BRD4 has also been shown to be an atypical kinase, capable of both 
autophospohorylation and the phosphorylation of the S2 residue of the RNA Pol II C-
terminal tail [52]. This RNA Pol II phosphorylation has been show to occur in vivo, and 
under conditions where other RNA Pol II kinases are inactive. Because RNA Pol II 
phosphorylation is necessary for the elongation phase of transcription and for mRNA 
capping and splicing, this is likely one mechanism by which BRD4 binding to acetylated 
chromatin at the promoters of select genes can then drive their transcription. BRD4 
has also been shown to phosphorylate the CDK9 subunit of the positive transcription 
elongation factor (P-TEFb), and the TFIID component of TAF7, two other kinases key to 
RNA Pol II activity [47] (figure 1.7B). Although not investigated as thoroughly BRD2 has 
also been identified as a potential atypical kinase [53], and BRD3 and BRDT may yet be 
shown to possess this activity. BRD4, furthermore, possesses a 1362-AA ‘long’ isoform 
containing two additional domains. One is a HAT domain which is believed to acetylate 
lysine residues in H3/H4 histone tails and the K122 residue of H3’s globular domain. 
This activity decompacts chromatin around downstream genes, enhancing 
transcription [54] (figure 1.7D). Finally, the CTD domain (also found in BRDT) interacts 
with P-TEFb, which is essential for transitioning from the initiation phase to the 
elongation phase of transcription [55]. The CTD directly interacts with both the CDK9 
and the cyclin T1 subunits of P-TEFb, and stimulates the phosphorylation of the RNA 
Pol II C-terminal tail at BET-regulated genes [56, 57] (figure 1.7C). The short isoform of 
BRD4 likely functions to maintain BD, ETD and atypical kinase-based functions, while 
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potentially acting as a competitive inhibitor of the long isoform with regards to HAT 
and CTD-mediated activities [54]. The HAT and atypical kinase activity of BRD4 is 
prevented by BET BD inhibitors [52, 54], highlighting the dominant nature of the 
bromodomains to BET protein function. 
 
Figure 1.7. BET protein activities. 
BD1 and BD2 bind acetylated lysine residues in histone tails (for clarity only 1 BD shown). A) ETD recruits 
NHPs (non-histone proteins), for various functions. B) Atypical kinase (AK) activity phosphorylates and 
activates RNA Pol II’s C-terminal tail directly, or through P-TEFb. C) CTD binds and stimulates P-TEFb 
activity. D) HAT acetylates histone tails, or H3’s globular K122 residue. Acetylated histone tails recruit 
additional BD proteins. H3 K122 acetylation causes chromatin decompaction. 
 In addition to inducing transcription of protein-coding mRNAs BRD4 has also 
been shown to bind acetylated histone at enhancer sites and, through P-TEFb/RNA Pol 
II interactions, stimulate the transcription of non-coding enhancer RNA (eRNA) [58]. 
Enhancer RNAs are not yet fully understood but are believed to help regulate 
transcription [59], and in a later study eRNAs were shown to interact with BRD4 BDs 
and stabilise interactions with acetylated histone tails [60].  
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The clinical significance of the BET proteins was first realised through their role 
in NUT-midline carcinoma (NMC), a squamous cell carcinoma. NMC’s highly-aggressive 
nature, under-diagnosis and a lack of effective treatments gives it a median survival 
time of 6.7 months after diagnosis [61, 62], and as of 2006 only one ‘long-term 
survivor’ was known of [62]. NMC has been shown to be caused by a chromosomal re-
arrangement fusing the nuclear protein in testes (NUT) gene to another gene, which in 
~80% cases is BRD4 or BRD3, leading to the expression of a fusion NUT-BET 
oncoprotein [63, 64]. NUT’s ability to recruit the HAT p300, and BRD4/3’s ability to 
bind acetylated chromatin and increase gene expression are believed to drive NMC’s 
proliferation and inhibit cell differentiation in two ways. First BRD4/3 binds acetylated 
chromatin around MYC promoters, and up-regulates its expression. Secondly, a 
positive feedback loop is created as NUT recruits p300 which acetylates the nearby 
chromatin, increasing NUT-BRD4/3 recruitment and thus depriving other pro-
differentiation genes of HAT activity [62].  
 BRD4, BRD3 and BRD2 are expressed in a wide range of tissues and cell-type 
and hence likely involved in a large number of biological functions. BRDT, in contrast, is 
expressed solely in the testes where it is necessary for spermatogenesis [65, 66]. BRDT 
is expressed during meiosis and is believed to contribute to spermatogenesis both by 
directly increasing transcription of downstream genes and by contributing to 
chromatin compaction. Knock-out or mutation of BRDT has been linked to low sperm 
count and male infertility [67, 68]. BRDT has also been seen to be ectopically expressed 
in some lung cancers [69]. Since BRDT is unlikely to be involved in any clinically 
important biological processes outside of spermatogenesis, it is not studied as 
thoroughly as the other BET proteins. Consequently at times both in this thesis and in 
the literature certain experiments may be performed on the other BET proteins but 
not BRDT.  
 
 





1.6 – BET Probes / Inhibitors: 
 Within the last decade there has been a surge in BET bromodomain inhibitor 
development. In addition to an array of ‘academic’ inhibitors used only in research 
(most famously (+)-JQ1) 17 BET inhibitors have been submitted for a total of 45 
registered clinical trials (as of June 2018) [70] (scheme 1.1) (figure 1.8). BET inhibitor 
development has been discussed thoroughly in the literature [41, 71-73]. 
 BET inhibitors were first published on by Mitsubishi Tanabe in a series two 
patents in 2008 [74] and 2009 [75], outlining the use of thienotriazolodiazepine 
compounds for anti-tumour and anti-inflammation uses. Despite this work BET 
inhibitors did not become widely used until 2010 with the key, concomitant 
publication of (+)-JQ1 [76] and I-BET762 [77]. (+)-JQ1, the premier academic BET 
inhibitor, was published by the laboratory of James Bradner in collaboration with the 
Structural Genomics Consortium and others, in a paper focusing on NMC. The 
compound was selected  following optimisation of the previously-mentioned 
compounds discovered by Mitsubishi Tanabe in an anti-cancer screen [75]. I-BET762, 
meanwhile, was originally discovered in a GSK screen for ApoA1 up-regulators [78]. I-
BET762 was first published in the context of inflammation suppression, but has since 
entered clinical trials for anti-cancer indications. Both compounds possess ~100 nM Kd 
values towards BET BDs and are based on the ‘privileged’ benzodiazepine scaffold [79]. 
This scaffold has since been used for the development of the clinical inhibitors OTX015 
[80] and CPI-0610 [81], as well as several academic inhibitors [82]. A variety of other 
scaffolds have since been utilised to produce BET inhibitors, with slight changes in 
potency and DMPK characteristics [41, 71, 72]. The only feature shared by all BET 
inhibitors is the presence of a Kac mimic moiety (scheme 1.2) (figure 1.8). In order to 
boost overall potency bivalent BET inhibitors have also been developed. AstraZeneca 
produced the asymmetric compound AZD5153 which has now entered clinical trials 
[83, 84], while the Bradner lab developed MT1 by conjugation of two (+)-JQ1 




Figure 1.8. BET inhibitors mimic the Kac mark 
X-ray co-crystal structures of BRD4 BD1 in complex with an H4 K(5,8)ac peptide (A) (3UVW) and (+)-JQ1 
(B) (3MXF). Critical N140 residue highlighted. Grey dash represents critical hydrogen bond.  
 In addition to ‘standard’ inhibitors a few molecules have been developed that 
have been functionalised for specific purposes. Bio-JQ1 was developed by linking (+)-
JQ1 to a biotin unit through a triple-PEG linker, and was used to show the localisation 
of (+)-JQ1 and its targets throughout the genome [86]. A photo-reactive (+)-JQ1 cross-
linker has also been developed, able to label bound proteins with azides/biotin (for on-
target and potential off-target pull-down) and fluorophores (for fluorescence 
microscopy) [87]. Later cross-linkers, based on GW841819X, were used in 
chemoproteomic experiments to identify a novel off-target [88]. (+)-JQ1 compounds 
with click-chemistry compatible labels have also been developed for protein labelling 





Scheme 1.2. BET bromodomain inhibitors developed as probes and clinical candidates 





BET bromodomain inhibitors have gone on to be used to study the BET proteins 
in a wide range of fields, thanks in part due to the availability of compounds like (+)-
JQ1. BET inhibitors have been shown to reduce the proliferation of a number of 
cancers [72], such as acute myeloid leukaemia (AML) [90]. This is understood to be 
primarily due to a reduction in BET-regulated expression of the oncogene C-MYC [91]. 
The anti-MYC activity of BET inhibitors has led to their use against a number of other 
MYC-dependent cancers [92, 93]. Additionally, BET inhibitors have shown to be active 
against a number of other cancer types, such as lung adenocarcinoma (LAC), in a MYC-
independent fashion. This activity is due to the role of BET proteins in regulating 
oncogenic signalling pathways such as FOSL1 and NF-B [94-96]. 
In addition to cell proliferation and differentiation the BET bromodomains have 
also been shown to regulate inflammation [77, 97, 98]. BET proteins are necessary for 
the production of inflammatory cytokines by macrophages, and BET inhibition has 
been shown to alleviate sepsis by reducing interleukin-6 (IL-6) and tumour necrosis 
factor alpha (TNF- levels). The importance of BET proteins to the activity of immune 
cells, such as TH17 helper cells, is likely connected to their significance in the 
previously mentioned haematological malignancies.  
The BET proteins also regulate the apolipoprotein A1 (ApoA1) protein, part of 
the high-density lipoprotein (HDL) complex and a key indicator of cardiovascular 
health. One effort to identify and develop ApoA1 up-regulators was led by GSK, for 
which they generated a HepG2 cell-line transfected with an ApoA1 luciferase reporter 
gene, and this led to the discovery of benzodiazepine (I-BET762) and 
tetrahydroquinoline (I-BET726) BET bromodomain inhibitors [78, 99].  A similar effort 
by Resverlogix led to the discovery of RVX-208 [100]. These represent prominent 
examples of successful forward chemical genetics. 
As BET inhibitors are used in more and more scientific fields and biological 
contexts more potential BET protein functions are revealed. These include such 
disparate roles as male fertility [101], HIV infection [102] and neuronal development 
[103, 104].  
 As is clear from the above chemical genetics studies, BET bromodomain 
inhibitors are believed to possess great therapeutic potential [72], leading to the 
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previously mentioned 45 federal drug administration (FDA)-registered clinical trials 
with 17 compounds from 15 companies [70]. About 75% (32) of these clinical trials are 
targeted towards anti-cancer indications (figure 1.9). Some of these anti-cancer trials 
(3) relate to the BET proteins key (and dysfunctional) role in NMC, but most (29) aim to 
take advantage of the BET protein’s control of key proliferative or anti-differentiation 
signalling pathways such as C-MYC. Outside of NMC the cancers targeted by BET 
bromodomain inhibitors are ‘advanced solid tumours’, ‘neoplasms’ and hematologic 
malignancies; specifically AML, castration-resistant prostate cancer (CRPC), MM, 
diffuse large B-cell lymphoma (DLBCL) and lung cancers. These anti-cancer trials are 
overwhelmingly at an early stage, with 24 in phase 1, 8 in 1/2, 3 in phase 2 and none so 
far in phase 3 [70] (figure 1.9). The majority of these trials utilise BET inhibitors as a 
monotherapy, or with standard background care (24), although in 16 trials they are 
used in combination with treatments such as androgen/estrogen receptor antagonism 
or monoclonal antibodies. The overall efficacy of BET inhibition in these trials, where 
complete, is difficult to assess. In general, BET inhibitors appear to be generally 
efficacious, but limited by a feedback looping triggering BET protein up-regulation. A 
major complication appears to be dose-dependent toxicity. The most common adverse 
effect observed is thrombocytopenia (platelet depletion), alongside more common 
toxicities such as fatigue and diarrhoea [105-108]. As these are observed in multiple 
trials, using differing scaffolds they are likely the result of undesired on-target activity. 
There is also concern that BRD4/2 inhibition may reactivate latent HIV (or other) 
infections [55, 102, 109, 110]. 
 All non-cancer-targeting clinical trials so far utilise Resverlogix’s RVX-208, which 
will be discussed in greater detail later. These trials possess indications focusing on 
cardiovascular health (atherosclerosis, coronary artery disease and acute coronary 
syndrome), diabetes, kidney disease and the metabolic disorder Fabry disease. Due to 
its earlier development RVX-208 has reached the later stages of clinical trials, with five 
phase 2 and one phase 3 clinical trials (figure 1.9). The phase 3 clinical trial, 
BETonMACE, aims to determine if RVX-208 treatment in type-2 diabetes can reduce 




Figure 1.9. BET bromodomain clinical trials. 
Data from clinicialtrial.gov, as of June 2018. In chart 3 ‘other’ refers to the following 10 compounds used 
in only one clinical trial each: AZD5153, ABBV-075, ABBV-744, BAY1238097, BI894999, BMS-986158, FT-





1.7 – Selective BET Probes: 
Unfortunately, the majority of BET bromodomains inhibitors developed so far 
have been pan-selective, meaning that though they are selective for the BET family 
over other bromodomains they are not selective within the family [41]. As these 
compounds bind to all BET bromodomains and proteins with roughly equal potency it 
has proved difficult to illustrate the significance of specific bromodomains/proteins or 
to link specific phenotypes and cellular functions with specific BET 
bromodomains/proteins. By combining chemical inhibitors with genetic tools and 
molecular biology some advances have been made on the protein-specific level [43, 
112-114], but this has failed to keep pace with the wealth of research illustrating the 
importance of the BET bromodomains on a family-wide scale. Thankfully, a small 
number of compounds have been released showing inter-BET selectivity, taking 
advantage of the small differences in sequence and conformation that exist between 
different bromodomains (figure 1.10). These efforts have been most successful in 
generating selectivity for the BET BD2s over BD1s (scheme 1.3). 
 For some years the only reasonably high-quality, selective BET inhibitor was 
Resverlogix’s RVX-208. Developed from a screen for ApoA1 up-regulators [100] RVX-
208 entered clinical trials before later being identified as a BET inhibitor with ~20-fold 
selectivity and ~200 nM potency for the BD2s [115, 116]. Structural biology and 
molecular dynamics simulations have been used to rationalise this selectivity. RVX-208 
is shown to pack against the H437 residue of BD2, an interactions not as favoured in 
the case of the BD1 equivalent residue (D144) [115, 116]. MD simulations, meanwhile, 
showed that RVX-208 can selectively re-orient the binding pocket of BRD2 BD2 in a 
more favourable fashion than in BRD2 BD1, improving the BD:RVX-208 affinity. This re-
orientation upon RVX-208 binding is most beneficial to binding with regards to the 
BD2s [117]. RVX-208 was confirmed to still be active in cells and could displace BRD3 
from chromatin, though to a lesser extent than the pan-selective PFI-1 [116]. RVX-208 
treatment was also shown to alter the regulation of genes in HepG2 cells, though again 
in a reduced fashion compared to pan-selective (+)-JQ1. RVX-208 affected ~10% of the 
genes affected by (+)-JQ1 [116]. Unlike the bulk of non-selective BET inhibitors, which 
are focused on cancer indications, RVX-208 has mainly been targeted against heart 
diseases and metabolic disorders. RVX-208 is, interestingly, the only BET inhibitor to 
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reach phase 3 clinical trials, although it is hard to say if this is due to its BD2 selectivity, 
its differing indications or pure chance.  
 RVX-208 has, in the last year been followed by Abbvie’s ABBV-744 [118-120] 
and GSK’S GSK268 and GSK340 BD2-selective inhibitors [121]. Finally, in 2016 the 
Alessio Ciulli lab developed a BD2-selective indole-derivative of the benzodiazepine 
scaffold [122].  
 
Scheme 1.3. BD2-selective BET bromodomain inhibitors.  
Potential Kac mimics in red. 
GSK268 and GSK340 were both developed from the very potent but pan-
selective tetrahydroquinoline I-BET726 [99] and display very promising qualities. Both 
compounds display, in a time-resolved-FRET (TR-FRET) assay, ~100 nM potency against 
BET BD2s, selectivity against BD1s from ~7-fold (BRDT) to ~45-fold (BRD4), anti-BET 
activity in cells at low concentrations and a wealth of good to moderate quality DMPK 
properties [121]. GSK340 was also tested in the DiscoveRX BROMOscan panel, wherein 
it possessed Kd values against BET BD2s of 100 to 10 nM and 40-230-fold selectivity 
against BD1s, in addition to negligible binding to non-BET BDs [121]. To achieve this 
remarkable selectivity GSK exploited two differences in protein sequence between BET 
BD1s and BD2s. The first variation is the identity of the ‘gatekeeper’ residue, which 
controls access to the WPF-shelf, corresponding to I146 in BD1s and V439 in BD2s 
(BRD4 numbering) – allowing for a differential steric clash with the ligand. The second 
difference was on the BC loop, wherein the BD1’s D144 and D145 contrast with H437 
and E438 in the BD2. The presence of E438 on the BD2 allows for the formation of a 
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BD2-selective water-mediated hydrogen bond, while H437 alters the conformation of 
an aryl moiety, improving interactions with the WPF shelf in BD2s [121]. Despite the 
strong potency and selectivity, cellular activity and strong DMPK characteristics neither 
GSK compound has been submitted for clinical trials, as their high intrinsic clearance 
(CLint) in rats prevents pre-clinical testing.  
Abbvie’s BD-selective ABBV-744, disclosed close to GSK’s compounds, also 
displays very promising properties. ABBV-744 was developed from the pan-selective 
pyrrolopyridone ABBV-075, which in a TR-FRET assay displays 1-15 nM potency for all 
BET BDs [123]. Through exploiting the I146/V439 and D144/H437 differences discussed 
above ABBV-744 achieved BD2 potency of 2-5 nM, and selectivity against BET BD1s of 
250-640-fold [118, 120]. In the cellular NanoBRET assay ABBV-744 possessed 28 nM 
potency against BRD4 BD2, and 750-fold selectivity against the BD1. ABBV-744 appears 
to retain ABBV-075’s strong DMPK properties, with similar oral bioavailability in mice, 
and nM potency against some BET-dependent cancer cell-lines. Interestingly, ABBV-
744 was shown to lack cytotoxicity for a number of (non-AML) cell-lines vulnerable to 
the pan-selective ABBV-075 [119], suggesting BD2 inhibition may have different 
therapeutic uses. Excitingly, ABBV-744 has already been submitted for a phase 1 
clinical trial against CRPC and AML [124], suggesting BD2-selective inhibitors may have 




Figure 1.10. Structural basis of BD1 / BD2 selectivity. 
A) Alignment of BET BD protein sequence, with notable differences between BD1s and BD2s highlighted. 
Numbering refers to BRD4 BD1 (top) and BD2 (bottom). B) Crystal structures of apo forms of BRD4 BD1 
(blue) (2OSS) and BD2 (red) (2OUO), with varying residues highlighted. Text explains how BD1/BD2 
differences are exploited by selective compounds, text colour refers to which BD group said interactions 
enhanced selectivity for (blue – BD1, red – BD2). 
 The Ciulli lab’s benzodiazepine-indole derivative was synthesised during 
attempts to develop allele-selective benzodiazepine analogues targeting W97F/H and 
W370F/H (BRD2 numbering) BET bromodomain mutants (discussed later). The indole 
compound was later seen to bind BRD4 and BRD2 BD2s with ~50 nM Kd values, and 
possess 10-15-fold selectivity against the relevant BD1s [122]. A co-crystal structure of 
the indole with BRD2 BD2 W370F showed it to possess the same overall binding mode 
to non-selective analogues, but with the BD2-specific H433 moved from an ‘open’ 
conformation pointing away from ligands to a ‘closed’ conformation wherein it formed 
a π-stack with the indole ring [122]. The synthesis of this indole compound was later 
optimised, and it was named TC AC 28 [125]. 
 In addition to the above published work, the pharmaceutical company Zenith 
Epigenetics is believed to have developed a small number of BD2-selective inhibitors 
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(ZEN-222, 297 & 2135) with <100 nM potency, ~50-fold selectivity and some degree of 
activity in cells [41]. No structures have been published nor have any such compounds 
progressed to clinical trials alongside their pan-selective ZEN-3694 [126], and they are 
likely intended for use as chemical tools. 
The development of BD1-selective inhibitors has, by comparison, been less 
successful, with no such compounds developed by pharmaceutical companies or 
submitted for clinical trials. All published BD1-selective inhibitors (scheme 1.4) were 
developed by the Ming-Ming Zhou lab, starting with the diazobenzene MS436 
compound published in 2013. This compound is highly potent (30-50 nM Ki) but has 
limited selectivity, with only a 10-fold preference for the BD1, and only in the context 
of BRD4 [127]. Structural studies suggest this selectivity was due to water-mediated 
hydrogen bonding to the K91 residue of BRD4 BD1, which corresponds to A384 in 
BRD4 BD2. In a later 2014 paper MS611 and Olinone were discussed. Olinone 
displayed a much weaker affinity (3.4 µM Kd) but enhanced selectivity for the BD1 over 
the BD2 of all somatic BET proteins (no quantifiable BD2 binding) [128].  This enhanced 
selectivity was shown to be due to favourable interactions with D144 in the BRD4 BD1 
binding pocket, contrasted to steric clashes with its BD2 equivalent, H437. Olinone, 
alongside additional BD1/BD2-selective inhibitors was used to probe the role of BET 
proteins in oligodendrocyte differentiation.  Interestingly, this work showed that while 
pan- and BD2-selective inhibitors inhibited differentiation; BD1-selective inhibitors 
instead up-regulated this process – hinting at differing roles for the different 
bromodomains [128]. Finally, MS611, another diazobenzene compound, possesses a Ki 
of 400 nM against BRD4 BD1, and 100-fold selectivity against BRD4 BD2 [128]. 
Unfortunately this very impressive potency and selectivity is not replicated with other 
BET proteins, with 1-6 µM Ki values against both BRD2 and BRD3 BDs.  
 
Scheme 1.4. BD1-selective BET bromodomain inhibitors.  
Potential Kac mimics in red. 
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In addition to BD1 selectivity, there has been some recent progress of inhibitors 
specific for a single bromodomain (scheme 1.5). BD1 and BD2-selective inhibitors are 
of use, seem able to generate differing phenotypes in cells and may be of differing 
therapeutic quality, but do not allow for interrogation of specific BET proteins or single 
bromodomains. A xanthine-based Kac mimic, published in 2016, showed moderate 
selectivity for BRD4 BD1, but with an overall potency of 1-5 µM [129]. In a TR-FRET 
assay this compound showed ~10-fold selectivity for BRD4 BD1 over BRD3 BD1 and 
BRD2 BD1, >20-fold selectivity against BRDT BD1 and no quantifiable binding to any 
BET BD2. Despite its low potency this xanthine did appear capable, at high enough 
concentrations, to supress the expression of C-MYC in Jurkat cells, and to impair the 
viability of said cells [129]. Through the use of co-crystal structures, and the synthesis 
and testing of less selective analogues, it was theorised that this selectivity is not, as 
one might expect, caused by ligand:protein interactions via residues unique to BRD4 
BD1. While the xanthine core allows for pan-selective BET inhibition a triazolo moiety 
forms an important bond with the D88 residue on the ZA loop. This D88 residue is 
conserved within the BET family, but the differing dynamics of the ZA loop between 
BDs limits the ability of the compound to make this hydrogen bond with other BDs – 
generating selectivity. In addition to this conformation-specific D88 interaction, 
selectivity against BRDT BD1 and the BD2s was enhanced through exploitation of 
sequence variation. While the xanthine compound forms van der Waals interactions 
with the side-chain of Q85 in BRD4 BD1 it clashes sterically with the equivalent 
arginine (BRDT BD1) and lysine (BD2s) residues [129].  
 
 
Scheme 1.5. BRD4 BD1-selective BET bromodomain inhibitors.  




Another paper, also published in 2016, revealed a 4-acyl pyrrole derivative with 
moderate selectivity for BRD4 BD1 [130]. The selectivity of this compound was not as 
thoroughly characterised as the xanthine, although as ITC was used instead of TR-FRET 
the measured Kd values are expected to be more reliable. The acyl pyrrole displayed 
~12-fold selectivity for BRD4 BD1 over BRD3 BD1 (similar to the xanthine compound) 
but only 10-fold selectivity against BRD3 BD2 [130]. No other BET bromodomains were 
tested. In contrast to the xanthine compound, however, the acyl pyrrole was a potent 
binder, with a Kd for BRD4 BD1 of 240 nM [130]. A number of features/interactions are 
presented as possible caused for said selectivity, mainly the occupation of the ‘WL 
trap’ formed by W81 and L92. In addition a hydrogen bond between the pyrrole unit 
and BRD4 BD1’s P82 residue, as well as a perpendicular T-shaped π–stacking 
interaction with W81, were suggested as means to generate selectivity. Through the 
use of QSAR it was shown that selectivity benefited from exploiting an acceptor 
feature within BRD4 BD1’s ZA channel [130]. Despite its superior potency to the 
xanthine compound the acyl pyrrole was not tested in cells. To date there is no known 















1.8 – Selective BET Degradation 
Interestingly, the parallel development of proteolysis-targeting chimera 
(PROTAC) compounds has led to the observation of inter-BET protein selectivity. 
PROTACs are heterobifunctional ligands, in which a ligand that binds to an E3 ubiquitin 
ligase is linked to a ligand that binds one’s protein of interest. Such a compound will 
then bring together the target protein and the E3 ligase to form a ternary structure 
that triggers ubiquitination of the target, leading to its proteasomal degradation [131] 
(figure 1.11A).  
Several BET PROTACs have been developed by a number of labs, with most 
remaining pan-selective, however the Alessio Ciulli lab has developed a number of 
PROTACs showing varying degrees of preference for BRD4 degradation [132]. The 
selectivity of the PROTAC MZ1 (figure 1.11B) does not appear to be due to any 
differences in bromodomain binary binding affinity. Instead, MZ1 has been shown to 
induce novel PPIs between the BET bromodomains and their E3 ligase (the von Hippel-
Lindau protein VHL), leading to the formation of cooperative ternary complexes. In this 
context cooperativity refers to the binding of the PROTAC to one of its protein binding 
partners enhancing its affinity for the remaining protein. At this ‘cooperativity’ level 
MZ1 shows greater cooperative binding and hence selectivity for BRD4 BD2 over other 
BET BDs (figure 1.11C). X-ray crystallography-derived ‘ternary’ structures of BRD4 BD2-
PROTAC-VHL complexes revealed PROTAC-induced interactions between BRD4 and 
VHL residues, as well as interactions between the BET-targeting ligand and VHL, and 
again between the VHL-targeting ligand and BRD4 BD2 [133]. Said structures also 
informed the development of newer PROTACs, like AT1, with varying selectivity for 
BRD4 [133]. This selectivity is ultimately based upon the ability of VHL and BRD4 BD2 
to interact with each other and does not lend itself to rational design of PROTACs 
selective for other proteins [131].  
BRD4-selective PROTACs have also been developed by a second lab, instead 
utilising the cereblon (CRBN) E3 ubiquitin ligase and not exploiting cooperativity [134]. 
These PROTACs take advantage of the plastic nature of the induced BRD4:CRBN 
interactions and a variety of potential conformations the two proteins can form.  
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PROTACs induce the degradation of their target proteins in their entirety. As 
such BET-targeting PROTACs cannot be used to interrogate the differing roles of BD1s 
and BD2s, but only those of different BET proteins. Additionally the phenotypes they 
generate in cells could be caused by the removal of non-bromodomain domains within 
BRD4, such as its ET domain, which would be unaffected by standard small-molecule 
inhibitors. As PROTACs act catalytically, that is each individual PROTAC molecule will 
over time bind and induce the degradation of many protein molecules, they do not 
require large concentrations to be effective, and MZ1 doses of 10-100 nM have been 
shown to completely degrade BRD4 within 24 hours [132]. This suggests PROTACs may 
be very effective treatments for BET-sensitive cancers, such as AML, although this will 
likely be impeded by the DMPK characteristics such large compounds will possess and 





Figure 1.11. Inter-BET selectivity with PROTACs 
A) Mode-of-action of PROTAC compounds, modified from Runcie et al, COCB, 2016 [1]. B) Chemical 
structure of BRD4-selective PROTAC MZ1. C) ITC-measured affinities of MZ1 for BET bromodomains 
(BD2), and associated cooperativity (X-fold increase in affinity for VHL, when MZ1 pre-incubated with 
BD2). Western-blot observed degradation of BET proteins in HeLa cells, following 24 h treatment. 
Affinity and cooperativity data from Gadd et al, Nat. Chem. Biol., 2017 [133], western-blot from Zengerle 








1.9 – Bump-&-Hole Theory: 
 One means by which selective inhibitors can be acquired is the design of an 
orthogonal protein/ligand pair, by engineering fully functional mutant proteins 
targeted by an allele-selective analogue of an existing probe [1, 135, 136]. By 
modifying a single existing pan-selective probe one can achieve a single allele-selective 
compound that can be used to inhibit multiple target proteins bearing the mutation. 
By doing this potentially years of compound design can be bypassed. This method is 
dependent on the orthogonal protein mutants retaining sufficient functionality in cells 
and in vivo to allow generation of viable mutant cell-lines or animal models. The 
resulting compounds will not have any immediate therapeutic use, as they will not be 
effective against wild-type (WT) proteins involved in disease. 
 There are several methods available to generate orthogonal protein/ligand 
pairs [135] (figure 1.12). Protein/ligand interactions that rely on charge-charge 
interactions can be made allele-selective through reversing the charge 
complementation: i.e. taking a positively-charged probe binding a negatively-charged 
binding site, and developing a negatively-charged probe that binds a positively-
charged mutant. A similar approach is to replace hydrophobic protein:ligand 
interactions with polar interactions, or vice-versa. Allele-selectivity can also be 
engineered through the introduction of a novel covalent interaction. Introducing a 
cysteine residue into a suitable position can allow for selective inhibition by probe 
bearing a suitable electrophile group (e.g. thiol or acrylamide) [137]. This method is 
best applied when structure-activity relationship (SAR) studies have been unable to 
produce high-affinity probes, as the covalent interaction should strongly boost 
potency. The reactive probe can suffer from low selectivity if it is able to form covalent 
bonds with cysteine residues on other, undesired proteins.   
Perhaps the most successful strategy to engineer selective protein:ligand 
binding is the exploitation of steric complementation – the ‘bump-&-hole’ approach 
(figure 1.13) [135, 136]. Replacing a large or medium-sized residue (phenylalanine, 
tyrosine, tryptophan, leucine, isoleucine) with a smaller residue (valine, alanine, 
glycine) can create a void (‘hole’) in the target protein’s binding site. Meanwhile, 
introducing a complementary steric ‘bump’ to an existing probe in a suitable position 
can confer upon it allele-selective binding. This is because the bump will weaken or 
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prevent binding to WT proteins through the introduction of a new steric clash, while 
increasing its affinity to mutant proteins by the introduction of a novel hydrophobic 
interaction if correctly complemented by the mutation ‘hole’. By not altering the 
intrinsic chemical nature of any residues (unlike charge or polar/hydrophobic reversal) 
this method is also the least likely to alter the functionality of the protein, a typically 
desirable characteristic of an allele-selective system.  
 
Figure 1.12. Strategies for design of orthogonal protein:ligand pairs. 
Example ligand, with and without orthogonal modification, paired with WT (blue) and mutant (red) 





Figure 1.13. ‘Bump-&-Hole’ strategy 











1.10 – Bump-&-Hole Examples (non-epigenetics): 
 Perhaps the best known application of the bump-&-hole method of engineered 
selectivity was the Kevan Shokat lab’s development of mutant selective kinase 
cofactors and inhibitors [138]. Kinase-dependent protein phosphorylation is a vital part 
of biological signalling and is involved in almost all cellular processes, but single-target 
inhibition of all ~500 human kinases is far-fetched and, even if attainable, would 
require the deployment of significant efforts and resources. This motivated the 
development of allele-selective strategies.  
The bump-&-hole approach was first performed on the viral tyrosine kinase 
vSRC, which was known to phosphorylate over 50 distinct proteins and to be 
responsible for the transformation of fibroblasts by Rous sarcoma virus [139]. The 
specific substrates of vSRC could not be sufficiently distinguished from those of other 
kinases, nor was any selective, potent and cell-permeable inhibitor in use. In its first 
iteration this system paired a V323A / I338A mutant kinase with an N6-cyclopentyl –
bumped ATP analogue, which was unreactive with WT vSRC but could be successfully 
catalysed by the mutant [139].  Although the mutant kinase retained some kinase 
activity, its catalytic efficiency (kcat/Km) with N6-cyclopentyl-ATP was 50-fold lower 
than that of WT vSRC for unmodified ATP (table1.1). This significant loss of activity 
made this bump-&-hole system unlikely to be able to compete with WT kinases in cells 
and allow for successful substrate identification. Addition structural biology and SAR 
work generated an optimised system, using an I338G mutation and N6-benzyl –
bumped ATP, which showed improved catalytic efficiency [140] (table 1.1) (scheme 
1.5). To emphasise generality and potential wide applicability of the bump-&-hole 
approach a related Src kinase, Fyn, was also engineered to produce a catalytically 




Table 1.1. Kinetics of kinase mutants and cofactor analogues 
Symbol ‘-‘ denotes no observed activity. Data from [139, 140] 
In addition to a mutant-selective cofactor a mutant-selective small-molecule 
inhibitor was developed. Based on the Src pan-selective inhibitor PP1 this bumped 
inhibitor possessed ~500 nM potency and >600-fold selectivity for vSrc and Fyn 
mutants over their WT counterparts [141]. This selectivity was then confirmed in cells, 
where treatment of mutant (but not WT) cells with the bumped inhibitor blocked the 
phosphorylation of protein and the vSRC-dependent formation of fibroblasts [141]. 
The use of mutant-selective inhibitors was later expanded to the rest of the 
kinome [142]. Kinases from five distinct families were engineered to include mutations 
comparable to the vSRC I338G mutations and tested against bumped modifications of 
two inhibitor scaffolds: the Src inhibitor PP1 used previously and the pan-kinase K252a 
inhibitor. This proved to be successful, with each tested kinase being targetable by at 
least one selective inhibitor, and the bumped analogues of the originally Src pan-
selective PP1 being potent and selective for mutants of other kinase families [138, 
142]. This approach was then applied to the fungal kinase Fus3, where the mutation 
had little impact on cell viability, and the bumped inhibitor showed high potency and a 
stark selectivity for the mutant [138, 142]. The same was done with the fungal CDK2 
homologue Cdc28, and the resulting phenotypes differed from that displayed by the 
Enzyme Substrate k cat  (min
-1) K m  (µM) k cat /K m  (M
-1 S -1 )
ATP 2 12 2.8 x 103
N6-cyclopentyl-ATP
N6-benzyl-ATP
ATP 0.8 150 8.9 x 101
N6-cyclopentyl-ATP 0.05 15 5.6 x x101
ATP 0.8 80 1.7 x 102
N6-cyclopentyl-ATP 0.1 15 1.1 x 102
N6-benzyl-ATP 0.2 5 6.7 x 102
ATP 2.5 70 6.0 x 102
N6-benzyl-ATP
Fyn ATP 0.8 90 1.5 x 102
T339A N6-benzyl-ATP 0.5 25 3.3 x 102
Fyn ATP 0.5 100 1.0 x 102
T339G N6-benzyl-ATP 0.3 7 7.1 x 102









previously used method of engineering temperature-sensitive mutants [142]. An 
alternative approach to engineering orthogonal protein:ligand pairs, the introduction 
of a covalent interaction, has also been trialled, with a c-SRC T338C mutant retaining 
activity and being selectively and covalently bound by thiol-modified kinase inhibitors 
[143].  
Another significant application of the bump-&-hole approach was the 
development of orthogonal FKBP dimerisers (scheme 1.6). A family of prolyl 
isomerases, the FKBP proteins are involved in protein folding and trafficking. Bivalent 
analogues of the FKBP-inhibiting immunosuppressant FK506 are able to induce 
dimerization of FKBP12, and this process has been used as a tool to engineer and 
manipulate PPIs to study and control protein localisation and function [144]. The 
bump-&-hole approach was first utilised in 1997. At this point in time rapamycin was 
used to induce dimerization of FKBP12 and the FRB domain of RAFT, but this approach 
suffered from rapamycin’s innate off-target activity. Using previously solved binary and 
ternary crystal structures a number of inactive, bumped rapamycin analogues were 
developed, and then screened against a library of FRB mutants. This approach 
eventually lead to the pairing of a methallyl bump and a triply-mutated FRB (T2098L, 
W2101F and K2095P), which was shown to be able to alter the cellular localisation of 
proteins in cells, by recruiting a kinase domain to the plasma membrane [145]. The 
methallyl-bumped compound displayed ~15 nM potency and ~50-fold selectivity for 





Scheme 1.6. Applications of bump-&-hole system. 
Chemical structures of WT and mutated residues of target protein, allele-specific enzyme co-factors, 





In a parallel study an orthogonal FKBP12 mutant and ligand pair was developed 
[146]. Mutations on the F36 residue were shown to retain binding to the FK506 ligand, 
and these mutants were then screened against a library of bumped FK506 compounds. 
The compound that emerged as best, bore a trimethoxyphenol bump, possessed high 
potency (IC50 = 2 nM) against a functional F36V mutant, and showed weak potency 
(IC50 = 3 µM) against the WT FKBP – resulting in outstanding selectivity of >3000-fold 
[146]. This compound (later termed Shield-1) was then coupled together to form a 
homobifunctional ligand (AP1903), able to recruit and dimerise two molecules of 
mutant FKBP protein. This system was then shown to activate Fas signalling in cells and 
in a mouse model [146].  The later inclusion of an additional L106P mutation created 
an unstable FKBP12 protein, which when fused to a protein of interest would trigger its 
rapid degradation unless stabilised by the bumped Shield-1 compound [147-149]. A 
fluorescent analogue of Shield-1 coupled with genetic tagging of the F36V FKBP12 
mutant to a target gene allowed for fluorescent microscopy study of the tagged target 
protein in cells [150]. 
This system was later developed further, to develop the dTAG system for 
targeted protein degradation [151]. The dTAG system is premised upon the idea of 
creating fusion proteins of a target of interest and FKBP12, and targeting this protein 
with a FKBP12-targeting PROTAC molecule developed previously. As the FKBP12 
component of the fusion protein is polyubiquitinated and degraded so too will the 
target protein be degraded, removing the need to develop a PROTAC molecule for 
each protein of interest. To avoid off-target effects emerging from endogenous FKBP12 
degradation, a mutant F36V FKBP12 tag was utilised and a PROTAC using the 
trimethoxyphenol-bumped ligand [151]. The bumped PROTAC was shown to 
selectively degrade the F36V FKBP12 mutant in cells, and the dTAG system was then 
used to degrade other target proteins such as BRD4, MYC and KRAS G12V [151]. For a 
final validation the dTAG system was used to degrade a luciferase enzyme in vivo, by 
expressing the tagged luciferase in MV4-11 cells grafted into the bone marrow of mice 






1.11 – Bump-&-Hole Examples (epigenetics): 
 Within the context of epigenetics engineered orthogonal selectivity has been 
used, almost exclusively on the enzyme/cofactor level, to better understand the 
activity of epigenetic writer proteins (scheme 1.7) (table 1.2).  
 Over a series of publications a bump-&-hole system was developed for the 
HKMT enzymes G9a and GLP1, which are known to introduce epigenetic marks such as 
H3 K9 methylation, as well as to methylate NHPs such as the tumour suppressor p53 
[152-154]. A number of bulky binding site residues (tyrosines, phenylalanines and a 
tryptophan) were replaced with alanine residues and tested for their ability to 
methylate H3 K9 peptides, with a Y/A mutation proving to be the most promising for 
both enzymes. The G9a Y1154A / GLP1 Y1211A mutants were tested against a range of 
SAM analogues wherein the donor CH3 was replaced with long carbon chains with 
terminal alkyne groups (for click-chemistry). The Y/A mutants were able to process an 
(E)-hex-2-en-5-ynyl-SAM analogue (Hey-SAM) with only a small (<20%) drop in 
efficiency [153, 154] and very similar kinetics [152]. This system originally relied on 
treatment with exogenous Hey-SAM, until later work developed a mutant enzyme 
capable of synthesising Hey-SAM in cells. The SAM synthase MAT2A, which catalyses 
the formation of SAM from methionine and ATP, underwent a mutagenesis screen 
following structural analysis of its binding site. An I117L mutation was shown to be 
capable of producing Hey-SAM from ATP and exogenous Hey-Met, with no observable 
drop in efficiency [153]. This optimised system was used in a ‘clickable chromatin 
enrichment with parallel DNA sequencing’ (CliEn-seq) approach through which the 
genome-wide chromatin methylation activities of G9a and GLP1 were studied and 
substrate loci were identified to a previously unobtainable enzyme-specific level [153]. 
In addition, bioorthogonal profiling of protein methylation (BPPM), was used to 
identify non-histone substrates, by pulling down the substrates and carrying out LC-
MS/MS analysis. These experiments identified a number of previously unknown 
G9a/GLP1 substrates, most of which were surprisingly revealed to be cytosolic, 




Scheme 1.7. Applications of the bump-&-hole system in epigenetics 
Chemical structures of WT and mutated residues of epigenetic writer proteins (and SAM synthase 
MAT2A), allele-specific enzyme co-factors and inhibitors (modifications in red).  
Another study attempted a similar strategy with the vSET HKMT from 
Paramecium bursaria chlorella virus, which specifically methylates H3 K27 and can be 
used as a more practical model for the SET-domain possessing EZH2 component of the 
PRC2 complex [155]. Rather than introducing a functional group (i.e. alkyne) this 
research aimed simply to generate a mutant vSET with no activity with the regular 
SAM co-factor, paired with a mutant-selective SAM analogue. Potential mutations 
were identified using a vSET/SAH/K3 K(27)me1 crystal structure, while bulky groups 
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were added to the 2’ and 3’-hydroxyl groups of the SAM ribose unit. Mass 
spectrometry and kinetic analysis identified the ideal combination as that of the L116A 
mutation and a dibenzyl-modified SAM [155]. Although the SAM analogue is highly 
selective for the mutant vSET, the mutant enzyme was still more active with 
unmodified SAM. The lack of cofactor selectivity from the mutant enzyme limits the 
usability of this system in cells [155]. 
 
Table 1.2. Kinetics of epigenetic enzyme mutants and cofactor analogues 
Symbol ‘-‘ denotes no observed activity. Data from [152, 155, 156] 
 One other HKMT study focused on the yeast enzyme RMT1, and like the vSET 
study aimed to produce an orthogonal enzyme:cofactor pair, without the addition of 
functional chemical groups. An E117G mutation generated an enzyme with a ~4-fold 
drop in activity with SAM compared to WT [156]. Interestingly, given the accessibility 
of yeast genetics, the mutant RMT1 was incorporated into yeast cells, and displayed 
only a very minor drop in growth rates. A benzyl-modified SAM analogue was shown to 
be inactive with WT RMT1, but unfortunately also showed a ~100-fold drop in activity 
with the E117G mutant, limiting its utility [156]. This study did not just generate an 
orthogonal enzyme cofactor, but also produced two SAH analogues that acted as 
Enzyme Substrate k cat  (min
-1) K m  (µM) k cat /K m  (M
-1 S -1 )
SAM 2.6 4 1.1 x 104
Hey-SAM
SAM 0.1 39 4.3 x 101
Hey-SAM 3.6 12 5.0 x 103
SAM 2.0 3 1.1 x 104
Hey-SAM
SAM 0.1 36 4.6 x 101
Hey-SAM 3.8 11 1.8 x 102
SAM 3.9 126 5.2 x 102
dibenzyl-SAM 0.4 173 3.9 x 101
SAM 7.4 60 2.1 x 103
dibenzyl-SAM 1.3 72 3.0 x 102
SAM 1.1 6.7 2.7 x 103
Bzl-SAM 3.2 4.9 1.1 x 104
SAM














inhibitors with >20-fold selectivity for the mutant enzyme [156]. This selectivity was 
shown both kinetically, and through the selective inhibition of downstream 
methylation in WT and mutant cell extracts. One selective inhibitor was then used, 
with the mutant yeast cells, to monitor changes in gene expression, identifying several 
genes involved in cellular organisation and metabolism as regulated by RMT1 [156]. As 
the selective inhibitors possessed low potency (Ki ~5 µM) these experiments required 
high doses (e.g. 500 µM) and the need for improved inhibitors was identified [156].  
 The final example of a bump-&-hole system for an epigenetic enzyme is a 2013 
study on a number of lysine acetyltransferase (KAT) enzymes. The main enzymes 
tested were GCN5 and MOF, from 2 separate KAT families, important to biological 
acetylation [157]. Like the studies into G9a and GLP1 this work aimed not just to 
engineer selectivity but also to introduce reactive groups (alkynes and azides) onto 
substrate proteins for further analysis. A number of mutation/cofactor pairs were 
identified with varying properties: 5HY-CoA was effective with GCN5 T612G/F622A and 
TG12G/L531A mutants and MOF I317A and I317A/H273A mutants, while 3AZ-CoA was 
effective with MOF I137A [157]. The ability to react with, and identify substrate 
proteins incorporating the modified analogues was validated through fluorescent 
labelling and SDS-PAGE. This bump-&-hole system was not actually used to study the 
full ‘acetylomes’ of these enzymes, perhaps due to difficulties in introducing modified 
acetyl-CoA analogues into cells and the lack of comprehensive kinetics data [157]. As 
such this research would greatly benefit from the development of a mutant enzyme 










1.12 – A ‘Bump-&-Hole’ System for BET Bromodomains 
Moving beyond writer enzymes into reader domains, the BET bromodomains 
provide, in principle, an ideal opportunity and a compelling case for the application of 
the bump-&-hole approach for developing an allele-selective, orthogonal 
protein:ligand pair. Many high quality, but pan-selective, chemical probes already exist 
and a wealth of chemical, SAR and cellular data is available in the literature, which 
should aid the development of allele-selective analogues without the need to develop 
new probes de novo. Additionally, the study of the BET proteins/bromodomains (both 
regarding basic biology but also for therapeutic use) would greatly benefit from the 
ability to selectively inhibit specific BET proteins and bromodomains. Pan-BET 
inhibition is already associated with several phenotypes, some of which are 
therapeutically advantageous or deleterious. In this context the BET proteins are often 
viewed as a monolith, with a list of biological roles. In reality this is much more 
complicated (figure 1.14) with each BET protein (and BD) generating different 
phenotypes when inhibited. In some cases different BET protein/BDs have been shown 
to have directly opposing roles [128, 158]. BET protein and BD-specific inhibition 
should reveal and dissect these differing roles, and may identify BET BDs whose 
inhibition generates therapeutically beneficial phenotypes, and others with more 
deleterious roles such as the observed on-target toxicity. This information would then 
go on to inform the development of selective BET inhibitors that may show more 
promise in the clinic. Selectively interrogating each BET bromodomain traditionally, 
through developing eight bromodomain-specific probes, might be unattainable given 
the high conservation of the binding pockets described, and even if achievable it would 
take a great deal of time and money, and would be hard to justify without the very 
bromodomain-specific phenotypic data we wish to obtain. By being able to (relatively) 
quickly engineer selective inhibition of all eight BET BDs we would have a new tool at 
our disposal that can help to better understand these proteins on an individual level 





Figure 1.14. Differing BET protein functions obscured by pan-selective inhibition 
Inhibiting all BET bromodomains with pan-selective BET inhibitors reveals a number of positive (green) 
and negative (red) biological effects. These phenotypes are actually generated by the inhibition of 8 BET 
bromodomains, with varying (if not directly opposed) biological functions. The exact roles of different 
BDs, and how they interact to generate observed phenotypes, remains poorly understood. 
 This work also provides an opportunity to broaden the general applicability of 
the bump-&-hole approach, as this system is rarely applied to small-molecule 
inhibitors, and instead typically focuses on enzymes and co-factors. In particular, the 
bump-&-hole approach had not previously been applied in the context of a protein-
protein interaction, and there was some scepticism that it would be possible to 
engineer sufficient selectivity within a PPI binding site. 
 The Ciulli laboratory decided to take on the challenge of developing allele-
selective PPI inhibitors in 2010, using the BET bromodomain as the system of choice. 
Since then development of the BET bump-&-hole system has required a combined 
effort using a number of disciplines such as computational biology, structural biology, 
chemistry and cell biology. Starting with initial analysis of BET bromodomain 
sequences and structures, followed by computational simulations of the impact of 
mutations, three binding site residues were identified as potential ways to engineer 




 The valine/alanine mutation (V/A) was quickly discarded, as initial 
characterisation revealed it to be highly unstable and showed the greatest loss in 
affinity for a tetra-acetylated H4 peptide. Additionally, thermal shift experiments 
suggested that the ligands designed as V/A-targeting were not selective for the 
mutants over WT [122]. 
The tryptophan mutations: W/F and W/H were more successful, but ultimately 
did not lead to a usable system. The W/F mutation had only a minor impact on the 
affinity for acetylated peptides, which was deemed a positive feature of these mutant 
proteins. Unfortunately, again the corresponding ligands were not sufficiently selective 
[122]. Nonetheless this research did generate some useful outputs. To design W/F-
targeting compounds, chemical means of substituting the chlorophenyl ring of I-
BET762 were developed, which opened up possibilities for developing new, non-
orthogonal, BET inhibitors. Additionally, as discussed previously one of the indole 





Figure 1.15. Alternative BET bump-&-hole mutations & ligands. 
Co-crystal structure of BRD2 BD1 in complex with I-BET762 (2YEK), with mutated residues highlighted. 
Chemical structures of WT and mutant amino acids, and mutant-targeting, I-BET762-derived ligands 
(bumps in red). MB-155 is earlier referred to as TC AC 28. 
 The leucine mutants, specifically the leucine/alanine (L/A) was by far the most 
successful strategy. Its success led to the first publication from the group on the BET 
bump-&-hole approach and is the foundation for the research in this thesis [159]. This 
initial, proof-of-concept, publication showed that the L/A BET bromodomain mutants 
retained the stability and overall structure of the WT domain and the ability to bind 
acetylated histone peptides [159]. It also discussed the synthesis of its allele-selective 
inhibitors. These ligands utilised the benzodiazepine scaffold, identical to I-BET762 but 
with a methyl-ester replacing the di-ethyl-amide moiety. Alkyl bumps on the 2nd 
carbon (adjacent to the ester Cα) were shown to generate potent and highly-selective 
inhibitors ME (with methyl bump) and ET (with ethyl bump). ET was shown to be 
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potent and selective across all BET bromodomains, with an average L/A Kd value of 
~100 nM and ~160-fold selectivity [159] (figure 1.16A-C). The system was validated 
through ITC experiments with tandem-BD constructs and using a cellular FRAP assay.  
 
Figure 1.16. BET bump-&-hole proof-of-concept 
A) Chemical structure of bumped ET compound, with ethyl bump highlighted. B) Selectivity box of ET for 
L/A vs WT BET bromodomains. C) Co-crystal structures of (+)-JQ1 bound to BRD2 BD2 WT (3ONI) and ET 
bound to BRD2 BD2 L383A (4QEW), with leucine/alanine residue highlighted. D) ITC-measured affinity of 
WT and L/A BET BDs to tetra-acetylated H4 peptide. E) Expression of C-MYC mRNA in U2OS cells, treated 
with mock or BRD4-targeting siRNA. U2OS cells stably transfected with exogenous WT or L/A BRD4, 
induced by treatment with 0.1 µg/ml tetracycline. Selectivity, peptide-binding and C-MYC expression 
data from Baud et al, Science, 2014 [159]. 
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As successful as the initial research was, there was a clear need for further 
optimisation before biological questions could be properly addressed. The L/A 
mutation allowed for potent and selective inhibition while retaining stability and basic 
functionality but further experiments, however, showed that L/A BET proteins would 
be significantly less functional in cells. This could result in mutant cell-lines or animal 
models being non-viable (a severe waste of resources) or, if less severe, reducing the 
value of any results obtained using the system. The L/A BET bromodomains were able 
to bind acetylated histone peptides, but with up to 10-fold reductions in affinity for the 
BD1s.  In a cellular rescue assay, L/A BRD4 was not able to induce the expression of C-
MYC as well as the WT form [159] (figure 1.16D-E). As a result, alternative leucine 
mutations were designed and trialled to identify a mutation that, while still allowing 
for selective inhibition, would likely have a more conservative impact on protein 
function. On the chemical side of the project, it was hoped that examination of 
additional modifications would allow for increased selectivity, potency and DMPK 
characteristics. This optimised bump-&-hole system could then be validated in cells 
and, once introduced into appropriate cell-lines, be applied to answer biological 














1.13 – Aims & Objectives: 
 The goal of this PhD project was to optimise the bump-&-hole approach for 
selective inhibition of BET bromodomains and utilise it to investigate the functions of 
the different BET proteins, hopefully gaining important biological insights that will also 
have therapeutic implications. 
 The first aim of the project was to optimise the ‘biology’ aspect of the bump-&-
hole system – the mutation. Alternative leucine mutants will be characterised, looking 
at stability, structure and their ‘functionality’ (ability to bind acetylated histone 
peptides / acetylated chromatin). This work will hopefully identify a mutation with 
little-to-no impact on bromodomain function while allowing for selective and potent 
inhibition. 
 The second aim was to optimise the ‘chemistry’ aspect of the system – the 
bumped compounds. The impacts of new chemical modifications, and the quality of 
resulting compounds, will be evaluated with regard to selectivity, potency and DMPK 
characteristics. Bromodomain:ligand co-crystal structures will be solved to rationalise 
observed SAR trends. The best compound(s) will be selected based on desirable 
criteria: the best compounds should possess >100-fold selectivity for the mutants, high 
potency (ideally 100 nM) and strong DMPK qualities (stability and cell permeability). 
Another way to improve upon the chemistry of the initial system is to develop a means 
to separate the active and inactive enantiomers of the best compounds, instead of 
using the racemic mixture as in the previous publication [159]. Finally, a selection of 
protein panels will be used to screen for off-targets. This will focus on non-BET 
bromodomains but will also check for unexpected, unrelated off-targets across other 
druggable protein families e.g. G-protein-coupled receptors (GPCRs) that would impact 
the usability of our compounds. 
 Following the system’s optimisation, the next aim will be to validate it in cells. 
Cellular assays will be developed and optimised to confirm the ability of bumped 
compounds to inhibit mutant BET proteins without effecting WT BET proteins or, 
through off-target activity, altering the phenotype of WT cell-lines. 
 As a final aim, the optimised bump-&-hole system will then be utilised to 
answer biological questions concerning the BET proteins/bromodomains. Following on 
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from previous experiments [159], the optimised system will be used in cellular assays 
such as FRAP to compare the relative importance to chromatin binding for each BET 
proteins BD1 and BD2. More advanced biological investigations will likely require the 
development of genome editing approaches to generate mutant cell-lines. These cell-
lines could be engineered to express mutant BET proteins at endogenous levels in 
place of the WT, without the need for transient overexpression of exogenous mutant 
proteins and concomitant knock-down of WT endogenous proteins.  
 
The aims & objectives may be summarised as: 
1 – Optimise biology 
 Characterise alternate mutation  
 Mutant stability 
 Mutant structure 
 Mutant functionality 
2 – Optimise chemistry 
 Evaluate new modifications/compounds, based on selectivity, potency 
& DMPK 
 Triage and select best compound(s) 
 Separate and characterise enantiomers 
 Solve co-crystal structures with new mutant bound to bumped 
compounds 
 Screen for off-targets 
3 – Validate system 
 Assess mutant functionality in cells 
 Measure compound efficacy/selectivity in cells 
 Check bumped compounds for impact on WT cells 
4 – Use optimised system to answer biological questions 
 Compare importance of BD1s and BD2s to each BET protein’s function 
 Develop cell-lines incorporating new mutation 


































2.1 – Introduction: 
The first iteration of the BET bump-&-hole approach utilised a leucine/alanine 
mutation, which allowed for strong selectivity by bumped compounds while retaining 
stability and the ability to bind acetylated histone peptides [159]. A deeper 
examination, however, raised concerns that introduction of an L/A mutation on BET 
proteins might impact on their cellular functions. This could compromise the viability 
of mutant cell-lines and render any obtained results less relevant to WT biology. In 
response alternate leucine mutations were trialled, with the aim of finding a mutation 
with minimal impact on protein function while allowing for selective inhibition by 
bumped compounds. 
 Two other leucine mutants have been trialled in the bump-&-hole system, but 
ultimately were not investigated to the same extent as the L/A mutation (figure S2.1). 
In an attempt to boost selectivity through generating a larger ’hole’ a leucine/glycine 
mutation was trialled early on. Although the bromodomain was not destabilised its 
functionality was greatly affected, and in isothermal titration calorimetry (ITC) 
experiments it showed no sign of binding an acetylated H4 peptide. A 
leucine/isoleucine mutation met with more success, with early peptide ITC 
experiments suggesting very strong functionality. Despite having the same mass as 
leucine, the isoleucine residue did seem to create some sort of ‘hole’ allowing for 
selective inhibition. Unfortunately, obtaining high selectivity proved difficult, with ET 
showing only ~10-fold selectivity.  
With the L/A mutation proving too disruptive and L/I hindering efforts to 
achieve selectivity a leucine/valine mutation was selected as the obvious next step 
(figure 2.1). Valine remains chemically similar to the original leucine residue: 
hydrophobic, non-polar, uncharged and lacking carbon cycles. Valine retains the 
branch at the end of its side-chain and is situated between leucine and alanine in 
terms of size. As such L/V mutations were introduced into BET constructs which were 
then purified for a thorough characterisation to investigate the impact of the mutation 




Figure 2.1. Amino-acid side-chain comparison. 
Comparison of WT leucine and alternate residues. Comparison of side-chain structure and mass 
(excluding Cα), selectivity of bumped compounds for mutant and ability of mutant bromodomains to 

















2.2 – Bromodomain Mutation & Purification: 
L/V mutant constructs were created by site-directed mutagenesis of previously 
cloned WT-encoding plasmids (residue numbering in figure S2.2). pNIC28 plasmids, for 
single-bromodomain purification, and pcDNA5 plasmids, encoding GFP-BRD4 for 
cellular experiments were mutated by Dr Kwok-Ho Chan. pcDNA5 GFP-BRD3 plasmids 
were mutated by Lars van Beurden. pcDNA5 GFP-BRD2 and pcDNA6 GFP-BRDT 
plasmids were mutated by myself. Mutagenesis was straightforward, although LV/LV 
double-mutant GFP-BET plasmids could not be created through a single, double-
mutation protocol, and instead through 2 rounds of mutagenesis. 
Single bromodomain constructs, used for the bulk of in vitro work, were 
expressed in E. coli BL21 (DE3) cells and purified by Ni+ column and then size exclusion 
chromatography. This protocol was developed in the lab, as described in Baud et al. 
[159] and was utilised for this project by several researchers. Final protein samples 
were consistently of high purity (figure S2.3) and gave final yields from ~2 mg/ml 
(BRDT BD2 and BRD3 BD1) to ~20 mg/ml (BRD2 BD2 and BRD4 BD2). Helpfully, this 
purification could be carried out at room temperature with no issues, an early 

















2.3 – Stability of Mutant BET Bromodomains: 
To confirm that the L/V mutation did not destabilise the BET bromodomains 
differential scanning fluorimetry (DSF) was performed.  DSF is used to measure the 
‘melting temperature’ (Tm) of proteins through the use of the SYPRO orange dye. As 
proteins are heated and begin to denature this dye interacts with newly exposed 
hydrophobic regions, where it is protected from the quenching effects of water and its 
quantum yield greatly increases. By incubating proteins with SYPRO orange and 
heating them step-by-step while measuring fluorescence a sigmoid curve is generated 
and its inflection point used to calculate the Tm. These experiments showed that the 
L/V mutation did not greatly affect the stability of any BET bromodomains (figure 2.2), 
with melting temperatures dropping by only 1-3°C (broadly consistent with the impact 
of the previous L/A mutation). 
 
Figure 2.2. Thermal stability of BET bromodomain mutants. 
A) Differential Scanning Fluorimetry (DSF)-derived melting points of WT, L/V and L/A BET single-
bromodomain constructs. Mean and standard error of three technical replicates. B) Normalised 




2.4 – Effect of L/V Mutation on Histone Peptide Binding (ITC): 
Moving on from structural stability, the ‘functionality’ of the BET bromodomain 
mutants was assessed. To this end we investigated the impact of the L/V mutation on 
the recognition and binding of acetylated histone peptides. These acetylated histone 
peptides act as binding epitope models for acetylated chromatin, which the mutant 
BET proteins must be able to recognise and bind to in order to drive downstream gene 
expression. Bromodomain binding to purified, acetylated nucleosomes would 
represent a biophysical model more closely representative of the endogenous 
biological system, and is described in the literature [34]. The use of acetylated 
nucleosomes would require either the purification of nucleosomes from human cells, 
which is a material-intensive process, and can create difficulties in obtaining 
nucleosomes with specific PTMs [160]. Alternatively, nucleosomes can be produced 
from the assembly of modified histone monomers, but this is also very time and 
material-consuming and has a low throughput [161]. Due to these practical limitations 
nucleosome-based assays were deprioritised in place of easily obtained synthetic 
acetylated histone peptides.  
ITC [162] was used to quantitatively assess the effect of the L/V mutation on 
the affinity of BET bromodomains for di- and tetra-acetylated H4 histone peptides: H4 
K(5,8)ac and H4 K(5,8,12,16)ac (commonly used in the literature as BET bromodomain 
substrates [32]). Titrations of peptides against WT and L/V bromodomains showed a 
~2-fold decrease in affinity (largest increase 2.4-fold, smallest 1.2-fold) (table 2.1). This 
effect is small and close to experimental errors but was also fairly consistent. This 
marks a clear improvement over the L/A mutants, which previously showed up to 10-
fold decreases in affinity [159]. To confirm this improved functionality, H4 
K(5,8,12,16)ac was titrated against BRD2 BD1 and BRD4 BD1 L/A, and showed much 
weaker binding and Kd values ~10-fold higher than against WT (figure 2.3A). The 
impact of the L/V mutation on binding affinity did not seem to change significantly 
between peptides (p = 0.3) or between BD1s and BD2s (p = 0.7). Our acetylated 





Table 2.1. Effect of L/V mutation on BET bromodomain binding to acetylated H4 peptides. 
Results of ITC titrations of di- and tetra-acetylated H4 peptides against WT and L/V BET bromodomains 
constructs.  For some weak interactions N was fixed to 1.0. 
 
In addition to measure binding affinity, ITC also allows for analysis of the 
thermodynamic parameters of an interaction – enthalpy (ΔH), entropy (TΔS) and Gibbs 
free-energy (ΔG). The L/V mutation did not substantially alter these values for any 
bromodomain:peptide interactions, suggesting that the binding mode of these 
interactions has not been changed (i.e. from principally hydrogen bond-mediated to 
hydrophobically driven). Additionally the titrations of peptides against L/A 
bromodomains shows much greater changes in the thermodynamic parameters, 






Figure 2.3. The impact of L/V and L/A mutations on BET bromodomain binding to acetylated H4 
peptides.  



















2.5. – Effect of L/V Mutation on Histone Peptide Binding (BLI): 
 Our peptide ITC titrations gave powerful insights into how the L/V mutation 
affected a few select BE:peptide interactions. The ITC work, however, did not cover 
many different acetylation marks or combinations thereof, and ITC has too low a 
throughput to study a large library of acetylated histone peptides. Without studying a 
larger number of Kac-combinations it cannot be determined if the L/V mutation has 
altered the specificity of the BET bromodomains (i.e. which Kac marks/combination 
they do and do not recognise). To determine this, a library of histone peptides, bearing 
many combinations of Kac modifications, was next purchased and screened against WT 
and L/V bromodomains through bio-layer interferometry (BLI) [163]. This gave a single-
dose response for each peptide against each bromodomain, and normalising these 
responses for each construct gave a number of binding profiles to compare (figure 
2.4). All WT bromodomains, and their L/V mutants, show a marked preference for a 
selection of poly-acetylated H4 peptides such as H4 K(5,8)ac, H4 K(5,8,12,16)ac and H4 
K(5,8,12,16)ac, consistent with previous investigations showing the di-acetylation of 
lysines 5 and 8 to be optimal for BET bromodomain binding [32]. A visual comparison 
shows that the L/V mutation has had little impact on the binding profiles of our 
bromodomains, with several of the BD1s showing almost identical binding profiles with 
WT and L/V constructs. 
 The L/V mutation is shown to be less disruptive than the L/A mutation when 
compared to WT. The L/A mutation in the binding profiles from [159] shows a much 
more severe impact, often resulting in more promiscuous binding to di- and tri-
acetylated H4 peptides. For a direct comparison BRD4 BD1 L/A was re-tested alongside 
its WT and L/V counterparts, confirming the supremacy of the L/V mutation (figure 
2.5). Non H4 peptides showed significantly weaker responses, and again little 
difference between WT and L/V constructs (figure S2.4). Some example curves for the 




Figure 2.4. The effect of the L/V mutation on binding profiles of BET bromodomains. 
Binding profiles of WT and L/V BET bromodomains for acetylated H4 peptides, derived from BLI screen. 
Responses normalised to strongest response of each construct, and colour-coded. Red ‘K’ in sequence 
denotes lysine acetylation. 
 
 
Figure 2.5. BRD4 BD1 histone peptide binding profiles. 
Binding profiles of WT, L/V and L/A BRD4 BD1 constructs for acetylated H4 peptides, derived from BLI 
screen. Responses normalised to strongest response of each construct, and colour-coded. Red ‘K’ in 








2.6 – Structural Impacts of BET Bromodomain Mutation: 
In an effort to rationalise the differing impacts of the L/V and L/A mutation on 
histone binding the X-ray crystal structure of BRD2 BD2 L/V apo was solved by Dr 
Kwok-Ho Chan, and compared to the previously solved WT apo structure (figure 2.6). 
Both mutants retain the broad, overall structure, and when aligned (in PyMol) with the 
WT structure the L/V mutant generated RMSD values of 0.15 Å and 0.73 Å (with and 
without outlier rejection), while the L/A mutant gives 0.31 Å and 1.43 Å. Close analysis 
of the binding pocket shows the L/V mutant to perfectly mirror the WT structure, while 
the L/A mutant shows a noticeable re-orientation of the ZA loop upon which the 
mutated alanine resides. The L/V apo structure was also compared to previously 
solved structures of WT BRD2 BD2 bound to two peptides bearing acetylated lysine 
marks. As expected, the L/V structure aligns extremely well with the WT bromodomain 
bound to a histone peptide, and similarly well to the WT bromodomain bound to a 
potential non-histone binding partner (Stat3 K(87)ac [112]). Although these promising 
alignments cannot tell us that the L/V mutant will show high functionality they do 
suggest that there are no major concerns. 
Comparing the apo crystal structures may also shed light on the reduced 
functionality of the L/A mutant. The ZA-loop re-orientation to a ‘closed’ state seen in 
the L/A mutant may be an attempt to ‘plug’ the void created by the mutation (figure 
2.6), and when bound to ligands this reverts to the WT-style ‘open’ conformation 
(figure S2.6). This suggested a need to re-orient the ZA loop during binding which 
might contribute to the loss in affinity between L/A bromodomains and histone 
peptides. It must be noted that the L/A mutant crystal structure presents an alternate 
space group to those of the WT and L/V bromodomains (C1,2,1 vs P21,21,2) and 
changes to crystal packing around the ZA loop (figure S2.7). With this data it cannot be 
determined whether the alternate conformation presented by the L/A mutant is 
caused by these crystallisation changes or if the unusual conformation has altered how 
the protein crystallises. 
This ‘ZA-loop reorganisation’ hypothesis could be better tested by crystallising 
each BRD2 BD2 construct under similar crystallisation conditions and obtaining 
identical space groups (if possible). A better response may be to use NMR to solve the 




Figure 2.6. Structural comparison of BET bromodomain mutants. 
Alignment of crystal structures of BRD2 BD2 WT (blue) (2DVV), L/V (red) (5O38) and L/A (green) (4QEU). 
BRD2 BD2 L/V also aligned with crystal structure of BRD2 BD2 WT bound to 15-mer H4 K(5,12)ac peptide 
(2E3K) and NMR structure of BRD2 BD2 WT bound to 12-mer Stat3 K(87)ac peptide (5U5S). Key 










2.7 – Assessing Cellular Function of Mutant BET Proteins with FRAP: 
Thus far our characterisation of the L/V mutants is restricted to single-
bromodomain constructs and histone peptides, which cannot fully replicate the 
interactions between full-length BET proteins and chromatin in cells. To monitor the 
functionality of mutant BET proteins within living cells we utilised a fluorescence 
recovery after photobleaching (FRAP) assay, which monitors the interaction of full-
length, nuclear-localised BET proteins (GFP-tagged) with chromatin [164]. In a FRAP 
assay U2OS cells are transfected to transiently overexpress GFP-BET proteins, creating 
brightly fluorescent nuclei. An area of a fluorescent nucleus is then bleached by a laser, 
and the random movement of GFP-BET proteins (in and out of the bleached spot) leads 
to a recovery of the fluorescence (figure S2.8) [165]. If the GFP-BET proteins are bound 
to (the largely immobile) chromatin the rate of exchange (of bleached protein out of 
the spot and unbleached protein into the spot) will be reduced and the recovery will 
be rather slow. The presence of mutations, small-molecules that inhibit chromatin 
binding and displace the GFP-BET proteins will increase the rate of exchange and 
hasten this recovery, resulting in a reduction of the measured recovery time (t½) 
(figure S2.9) [164, 165]. This technique, and later assays using GFP-BET constructs, use 
the long isoform of BRD4. 
In our assay WT BRD4, BRD3 and BRD2 gave recovery times of 3.5 – 4s, with 
BRDT presenting recovery times of ~1.5s (figure 2.7). To show the recovery rate for a 
protein completely unable to bind chromatin, and that its recovery is limited only by 
diffusion, GFP alone was tested in the assay – giving an average recovery time of 0.4s. 
All double LV/LV mutants showed statistically significant reductions in t½, suggesting 
weaker chromatin binding. However these decreases were fairly minor, in contrast to 
the LA/LA mutant of BRD4 which showed a much more severe reduction in recovery 
time (figure 2.8). Single L/V mutants (LV/WT or WT/LV) showed less noticeable 
changes in recovery time, with most not being statistically significant. Thus, with 
regard to BET protein:chromatin interactions the L/V mutation has a minor impact on 




Figure 2.7. BET proteins & chromatin binding. 
Recovery times of GFP-labelled BET protein constructs following 0.5s laser bleach event, at 2 µM SAHA 
and 0.03% DMSO. Each bar is mean ± SE of ~40 U2OS cells tested over two separate experiments. 





Figure 2.8. FRAP recovery of BRD4 constructs. 
A) Normalised fluorescence recovery of GFP-BRD4 (L) constructs (or GFP) transiently overexpressed in 
U2OS cells, with 0.03% DMSO and 2 µM SAHA, following 0.5s laser bleach event. Each data point is 
mean ± SEM of ~40 cells from two independent experiments. Data points after 30s omitted for clarity. 
B) Nuclei of cells from A. Cells shown are representative of their population. Bleach spot highlighted 








2.8 – Assessing Cellular Function of Mutant BET Proteins with a Luciferase Assay: 
 BET proteins do not exist solely to bind chromatin, but instead to regulate the 
expression of downstream genes. To assess this function a luciferase reporter assay 
was developed, inspired by [95], measuring the ability of over-expressed GFP-tagged 
BET proteins to induce the expression of a luciferase enzyme regulated by a NF-B 
response element (NF-B-RE). This NF-B-RE luciferase can be used as a reporter of 
BET protein functionality due to the observation [95] that BRD4 interacts with NF-B to 
up-regulate its target genes. In this assay HEK293T cells are transfected with both a 
plasmid for overexpressing GFP-BET constructs (or GFP as a control) and the reporter 
plasmid dependent on NF-B signalling (figure 2.9A). The impact of NF-B activity on 
the luciferase is maximised by the combination of a low-activity promoter with 5 NF-
B response elements. Additionally, the Kozak sequence (nucleotides at the translation 
start site) of the gene is designed to maximise the translation of any transcribed mRNA 
and a PEST sequence reduces the half-life of the resulting luciferase, lowering overall 
signal but increasing how responsive the reporter is to varying NF-B levels.  
 In this assay, WT BET proteins showed a clear 2.5 to 6-fold increase in luciferase 
expression compared to GFP alone and, as expected, this increase is maintained by the 
L/V mutants (again with some small but statically significant differences) (figure 2.9B). 
The LA/LA mutant of BRD4 was not able to maintain this increased transcription, giving 
luminescence values barely above the GFP control. This shows that, as the L/V 
bromodomains retain their ability to bind acetylated histone tails and chromatin, the 
L/V BET proteins can still be used to recruit complexes to specific downstream genes 






Figure 2.9. BET proteins and NF-B-mediated luciferase expression. 
A) Diagram of key components of NF-B-RE / Luciferase plasmid. B) Luminescence of HEK293T cells 
transfected with GFP-labelled BET proteins and a NF-B-RE/luc2P reporter plasmid. Luminescence 
normalised to GFP control. Statistical significance (related to WT/WT) determined with two-tailed t 









2.9 – Discussion:  
For the cellular FRAP assay, GFP alone was chosen as a non-binding control to 
give context to the reductions in t½ caused by mutations, and later, the addition of 
inhibitors. Even a protein that lacks any interaction with chromatin will present a low 
but non-zero t½, as its movement will be limited by diffusion and hence its 
fluorescence recovery will not be instant. Alternatively, BD1/2-deletion BET proteins or 
inactive N/F mutants could have been used as controls. Their t½ values may be a 
better representation of BET proteins completely displaced by mutations or 
compounds, as they would be roughly the same size and would contain other domains 
(i.e. ETD) that may contribute recovery time. On the other hand, this would have 
required an investment of time and resources into mutagenesis and would require a 
different control be used for each BET protein tested. GFP does not contain a nuclear 
localisation signal, but due to its small size GFP monomers and dimers are often 
present in the nucleus [166], which for many of our cells could be visually identified 
(figure S2.10) and bleached. 
Despite giving similar Kd values in the peptide ITC experiments BRDT showed 
much weaker chromatin binding in the FRAP assay (t½ of 1.5 s compared to ~4 s). 
Without further data this should likely not be taken as evidence that BRDT is in fact 
any worse at chromatin binding than the other BET proteins. As the different BET 
proteins likely prefer different epigenetic marks it may be that BRDT, a testes-specific 
protein [167], does not bind strongly to the epigenetic marks presented in the SAHA-
treated U2OS cells (epithelial cells from an osteosarcoma) used in FRAP.  
In our FRAP assay BRD2 showed a much more severe response to the L/V 
mutation, with the LV/LV construct giving a t½ of 2s. Both the ITC and BLI data with 
histone peptides do not show BRD2 to be any more affected by the L/V mutation. This 
could be an indicator that ITC assays with peptides are not a reliable indicator of 
interactions between full-length proteins and chromatin. BET protein:chromatin 
interactions are complicated by numerous factors that do not contribute to BD:peptide 
binding. Nucleosomes, with the presence of 8 globular domains and 8 histone tails, as 
well as associated DNA, may generate a large number of steric clashes that alter 
binding. Again, the presence of multiple histone tails, and the presence of 2 BDs in a 
BET protein, creates opportunity for multivalent interactions. Finally, there are the 
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previously mentioned possibilities that BET proteins may interact with DNA [34] or 
even interact with chromatin indirectly through ETD-recruited NHPs. The recovery time 
of BRD2 might not be dependent on interactions with the H4 histone tail, but instead 
other histones or chromatin-bound proteins which we have not tested in ITC and 
hence could be impacted more by the L/V mutation.  
The unusually severe impact of the L/V mutation on BRD2 in the FRAP assay is 
most likely an artefact of said FRAP assay. In the cellular luciferase assay the LV/LV 
BRD2 construct did not show such a severe impact, and was much more consistent 
with the BLI and ITC data. Additionally given the conserved nature of the BET BDs it 
would be surprising if one protein were to be affected so much more severely than the 
others. Finally, subsequent FRAP work (discussed later) generated unusual results with 
GFP-BRD2. Specifically, when both the BD1 and BD2 of GFP-BRD2 were inhibited the 
construct was shown to aggregate (or undergo a significant change in localisation) 
which complicated the acquisition of t½ values. The low t½ values of uninhibited LV/LV 
GFP-BRD2 are likely connected to this phenomenon, and are not an accurate indicator 
of the construct’s ability to bind chromatin.  
 
2.10 – Conclusion: 
 Through extensive characterisation of the L/V mutation: covering stability, in 
vitro peptide binding, crystal structures and cellular function we have consistently seen 
the L/V mutation to be very conservative and a clear improvement over the L/A 
mutation, rendering a functionally silent mutant behaving as closely as reasonably 
required to wild-type. L/V BET bromodomains are stable, bind acetylated histone 
peptides both with high affinity and similar binding profiles (to WT) and show no 
marked conformational changes; while full-length L/V BET proteins recognise and bind 
chromatin almost as well as WT and can translate this into increased expression of 
downstream genes. The L/V mutation is not perfect, and produces a small but 
consistent impact on functionality. However, in all cases (except interestingly stability) 
the L/V mutation is a clear improvement on the previously used L/A mutation, which 
our cellular experiments show would not function properly in cell or animal models. 
Once implemented into cells we expect the L/V mutation to be viable and allow for 






















Chapter 3  










3.1 – Introduction 
 With the new and more functional L/V mutation characterised and validated 
we decided to shift attention to the chemical aspect of the bump-&-hole system. 
Specifically, the ‘bump’ and other modifications used, as well as the selectivity, 
potency and DMPK qualities of the final compound had scope for optimisation at this 
stage of the project. By moving to a more conservative mutation existing bumped 
compounds will display different SAR, with a smaller mutation potentially hindering 
selectivity. By trialling a greater range of chemical modifications it was hoped that, 
despite the ‘more difficult’ mutation, bumped compounds could be developed with 
selectivity greater than that observed with the ET compound in the old L/A mutant 
bump-&-hole system. 
 
3.2 – Bumped Compound Rational & Synthesis 
 To optimise the chemical aspect of the bump-&-hole system we trialled a range 
of modifications to three parts of our scaffold (scheme 3.1 & 3.2) (scheme S3.1). While 
the original bump-&-hole research tested only the methyl and ethyl bumps the longer 
propyl bump was trialled too. Additionally an allyl bump was tested, to observe the 
importance of the bump’s degree of rotational freedom. The wealth of BET inhibitor 
SAR in the literature contains several simple modifications that reduce the WT potency 
of the I-BET762 scaffold, and it was thought that these might be ways of generating 
selectivity. Moving the methoxy-group from the 8’ to the 9’ position is one such 
modification [78], which creates a steric clash that we hypothesise could be better 
accommodated by the mutated binding site. This modification was also expected to 
not alter our compounds’ DMPK properties. Our original compounds feature a methyl-
ester ‘side-group’ adjacent to the alkyl bump, which we decided to replace for two 
reasons. The residual WT binding displayed by early compounds is likely the result of 
the flexible methyl-ester side-group rotating and re-orienting in ways that relieve the 
key steric clash. This hypothesis is supported by co-crystal structures of bumped 
compounds bound to L/A bromodomains and I-BET762 bound to WT, which showed 
significant movement of the side-group [159]. To ‘lock’ the side-group in place we 
introduced a polar ethyl-amide side-group, as in I-BET762, which we expected to form 
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a hydrogen bond with the side-chain of N140. We also tried a tert-butyl-ester side-
group, based on (+)-JQ1, which may form favourable hydrophobic interactions and 
may display limited flexibility due to its bulky nature. These alternate side-groups were 
also expected to fine-tune the DMPK properties of our compounds.  
 
 
Scheme 3.1. Rational for bumped compound optimisation. 
Chemical structure of scaffold, with modification sites highlighted. 
 
Compounds were synthesised by Dr Michael Zengerle and Dr Matthias Baud, 
the details of which are published [122, 159, 168]. As carbons 2 (when bumped) and 3 
form chiral centres this synthesis produced a mixture of 4 isomers (scheme S3.2). 
Previous analysis of co-crystal structures showed that only the 2R,3S enantiomer can 
bind BET bromodomains [159]. The inactive 2S,3S and 2R,3R diastereomers were 
removed through reverse-phase HPLC, but the active 2R,3S and inactive 2S,3R 
enantiomers were not separated at this stage, and unless stated otherwise they were 
tested as a racemic mixture. As such, ligand concentrations, IC50 values and related 





Scheme 3.2. Bumped compound modifications. 
Chemical structure of scaffold compound (A), alkyl bumps (B), methoxy-shift modification (C) and 

















3.3 – Development of AlphaLISA Assay 
 In the early stages of the bump-&-hole project compounds were tested through 
ITC and the thermal shift assay [169]. ITC is very powerful and reliable, but is not 
suitable for testing a large number of interactions, while the project necessitated 
testing >20 compounds against 16 proteins (8 BET bromodomains, WT and L/V). The 
thermal shift assay does possess reasonably high throughput, but is not very reliable 
nor is quantitative. The thermal shift assay measures the change in protein stability 
upon ligand binding (ΔTm values). While the size of the observed ΔTm is often seen to 
be related to binding strength, it cannot be directly correlated to Kd or IC50 values. 
Hence it was decided to develop a high-throughput, quantitative assay in a 384-well 
format that could be used to titrate all bumped compounds against all WT and L/V 
bromodomains.  
 Following a review of the literature, it was decided to develop an AlphaLISA 
assay, wherein a biotinylated histone peptide is displaced from a his-tagged 
bromodomain. The assay signal is generated by a pair of AlphaLISA beads, with donor 
beads binding to the peptide through a streptavidin group and acceptor beads binds 
the bromodomain through an anti-His6 antibody. During the assay the donor beads, 
when excited by light at 680 nm, produce singlet oxygen which triggers emission of 
light at 615 nm from the acceptor beads, provided they are within 200 nm. This 
condition is satisfied when the peptide is interacting with the bromodomain [170].   
 Titrations of biotinylated, di-acetylated H4 K(5,8)ac peptides against WT and 
L/V BET bromodomains showed that concentrations of 200 nM bromodomains and 
200 nM peptide would generate the strongest signal (figure 3.1A). These experiments 
also showed similar affinity for WT and L/V bromodomains, suggesting WT and L/V IC50 
values could be reliably compared (table S3.1). Despite early successes (figure 3.1B), 
when the screening began the results were very poor and generated unusable dose-
response curves (figure 3.1C). This suggested that the assay was not as robust as 
believed, and may only generate usable results when performed in a low-throughput 
capacity with the use of very exact concentrations, timings or handling procedures. 
Further investigations revealed that, although removing the peptide probe reduced 
the signal ~70-fold, removing the bromodomain had little impact on signal (figure 
3.1D-E). This explained why even large concentrations of potent inhibitors had little 
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impact on assay signal, and suggested that the biotinylated peptides were generating 
Alpha signal independent of any bromodomain binding. Titrations of biotinylated 
peptides against AlphaLISA beads in the absence of bromodomain generated sigmoid 
curves with EC50 values of ~20 nM (figure 3.1F), showing that the biotinylated peptides 
were somehow interacting directly with the acceptor beads or their anti-his6 
antibodies. Increasing bovine serum albumin (BSA) concentrations, and the 
introduction of Tween-20 and Triton-x100 reduced these non-specific interactions but 
failed to improve assay quality (figure 3.2A-B). Alternate acceptor beads that bind his-
tags through a Ni-chelator also generated this non-specific signal (figure 3.2C-D). Based 
on these results it was decided that, for an AlphaLISA assay to work, it was not possible 
to use a labelled peptide probe to monitor displacement and labelled small-molecules 
would have to be used instead. 
Following the failure to ‘fix’ the peptide-based AlphaLISA assay it was decided 
to measure instead the displacement of a biotinylated derivative of (+)-JQ1. One 
biotinylated (+)-JQ1, using an aminohexanoic linker, (MZ-70) (figure 3.3A) failed to 
generate any assay signal, presumably as its linker was not long enough to 
accommodate both the bromodomain and streptavidin (figure 3.3C). Later a 3-PEG 
linker was tried, based on the development of Bio-JQ1 by Anders et al. [86], and 
succeeded in generating Alpha signal with bromodomains (but crucially not beads) 
(figure 3.3B-C). Bio-JQ1 was titrated against all BET bromodomains and all showed 
Alpha signal generation. Additionally, Bio-JQ1 bound all WT and L/V BET 
bromodomains with similar affinity, with a ~2-fold decrease in affinity for L/V 
bromodomains compared to their WT equivalents (figure 3.3D-E) (table S3.2). 
Concentrations of 100 nM bromodomain and 5 nM Bio-JQ1 provided high-quality 
dose-response curves with IC50 values close to known Kd values (figure 3.3F). Tests with 
inhibitors showed a ~100-fold assay window and a Z-factor of 0.77 (indicating a high-
quality assay) (figure 3.3G) [171]. Test titrations with ET against WT and L/V BDs gave 
high-quality data in-line with expectations (figure 3.3H) and in additional experiments 
the assay was able to accurately rank BET inhibitors and even detect fragment binding 
(figure S3.1). Following these tests it was decided to proceed with the full compound 





Figure 3.1. Peptide-based AlphaLISA assay. 
A) Titration of biotinylated H4 K(5,8)ac against BRD4 BD1 constructs in AlphaLISA assay. B) Successful 
titration of I-BET762 against BRD4 BD1 in peptide AlphaLISA assay C) Failed titration of I-BET762 against 
BRD4 BD1. D) Signal of AlphaLISA assay in absence/presence of assay components. E) Signal/noise and Z-
factor of peptide AlphaLISA assay. F) Titration of biotinylated, acetylated H4 peptides against AlphaLISA 




Figure 3.2. Attempts to fix peptide-based AlphaLISA assay. 
A) Signal of AlphaLISA assay in presence of BSA. B) Signal of AlphaLISA assay in presence of Tween-20 
and Triton-100. C) Signal of AlphaLISA assay, with Ni-chelator acceptor beads, in absence/presence of 
assay components. D) Titration of biotinylated, acetylated H4 peptide against AlphaLISA beads (with Ni-









Figure 3.3. Development of Bio-JQ1-based AlphaLISA assay. 
Chemical structures of MZ-70 (A) and Bio-JQ1 (B). C) AlphaLISA titration of MZ-70 and Bio-JQ1 against 
BRD2 BD2 WT and Bio-JQ1 against beads alone. D) AlphaLISA titrations of Bio-JQ1 against BRD2 BD2 WT 
and L/V. E) ITC titrations of Bio-JQ1 against BRD4 BD1 WT and L/V. F) AlphaLISA titrations of (+)-JQ1 
against 100 nM BRD2 BD1 WT and varying concentrations of Bio-JQ1. G) Robustness of final Bio-
JQ1/AlphaLISA assay. Positive control = no inhibitor, negative control = 30 µM (+)-JQ1. H) AlphaLISA 






3.4 –Primary AlphaLISA Screen of Bumped Compounds 
 The AlphaLISA screen produced a large amount of SAR data (table 3.1) (figure 
3.4) (table S3.3), showing several clear trends associated with various modifications. 
One immediately noticeable trend is that, overall, our compounds are very successful 
as L/V bromodomain probes. Almost all compounds have L/V potencies below 1 µM 
and selectivity against WT bromodomains of at least 10-fold. Many bumped 
compounds are as potent (or more) against L/V bromodomains as our scaffold and 
established BET inhibitors (+)-JQ1 and I-BET762 are against WT. Meanwhile we are 
able to greatly weaken WT binding, in some cases comparable to the inactive (-)-JQ1 
molecule. This screen showed that the methyl, ethyl and allyl bumps, the methoxy-
shift modification and the methyl-ester and ethyl-amide side-groups were all 
tolerated. Finally, the propyl bump, the di-ethyl-amide and tert-butyl-ester side-groups 
were shown to not be beneficial. 
The alkyl bumps are the main determinant of potency and selectivity. Smaller 
bumps show stronger binding to both WT and L/V bromodomains, with these 
potencies decreasing with larger bumps.  Against L/V bromdodomains, methyl-ester 
compounds with the ethyl and allyl bumps are about as potent as the scaffold, 
suggesting these bumps are not introducing steric clashes. The methyl bump 
meanwhile, shows a clear increase in potency suggesting this small bump essentially 
forms a novel hydrophobic interaction with the valine ‘hole’. Regarding overall 
selectivity, the ethyl bump is optimal, while the long propyl bump is the least effective, 
with <10-fold selectivity and a clear drop in potency. Interestingly, the low potency and 
selectivity of the propyl bump is likely not the result of a steric clash, but instead due 
to its high degree of rotational freedom which must be constrained upon binding. The 
similarly sized allyl bump is much more potent, and its SAR is much more similar to the 
ethyl bump with which it shares the same degree of rotational freedom.  
Shifting the methoxy group from the 8’ position to the 9’ has a clear impact on 
the potency of the scaffold, without altering selectivity. Meanwhile when the methoxy 
group is shifted on bumped compounds it generally maintains potency and selectivity. 
When paired with the large allyl bump or other modifications such as the amide side-
groups the methoxy shift noticeably reduces potency, and it only produces a clear 
increase in L/V selectivity when paired with the methyl bump. Hence the methoxy shift 
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is best paired with more subtle modifications, likely as it is in these conditions where 
the methoxy is best accommodated in the mutant binding site. 
The ethyl-amide side-group, introduced to replace the methyl-ester moiety and 
hopefully ‘lock’ the bump in place, had a clear impact on binding. WT binding was 
greatly weakened, by roughly ~0.7 log units, which is likely due to the desired 
hydrogen bond to N140 preventing bump re-orientation and accommodation within 
the WT binding site. This hydrogen bond did not strengthen L/V binding, as hoped, but 
instead also weakened binding to L/V bromodomains by again ~0.7 log units, resulting 
in broadly similar overall selectivity. Combining the ethyl-amide side-group, ethyl 
bump and 9’ methoxy shift generates 9-ET-Am1, which showed the weakest WT 
binding of all bumped compounds. Meanwhile, the di-ethyl-amide side-group has very 
similar SAR to the ethyl-amide, but it does show slightly reduced selectivity (~1.2 vs 
~1.5 ΔpIC50). 
The tert-butyl ester side-group is perhaps the most deleterious modification 
introduced, with all compounds possessing it showing less than 10-fold selectivity for 
the L/V bromodomains. Combining this with the methoxy-shift modification creates an 
even more severe drop in selectivity. This modification, in most cases, both reduces 
potency against the L/V bromodomains while increasing off-target WT binding. As the 
highly-potent (+)JQ1 features an identical tert-butyl ester this modification is likely not 




Table 3.1.  AlphaLISA primary bumped-compound screen. 
Mean pIC50 values of bumped compounds for all somatic bromodomains. JQ1 possesses a thiophene 
ring and hence has no methoxy group. Refer to scheme 3.1 for positions of Ri and Rii. pIC50 values for 




Figure 3.4. Structure-activity relationships of bumped compounds in AlphaLISA screen.  
A) Mean pIC50 values of compounds for all somatic WT and L/V BET bromodomains. B) Effect of different 
alkyl bumps on scaffold. C) Different side-groups create ‘clusters’ of SAR. Each cluster has 1 structural 











3.5 – Investigation of AL-tBu Binding 
 Although generating a large amount of useful SAR data, the AlphaLISA screen 
did show one significant problem. Previous to this work the bumped compounds had 
been assessed by Dr Michael Zengerle through ITC (table S3.4). This had shown AL-tBu 
to be the best bumped compound – showing no detectable WT binding and an average 
L/V Kd of 320 nM. The AlphaLISA screen instead showed Al-tBu to be one of the worst 
compounds and in fact all four tert-butyl-ester compounds show less than 10-fold 
selectivity for L/V (table 3.1). This discrepancy seems much too severe to blame on 
inter-assay variation so the assessment of bumped compounds was put on hold until 
this issue could be addressed and either dataset could be determined reliable.  
 The divergence between ITC and AlphaLISA results was greatest with regards to 
WT binding (figure 3.5A), suggesting that one possible cause of the disagreement was 
that AL-tBu did show moderate WT binding, but this was obscured in its ITC titrations. 
Further reading revealed that the tBu compounds were too insoluble for the default 
ITC titration and had to undergo a reverse titration of protein injected into compound 
(as opposed to compound into protein). Any change in protocol for a binding assay like 
this will change the threshold at which point weak binding will not be detected, and in 
general such reverse ITC titrations are believed to be less sensitive. To confirm that AL-
tBu’s WT binding was obscured by the change in ITC protocol, compounds that 
possessed similar AlphaLISA WT potency, and measurable WT binding in the default 
ITC protocol, were re-tested in the reverse ITC protocol (figure 3.5B-D). Using the 
reverse ITC protocol this previously-observed moderate WT potency disappeared, 
leaving no detectable binding. This confirmed that the high selectivity displayed by AL-
tBu in the early ITC work was due to poor interpretation of ‘no binding’ results, and 





Figure 3.5. Investigating AL-tBu binding 
A) AlphaLISA and ITC-derived affinity values for bumped compounds and BRD2 BD1 constructs. ET and 
ME-Am1 results from standard compound-into-protein titrations, AL-tBu results from reverse protein-
into-compound titration. B) AlphaLISA titration of AL-tBu against BRD2 BD1 WT and L/V. C-E) ITC reverse 







3.6 – Secondary DMPK triage of Bumped Compounds 
 Determining the best bumped compounds clearly required intensive ITC 
screening of select compounds against all WT and L/V BET bromodomains. To narrow 
down the list of potential compounds, and ensure our best compound would be usable 
in vivo, a secondary triage was carried out focusing on DMPK characteristics. These 
assays were carried out by Dr Ola Epemolu and Dr Lucy Ellis of the Drug Development 
Unit (DDU) (Kevin Read lab) and looked at the stability of compounds, in both plasma 
and liver microsomes, and their apparent intrinsic permeability as measured by the in 
vitro parallel artificial membrane permeability assay (PAMPA) (table 3.2). 
 The stability of our compounds in plasma (recorded as half-life t½) is a strong 
indicator of vulnerability to esterase activity [172]. This has previously been identified 
as a potential threat to compound cellular activity, as cleavage of the methyl-ester 
side-chain to a carboxylic acid leads to a marked reduction in potency and selectivity 
(table 3.1). Both our scaffold compounds were shown to be unstable in plasma, with 
half-lives of ~1 hour, while (+)-JQ1 and I-BET762 which instead possess a tert-butyl 
ester and ethyl-amide side-groups, respectively, show no significant degradation. 
Interestingly, these alternate side-groups were shown not to be necessary to prevent 
breakdown of our bumped compounds, as none of them showed any degradation in 
plasma. Fortunately, the presence of our alkyl bump on the ester-bonds -carbon is 
enough to prevent any significant esterase activity. The esterase reaction relies on 
interactions between enzyme residues and the ester bond’s two oxygen atoms and 
carboxylic carbon atom [173]. As the -carbon is not involved in the reaction 
mechanism it is likely that the alkyl bumps protect the ester bond through sterically 





Table 3.2. Bumped compound secondary DMPK triage 
(+)-JQ1 possessed a thiophene ring and hence has no methoxy group. Refer to scheme 3.1 for positions 
of Ri and Rii. CLogP measured in Stardrop. Controls: proacaine (low plasma half-life), verapamil (high 
intrinsic clearance), atenolol (low permeability) and propranolol (high permeability). 
 
In addition to plasma stability we also looked at stability in the presence of liver 
microsomes, a way of monitoring CYP-mediated metabolism key to in vivo stability 
[172]. In this assay both our scaffolds showed low CLint values which were largely 
unaffected by alkyl bumps, the shifted methoxy group or the ethyl-amide side group. 
As CYP enzyme binding is primarily driven by hydrophobic interactions [174] it was not 
surprising to see increased clearance for compounds with the tert-butyl ester (and to a 
lesser extent the propyl bump). Compounds with the di-ethyl-amide side-group also 
showed excessively high intrinsic clearance, although it is likely that these compound 
are simply being converted to the mono-ethyl-amide side-group [175]. Finally, the allyl 
bump showed some small increases in clearance that did not necessarily disqualify any 
compounds but was recognised as not ideal moving forwards. This effect is probably 
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the result of epoxide formation  [176], a known issue limiting the utilisation of allyl 
groups on drug development. This assay proved very useful in reducing the list of 
candidate compounds for ITC screening, by disqualifying the propyl bump, di-ethyl-
amide side-group and the tert-butyl ester side-group, while highlighting the methyl 
and ethyl bumps, methoxy-shift and methyl-ester/ethyl-amide side-groups.  
 As several compounds had already been disqualified at this stage, the PAMPA 
assay was next carried out on a more select range of compounds. By measuring the 
movement of compounds across an artificial membrane this assay makes for an easy 
and reliable (although not perfect) indicator of passive cell membrane permeability 
[172]. The PAMPA assay’s main limit is that it does not cover active transport into and 
out of cells. The key outcome of this assay was to show that, although all tested 
compounds could be considered to possess high-permeability (>20 nm/s) the presence 
of the original methyl-ester side-group generated very high permeability (127-185 
nm/s) compared to the ethyl-amide side-group (25-59 nm/s), and highlighted these 
compounds as the favourites going into ITC screening. The nature of the bumps and 
position of the methoxy group show little impact on permeability. 
 
3.7 – Tertiary ITC Screen of Bumped Compounds 
Taking together the results of the primary AlphaLISA screen and the secondary 
DMPK triage the following modifications were chosen as the most promising: the 
methyl, ethyl and allyl bumps (with allyl as the least promising), the methoxy group at 
the 8’ or 9’ position, and the methyl-ester and ethyl-amide side-groups (with the 
methyl-ester most promising). This resulted in the following compounds undergoing 
further characterisation: ET, AL, 9-ME, 9-ET, ME-Am1, ET-Am1 and 9-ME-Am1. 
As expected, based on their success in previous SAR tests, all compounds 
excelled in this thorough ITC screening, with L/V affinities close to or exceeding that of 
our un-bumped scaffold (180 nM) and L/V selectivity of >30-fold (table 3.3). Of these 
compounds 9-ME and 9-ET were the clear outliers and their ITC titrations were 
replicated until three consistent Kd values were recorded for each construct (table 
S3.5). This additional testing showed these compounds to possess mean selectivity 
values >100-fold while maintaining potency (figure 3.6). Of the two compounds, 9-ET 
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showed greater overall selectivity, but at the cost of reduced L/V potency. Both 
compounds can be used as highly selective chemical probes, but for the bulk of later 
experiments 9-ME was preferred as it is the more potent compound while showing 
>100-fold selectivity, a slightly better DMPK profile and a lower molecular weight. 
 
 
Table 3.3. Bumped compound tertiary ITC screen 
Results of ITC titrations of bumped compounds against all somatic WT & L/V BET bromodomains. Refer 
to scheme 3.1 for positions of Ri and Rii. Scaffold tested only against BRD4 BD1. 9-ME & 9-ET titrations 
replicated until 3 consistent Kd values observed for each construct. 
 
 
Figure 3.6. Selectivity of 9-ME & 9-ET. 
Chemical structures and selectivity grids of 9-ME & 9-ET. Selectivity grids based on ITC titrations, 
replicated until 3 consistent Kd values were observed for each construct. 
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3.8 – Crystallographic Structural Analysis of Bumped Compounds 
 Throughout the compound evaluation process a number of compounds were 
co-crystallised with BRD2 BD2 L/V and their structures solved to better inform 
observed SAR (figure 3.7). All of these compounds were shown to bind in the same 
basic orientation, with none of the modifications drastically altering binding. Some 
modifications did lead to slight re-organisations of the ligand or nearby protein. These 
structures also confirmed that only the 2R,3S enantiomer is an active inhibitor of the 
BET bromodomains (figure S3.2). Ligand Fo-Fc maps are shown in figure S3.3.  
While the AlphaLISA SAR emphasises the importance of each bump’s rotational 
freedom to L/V potency analysis of co-crystal structures does show that the bump’s 
size alone also plays a role. Moving from smaller to larger bumps the alkyl bump and 
valine ‘hole’ can be seen to interact less intimately, with the measured distance 
between the valine C and the ligand’s C2 (the base of the bump) increasing from 6.8 
Å for ME to 7.2 Å for ET and 7.5 Å for AL (figure 3.7A). This is not surprising, with the 
L/V mutation only ‘removing’ one heavy atom from the binding site and clearly not 
making sufficient room to fully ‘bury’ 2 or 3 carbon chains. 
The co-crystal structures of 9-ME (figure 3.7C) shows that shifting the methoxy 
group to the 9’ position has not visibly altered how the ligand binds the L/V 
bromodomains. While the methoxy group has now been moved towards the binding 
site surface there are no residues it can be seen to clash with. The co-crystal structure 
of 9-ET however, still does not show any clear steric clash, but seems to have slightly 
re-oriented the ligand and the valine-bearing ZA loop. It is possible that the methoxy-
shift only creates a serious steric clash with regard to WT bromodomains, where one 
can see how it would be difficult for a ligand to orient itself such that the alkyl bump 
does not clash with the leucine side-chain, while the 9’ methoxy does not clash with 









Figure 3.7. Analysis of bumped-compound co-crystal structures. 
Comparison of aligned BRD2 BD2 L/V : bumped compound co-crystal structures. BRD2 BD2 L/V in 
complex with (left-to-right, top-to-bottom): ME (5O39), ET (5O3A) and AL (5O3B); AL and AL-tBu (5O3I); 
ME and 9-ME (5O3C); ET and 9-ET (5O3D); ME and ME-Am1 (5O3E); ET and ET-Am1 (5O3F); 9-ME and 9-
ME-Am1 (5O3H). Black dashes denote amide:asparagine hydrogen bonds. Coloured dashes represent 
inter-atom distances of interest. C – alpha atom of valine residue; C2 – carbon #2 in ligand; Cester – 
carbon after ester bond. 
 
The ethyl-amide and di-ethyl-amide side-group modifications were introduced 
with the aim of restricting the movement of the alkyl bump through hydrogen bonding 
to a conserved asparagine. The co-crystal structures of ME-Am1, ET-Am1 and 9-ME-
Am1 all show this hydrogen bond (to N429 in this case) to be present (figure 3.7D). For 
ME-Am1 and 9-ME-Am1 this hydrogen bond has not altered the orientation of the 
alkyl bump or surrounding protein. ET-Am1, however, shows some disruption to the 
rest of the compound and the ZA loop around the mutated valine, which may be 
connected to its reduced L/V potency. The large drop in WT potency observed by all 
amide compounds can be seen to be the product of these hydrogen bonds, preventing 
the bump and flexible methyl-ester from moving into more WT-favourable 
orientations. Unfortunately our SAR also shows similar reductions in L/V potency (for 
some compounds) – leaving similar overall selectivity – which may be due to the 
entropic penalty associated with ligand:protein hydrogen bonding. This impact is most 
severe with ET-Am1, where our structures also show the amide group has disturbed 
much of the binding site. 
Comparing the co-crystal structures of AL and AL-tBu gives insights into the 
poor performance of the tert-butyl-ester compounds (figure 3.7B). The tert-butyl 
group appears to be clashing sterically with L381, with the distance between the L381 
C and the Cester (carbon atom following the ester bond) changing from 4.8 Å with AL 
to 5.9 Å with AL-tBu. This clash is likely the main cause of the drop in potency 
observed, although the high-potency of (+)-JQ1 suggests this occurs only when paired 





3.9 – Separation and Evaluation of Enantiomers 
As discussed previously, our compounds are synthesised as a mixture of four 
isomers with the carbons in positions 2 and 3 forming chiral centres. The inactive 
2R,3R / 2S,3S diastereoisomer was removed by reverse-phase HPLC, leaving the active 
2R,3S and inactive 2S,3R enantiomers. Due to practical issues with separating these 
enantiomers, compounds were tested as racemic mixtures, through the described 
screening, using just the concentration of the active form. Following discussions with 
Reach Separations Ltd (a company specialising in analytical and preparative 
supercritical fluid chromatography SFC) it was decided to send in samples of 9-ME and 
9-ET for separation. Separated enantiomers would then be assayed to confirm our 
active/inactive hypothesis, inform to what extent using the racemic mixture was still 
advisable, and test if using the purified active enantiomer would bring any benefits.  
9-ME and 9-ET were re-synthesised in bulk by Dr Andrea Testa and sent to 
Reach Separations Ltd. Racemate powder was solubilised in ethanol at 20 mg/ml, and 
then purified by HPLC on a Lux A1 column (21.2 mm x 250 mm, 5 µm). Samples were 
injected at a volume of 1 ml with 4:6 HEPT:EtOH (0.1% v/v NH3) and ran at a flow rate 
of 21 ml/min. This protocol gave recovery rates of ~50% (25% for each enantiomer 
(Table 3.4.).  Compounds could be separated into two clear peaks of high purity (figure 
S3.4.), for testing by AlphaLISA and ITC. For the purposes of these assays ligand 
concentrations refer to total compound and not just the active enantiomer, for 
example 100 nM racemate means 50 nM each of the 2 enantiomers. 
 
Table 3.4. Separation of bumped-compound enantiomers 
Data from Reach Separations Ltd. 
Separated 9-ME and 9-ET enantiomers were tested first in the AlphaLISA assay, 
against BRD4 BD1 WT and L/V (figure 3.8A,C). For both compounds the first peak (9-
ME-1 and 9-ET-1) showed as both more potent and selective than the racemic mixture, 
while the second peak (9-ME-2 and 9-ET-2) was the least potent and L/V-selective. This 
Compound














9-ME 42 96 11 98 9 97
9-ET 15 95 5 100 4 97
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strongly suggested that the first peak was the active 2R,3S enantiomer and the second 
peak the inactive 2S,3R enantiomer, but it was decided to use ITC to fully confirm this.  
ITC titrations of the 9-ME and 9-ET enantiomers (again against BRD4 BD1 WT and L/V) 
confirm that the first peak is the active enantiomer, with high-affinity interactions with 
N values close to 1, and that the second peak is inactive, with no measurable binding 
even to the L/V bromodomain (figure 3.8B,D). The racemic mixture then shows less 
potent binding and with elevated N values – suggesting only half of the mixture is 
active.  
 
Figure 3.8. Identification of active/inactive enantiomers 
Purified 9-ME enantiomers, and racemic mixture thereof, titrated against BRD4 BD1 L/V in AlphaLISA 





Following the identification of the active 2R,3S 9-ME enantiomer (hereafter 
named 9-ME-1) this compound was titrated against all WT and L/V BET bromodomains 
in ITC, to determine the new potency and selectivity values (figure S3.5). This testing 
showed 9-ME-1 to be, on average, slightly more potent and selective than 9-ME. This 
improvement was not universal however, with a slight increase in potency for WT 
BRD3 BD1 and BD2 and a corresponding decrease in selectivity against these 
bromodomains.  
Based on this ITC data, alongside our AlphaLISA SAR and DMPK investigations, 
9-ME-1 was selected as the preferred bumped compound for selective inhibition of L/V 
bromodomains. Starting with our scaffold compound, with no selectivity, ~150 nM 
affinity and excellent DMPK properties (with the exception of esterase vulnerability) 
we have progressed to a compound with ~200 nM affinity, ~200-fold selectivity and 








Figure 3.9. 9-ME-1 as an L/V-selective bumped BET inhibitor 
A) Chemical structure of 9-ME-1. B) Co-crystal structure of 9-ME-1 bound to BRD2 BD2 L/V, with key 
residues highlighted. C) SAR of scaffold, 9-ME and 9-ME-1. 9-ME-1 AlphaLISA data and scaffold data 
from BRD4 BD1 only, other data is mean ±SE of titrations against all somatic BET bromodomains. D) 













3.10 – Screening for Off-Targets 
 Throughout our compound evaluation we focused on the selectivity of our 
compounds for L/V BET bromodomains over their WT counterparts. This approach did 
not take into consideration the possibility of off-target binding to other 
bromodomains, or completely unrelated proteins. Off-target screening of other related 
BET-inhibitor scaffolds [76, 99, 115] suggest our scaffold should show little binding to 
non-BET bromodomains, and presumably the presence of our bumps should minimize 
this even more. Despite this, it was decided to confirm these assumptions thoroughly, 
and to check for binding to completely unrelated proteins, which has been shown by 
other BET inhibitors [76]. To do this 9-ME-1 was screened against three commercial 
protein panels: 1) DiscoverRX’s BROMOscan panel of 32 (of 56) human bromodomains, 
2) the MRC ICKP’s express screen of 50 kinases and 3) CEREP’s ExpresS Profile of 55 
receptors, ion channels and transporters.  
 As a positive control for the BROMOscan assay we first had our scaffold titrated 
against BRD4 BD1 WT (figure 3.10A), which produced a Kd value of 15 nM – 10-fold 
lower than the equivalent values from ITC (150 nM) and AlphaLISA (140 nM) (figure 
3.10B). This increased sensitivity in BROMOscan assays has been observed previously 
and theorised to be due to differences in construct design and assay format [99, 121]. 
9-ME-1 was then screened against their WT bromodomain panel at a concentration of 
1 µM, this dose was chosen as it was generally realistic, yet high enough to allow 
detection of even weak off-target activity. Against the panel 9-ME-1 showed 50-80% 
displacement of WT BET bromodomains, which is surprisingly high given our ITC data, 
however our scaffold titration data suggests the assay is ~10-fold more sensitive than 
other assays, so this activity was not discouraging. More importantly, 9-ME-1 displaced 
other, non-BET bromodomains to a lesser extent than the WT BET bromodomains 
(figure 3.10C). Based on this data, it can be concluded that if 9-ME-1 has ~200x 
selectivity for L/V BET BDs versus WT BET BDs, it should possess >200x selectivity for 




Figure 3.10. 9-ME-1 BROMOscan results 
A) Titration of scaffold compound against WT BRD4 BD1 in bromokdELECT assay. B) Affinity of scaffold 
compound for WT BRD4 BD1, measured by different assays. C) Retention of WT bromodomains, 
following incubation with 1 µM 9-ME-1, with BET bromodomains in blue and non-BET bromodomains in 







Outside of the bromodomain family, 9-ME-1 showed no off-target binding to 
any kinase tested in the MRC express screen, with no more than 20% inhibition at a 
concentration of 1 µM (figure 3.11). In the CEREP ExpresS Profile of receptors, ion 
channels and transporters 9-ME-1 at 1 µM also showed less than 20% inhibition 
against all targets, with the sole exception of the MT1 melatonin receptor (figure 3.12). 
The relevance and implications of this identified off-target are elaborated upon in the 
Discussion (section 3.11) .Pleasingly, despite being based on a benzodiazepine scaffold, 
9-ME-1 showed no binding to the central benzodiazepine or GABA receptors, likely due 
to the presence of the bump and side-group [76]. 
Following the off-target screening in three diverse panels, containing 137 
proteins, 9-ME-1 was shown to be highly specific for the L/V BET bromodomains, with 
little binding to WT non-BET bromodomains and only a single strong off-target. As 
such, we can confidently conclude that phenotypes arising from its use in cells can be 






Figure 3.11. 9-ME-1 kinase screen. 
Remaining activity of panel of human kinases following incubation with 1 µM 9-ME-1. Dundee MRC-PPU 




Figure 3.12. 9-ME-1 receptor, ion-channel & transporter screen. 
Activity of panel of human receptors, ion-channels and transporters following incubation with 1 µM 9-
ME-1. Green denotes central benzodiazepine and GABA receptors, yellow denotes known (+)-JQ1 off-







3.11 – Discussion 
For the high-throughput bromodomain-inhibition assay the newer and more 
expensive AlphaLISA format was chosen over the older AlphaScreen technology. 
AlphaLISA uses europium-chelate based acceptor beads, instead of Alphascreen’s 
anthracene and rubrene dyes (both beads also utilise thioxene). This results in 
AlphaLISA beads emitting light over a much narrower range of wavelengths – 607-623 
mm compared to 520-620 nm – reducing its susceptibility to absorbance by interfering 
compounds or protein/bead precipitation [170]. Additionally, the AlphaLISA acceptor 
beads are recruited to His-tagged proteins through an anti-His6 antibody instead of the 
Ni chelator used by Alphascreen, which is also more vulnerable to interference. 
Previous projects within the group faced difficulties in developing reliable Alphascreen 
assays, but saw a clear improvement with the AlphaLISA beads. The AlphaLISA format 
is, theoretically, still vulnerable to interference from compounds that quench singlet 
oxygen or compete with Bio-JQ1 for the streptavidin conjugated to the donor beads. 
Despite this, given the limited number of compounds tested, and their high structural 
similarity, such interference was not expected to be an issue. During this project a 
similar AlphaLISA-based Bio-JQ1 / BET bromodomain assay was developed and 
validated by another lab [177]. The proximity-based nature of the AlphaLISA assay lead 
to its re-purposing for another project in the lab: PROTAC development. In this assay 
instead of measuring the ability of a biotinylated probe to bring together a BRD and a 
streptavidin-labelled bead, PROTAC compounds were assessed by their ability to bring 
together BRDs and biotinylated E3 ubiquitin ligases [133, 178, 179]. This assay was able 
not just to confirm whether specific PROTACs could recruit both their BRD and E3 
targets, but was also able to indicate which PROTACs may display stronger 
cooperativity of ternary complex formation, a parameter now known to be very 
important to PROTAC design [131]. 
If our compounds did interfere with, and prevent the use of, the AlphaLISA 
assay format then some alternate technologies could be used. TR-FRET assays are very 
similar to AlphaLISA, monitoring the proximity of a fluorophore-labelled probe 
compound and a Europium chelate recruited to His-tagged proteins, but relies on the 
FRET phenomenon rather than singlet oxygen diffusion to trigger a signal. This 
technology has previously been used to study BET inhibitors (especially by scientists at 
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GSK) with much success [99, 121, 180]. The assays would likely be more practical to 
run, as there are fewer components to add and no need to protect the assay plate 
from light, although the shorter range of the FRET phenomenon may require careful 
construct and probe design. One final plate-based technique is fluorescence 
polarisation (FP), in which a fluorophore-labelled probe is observed. The light emitted 
by the excited fluorophore is polarised and the difference between the parallel and 
perpendicular intensity is quantified. As interacting with the BRD will, in effect, 
increase the MW of the fluorophore it will slow its rotation and increase the 
polarisation of the emitted signal [181]. This technology allows for an even simpler 
protocol than TR-FRET, and is also seen in the literature [99], but is limited by the 
inability to detect binding stronger than that possessed by the labelled probe. The 
biophysical techniques of BLI and SPR [163] could also be developed for evaluating BET 
bromodomain inhibitors, but this would prevent the use of high-throughput 384-well 
plates, and such techniques will detect binding to any part of the bromodomain 
construct while the competitive AlphaLISA / TR-FRET / FP assays require compounds to 
actually bind the Kac binding site of the bromodomain. 
One rational behind the decision to trial the methoxy-shift modification was 
that, as no chemical groups are removed or added, it was not expected to greatly alter 
the compound’s DMPK characteristics compared to the non-shifted compound. This 
was largely observed to be true (table 3.5.) with no changes to CLogP or plasma t½. 
The only large changes were in the CLint of ET and AL compounds, and the Pe of ME-
Am1 and ET-Am1. Additionally, the hypothesis that changes to the side-groups 
(originally a methyl-ester) would be an effective means of tuning DMPK properties was 
also confirmed (figure 3.13). Alternate side-groups did not have any visible impact on 
plasma t½, as it was revealed that the mere presence of the alkyl bump was enough to 
prevent esterase metabolism. The tert-butyl ester side-group had a massive effect on 
CLint, due to its increased hydrophobicity, and the main determinant of Pe was the 




Table 3.5. Effect of methoxy-shift on DMPK properties. 
 
 
Figure 3.13. DMPK properties of different side-groups. 
Bars represent the mean ± SE of each compound with each listed side-group. Statistical significance 
determined with two-tailed t tests: ns P>0.05; * P≤0.05; ** P ≤0.01; *** P≤0.001; **** P<0.0001. 
 9-ME-1 was chosen as the ‘best’ bumped compound, as out of the two 
compounds showing >100-fold selectivity it possessed greater potency and stability. 
Several of our other compounds could, nonetheless, still prove useful, as different 
projects or experiments may prioritise different parameters. 9-ET-1, while not as 
potent, possessed even greater overall selectivity; while ET does not show consistently 
>100-fold selectivity but features potency of almost 100 nM. Furthermore, ME-Am1 
was the most potent compound to reach the final ITC screen, while ET-Am1 showed no 
detectable binding to any WT bromodomain.  
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 The bump-&-hole concept need not be utilised solely in the context of small-
molecule inhibitors. Bumped compounds could be attached to functional groups, in a 
manner similar to Bio-JQ1 [86], photo-crosslinkers [87, 88] and click-chemistry enabled 
probes [89], for protein pulldown, fluorescence microscopy and other techniques. 
Instead of functional groups bumped compounds could be linked to other small-
molecules, either to form bivalent BET inhibitors like MT1 [83, 85], dual-inhibitors 
[182], or PROTAC compounds. Hopefully such efforts will be aided both by our 
extensive bumped-compound SAR and the extensive characterisation of 
benzodiazepine-scaffold BET inhibitors in the literature.  
 Our off-target screening efforts were, ultimately, encouraging but 
unfortunately did show significant off-target activity against the melatonin receptor 
MT1, against which we estimate 9-ME-1 has a Kd of roughly ~500 nM. If 9-ME-1 binds 
MT1 with 1:1 stoichiometry there should be 1 log unit of 9-ME-1 concentration 
between 50% and 90% inhibition, hence ~77% inhibition at a dose of 1 µM suggests an 
IC50/Kd value well between 100 nM and 1 µM. Although this off-target screen is not 
perfect it can still be considered very encouraging, as the widely used (+)-JQ1 also 
bound MT1 (more weakly) and in addition presented strong binding to the NK2 
neurokinin and A3 adenosine receptors [76, 85]. As MT1 is primarily expressed in the 
CNS and regulates processes such as the circadian rhythm off-target MT1 inhibition is 
unlikely to complicate the sort of experiments we aim to use 9-ME-1 for [183].  
 Structural analysis of MT1, and computational docking experiments with 9-ME-
1 were not performed as there are currently no crystal or NMR structures of MT1 and 
there is some disagreement between homology models [184]. Nevertheless, 
comparing the chemical structures of 9-ME-1 and a selection of MT1 agonists [185] 
showed some structural similarities (scheme 3.3). MT1 binding may be enhanced by 
the 9’ methoxy ring, and altering this group may weaken MT1 binding, at the cost of 
L/V selectivity.  The use of further modifications may weaken MT1 binding, but is 
unlikely to remove this issue. Despite lacking features like the 9’ methoxy ring (+)-JQ1 
also binds the MT1 receptor. Additionally, melatonin and other MT1 agonists contain a 
Kac mimic, suggesting the triazolo moiety of 9-ME-1 and (+)-JQ1 is key to MT1 binding; 




Scheme 3.3. 9-ME-1 & MT1 agonists. 



















3.12 – Conclusions 
 A small library of novel bumped compounds were designed and synthesised, 
combining a number of modifications to three distinct sites of the scaffold. Through a 
3-step compound evaluation workflow, alongside extensive structural studies, a wealth 
of SAR data was collected illustrating the workings of the bump-&-hole system. The 
chemistry of the bump-&-hole system was then further improved through the 
separation of the active 2R,3S and inactive 2S,3R enantiomers, which further boosted 
selectivity for L/V bromodomains. From this work, 9-ME-1 was highlighted as the ideal 
bumped compound, with >200-fold selectivity, high potency and excellent DMPK 
characteristics. The BET bump-&-hole system, in addition to possessing a new and 
more functional mutation, has now also been bolstered by the development of more 



















































4.1 – Introduction: 
 With the development of the more conservative and functional L/V mutation 
(chapter 2), and the development of the highly L/V-selective bumped inhibitor 9-ME-1 
(chapter 3), it was next attempted to validate the bump-&-hole system in cells and 
confirm its ability to provide BD-specific inhibition. It was also necessary to confirm 
that our bumped compounds would not affect the phenotype of cells not possessing 
any L/V-mutant BET proteins.  Once the system was validated it could then be used to 
investigate the BET proteins and answer biological questions regarding their cellular 
function.  
 
4.2 – Cellular Validation of Bumped Compounds 
 The main technique by which we verified that our bumped compounds were 
active & selective in cells is the FRAP assay, previously used to monitor the impact of 
the L/V mutation on chromatin binding. In this assay as our bumped compounds bind 
to L/V bromodomains the mutant BET proteins will be displaced from chromatin, 
dramatically reducing the measured t½. Following on from experiments in [159] some 
FRAP experiments were carried out by Lars van Beurden, showing that several 
compounds were active and selective for BRD4 L/V constructs (figure S4.1). The assays 
were hampered however, by the low t½ values recorded for uninhibited BET proteins 
(~1s) leading to a ~2-fold assay window. This small window will obscure small effects, 
like the impact of L/V mutations or weak off-target WT binding from bumped 
compounds. This small assay window is presumably principally caused by the fact that 
our GFP-BET proteins are overexpressed, meaning that the majority of proteins at any 
one point are not actually bound to chromatin. Although several ideas were suggested 
this issue was tackled by altering the acetylation state of the chromatin. By treating 
with an HDAC inhibitor, SAHA (suberoylanilide hydroxamic acid, Vorinostat) (scheme 
4.1), the acetylation state of the chromatin was increased, reducing the proportion of 
GFP-BET protein that was not bound to chromatin [164]. Dose-response experiments 
showed an assay window of ~6-fold at SAHA concentrations of 1 µM or higher, with 2 
µM taken as a concentration that would reliably generate a large-enough window 





Figure 4.1. FRAP assay optimisation. 
Recovery times of GFP-labelled WT BRD4 (L) or GFP alone (green) following 0.5 s laser bleach event, at 
varying concentrations of SAHA, within nuclei of U2OS cells treated with DMSO (dark blue) or 1 µM I-
BET762 (light blue). Each bar is mean ± SE of ~20 cells.  
 
 With the FRAP assay now optimised a selection of compounds were tested 
against WT and LV/LV BRD4. This experiment showed that our bumped compounds 
were able to enter our U2OS cells, cross into the nucleus, bind BET bromodomains in 
an L/V-selective fashion and displace L/V proteins from chromatin (figure 4.2A). 
Several compounds were able to displace L/V BRD4 to a similar extent as (+)JQ1, while 
others had no impact on WT BRD4, in line with what is observed with the non-binding 
control (-)JQ1. Additionally, 9-ME-1 (our preferred compound) was tested at a range of 
concentrations against WT & L/V BRD4, giving a cellular IC50 of ~50 nM (figure 4.2B-C). 
This showed that, with some tweaking of dosage, it is possible to almost completely 
inhibit L/V BET proteins, while leaving their WT counterparts relatively untouched. As a 
result of this experiment 9-ME-1 was used at 200 nM for further FRAP experiments to 
ensure >50% of the target was displaced from chromatin while keeping a minimal 
impact on the WT protein. Finally, the inactivity of the 2S,3R enantiomer was again 




Figure 4.2. Validation of bumped compounds with FRAP. 
A) Recovery times of GFP-labelled BRD4 (L) constructs following 0.5 s laser bleach event, at 2µM SAHA and 0.03% 
DMSO, treated with 1µM bumped compound. Each bar is mean ± SE of ~40 U2OS cells tested over two separate 
experiments. Statistical significance (compared to each construct’s DMSO treatment) determined with two-tailed t 
tests: ns P>0.05; * P≤0.05; ** P ≤0.01; *** P≤0.001; **** P<0.0001.  B) As for A, but cells treated with range of 9-















4.3 – Biological Question – Chromatin Binding 
 With the bump-&-hole system validated in cells we were now able to utilise it 
to answer a biological question. By testing the impact of 9-ME-1 on each individual BET 
BD their importance to chromatin binding can be determined. BET BDs necessary for 
chromatin recognition will cause large drops in t½ values when mutated and inhibited 
by 9-ME-1, while BDs less important to chromatin binding will produce smaller changes 
in recovery rates. To this end 9-ME-1 was tested, at 200 nM, against each WT and L/V 
GFP-BET construct. Mean raw and normalised t½ values are listed in table S4.1. 
 
Figure 4.3. Importance of individual BET BDs to chromatin binding. 
Recovery times of GFP-labelled BET protein constructs following 0.5 s laser bleach event, at 2µM SAHA and 0.03% 
DMSO, treated with 200 nM 9-ME-1. Each bar is mean ± SE of ~40 U2OS cells tested over two separate experiments. 
Statistical significance (compared to each construct’s DMSO treatment) determined with two-tailed t tests: ns 
P>0.05; * P≤0.05; ** P ≤0.01; *** P≤0.001; **** P<0.0001. † denotes aggregation of construct. 
One immediately visible trend between BET proteins is that targeting (mutating 
and inhibiting) the BD1 has a larger impact than targeting the BD2 (figure 4.3), showing 
that the BD1s are more important to chromatin binding. Additionally, the degree to 
which BD1 inhibition has a larger impact varies between BET proteins. BRDT shows no 
response to BD2 blockade, while targeting the BD1 alone has the same impact as 
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targeting the LV/LV double-mutant (figure 4.3D). BRD4 shows some response to BD2 
inhibition, but it is significantly smaller than the BD1, and BD1 inhibition gives a 
response almost as strong as the double-mutant (figure 4.3A). BRD3, meanwhile, 
shows the strongest BD2 response, which is almost as strong as the BD1, targeting 
both BDs generates further displacement (figure 4.3B). BRD2 was an interesting case, 
with no BD2 response and a small BD1 response, meanwhile treating the double-
mutant with 9-ME-1 caused aggregation of the GFP-BRD2, preventing the 
measurement of recovery times (figure 4.3C).  
The aggregation of BRD2 was unexpected, and not seen in any other BET 
proteins even with higher compound doses. It is also unusual as targeting the BD2 had 
no impact on recovery times (figure 4.3C), which would imply that inhibition of LV/WT 
and LV/LV would generate the same results. This aggregation could be quantified by 
taking a line across a cell, plotting the brightness along this line, plotting a linear line-
of-best-fit through said plot and then recording the quality of said fit (figure 4.4). 
Further experiments showed that this aggregation is caused by strong inhibition of 
both BRD2 BDs, as 200 nM (+)-JQ1 causes aggregation of WT GFP-BRD2 (which also 
shows this aggregation is not the result of the L/V mutation), while 9-ME-1 is only able 
to induce this effect when targeting the LV/LV double-mutant. Reducing the 9-ME-1 
dose to 40 nM produced less severe aggregation, and t½ could again be measured.  
The FRAP assay was also repeated in HEK293T cells, to investigate whether the 
observed aggregation effect might be a cell-line-specific phenomenon. Unfortunately 
GFP-BRD2 also aggregated in these cells when inhibited, although to a slightly reduced 
extent (figure 4.5). Additionally, the assay window was reduced and the semi-adherent 
nature of HEK293T cells complicated the practical elements of the assay. The faster 
growth of HEK293T (compared to U2OS), combined with their vulnerability to being 
accidentally dislodged from the microscope dish, resulted in extreme variance in 
transfected cell-density. Many areas of the microscope dish would show no 
transfected cells, while transfected cells were often found so densely packed together 






Figure 4.4. Inhibition-induced aggregation of GFP-BRD2. 
A) Nuclei of U2OS cells transfected with GFP-BRD2 constructs and treated with 2 µM SAHA, 0.03% 
DMSO and test compound. Line drawn cross cells and brightness profile plotted, and linear line of best 
fit added (dotted lines). B) Quality of fit of linear line recorded as SD of residuals (Sy.x) and used to 
quantify aggregation, with larger values representing greater aggregation. Each bar is mean and SE of 
>25 U2OS cells from two separate experiments. Statistical significance (compared to each construct’s 




Figure 4.5. GFP-BRD2 aggregation in HEK293T cells. 
A) Recovery times of GFP-labelled BRD2 constructs in HEK293T cell FRAP assay, following 0.5 s laser 
bleach event, at 2 µM SAHA and 0.03% DMSO. Each bar is mean and SE of ~30 HEK293T cells. † denotes 
aggregation of construct. B) Nuclei of transfected HEK293T cells, treated with 2 µM SAHA, 0.03% DMSO 
and 200 nM 9-ME-1. C) Brightness profile of nuclei plotted. Linear line of best fit (dotted line) plotted, 
and quality of fit tabulated. 
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BRD2 was re-tested in the U2OS FRAP assay, but with a reduced dose of 40 nM 
9-ME-1, with the hope that double-mutant t½s could be measured and compared to 
those of the BD1 and BD2 mutants. This experiment was successful, and produced a 
set of results similar to that displayed by BRDT – no response from BD2, BD1 inhibition 
matching that of the double-mutant (figure 4.6).  
 
Figure 4.6. Importance of individual BRD2 BDs to chromatin binding. 
Recovery times of GFP-labelled BRD2 constructs following 0.5s laser bleach event, at 2µM SAHA and 0.03% DMSO, 
treated with 40 nM 9-ME-1. Each bar is mean ± SE of ~40 U2OS cells tested over two separate experiments. 
Statistical significance (compared to each construct’s DMSO treatment) determined with two-tailed t tests: ns 
P>0.05; * P≤0.05; ** P ≤0.01; *** P≤0.001; **** P<0.0001.  
 All of these results taken together show the BD1 to be the dominant domain 
for acetylated chromatin binding (table 4.1). Both BRD2 and BRDT appear to bind 
chromatin solely through their BD1s, and their BD2s have no observable significance. 
BRD4 BD2 does play a small role in chromatin binding, but BRD4 BD1 is both necessary 
and sufficient for chromatin binding as of itself. Chromatin binding of BRD3 meanwhile 
is almost balanced, with the BD2 playing only a slightly smaller role than the BD1. Our 
results for BRD4 and BRDT match those previously obtained in the literature using 
alternate techniques. Pulldown of BRD4 constructs mixed with custom nucleosomes 
bearing specific Kac combinations showed BRD4 BD2 to play a minor but non-zero role 
in chromatin binding [186], while ITC titrations and NMR experiments showed BRDT 




Table 4.1. Importance of each BET BD to chromatin binding 
Percentage inhibition of chromatin binding by 9-ME-1 treatment (200 nM for BRD4, BRD3 and BRDT; 40 
nM for BRD2), calculated with regard to the impact of 9-ME-1 on each BET proteins LV/LV construct. 
Note: LV/LV construct may retain some chromatin binding even after 9-ME-1 treatment. Colour scale: 


















L/V BD WT BD1 BD2 Both
BRD4 13 90 41 100
BRD3 -1 72 53 100
BRD2 0 79 14 100
BRDT -9 99 11 100
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4.4 – Biological Question - Transcription 
 In addition to measuring BD1/BD2 importance to chromatin binding through 
FRAP, the previously discussed NF-B/luciferase assay (chapter 2.14) was applied to 
measure the importance of each BD to inducing the transcription of NF-B target 
genes (figure 4.7). In the NF-B/luciferase assay HEK293T cells are transfected with a 
plasmid encoding a luciferase reporter enzyme controlled by NF-B signalling through 
5 NF-B response elements. Co-transfection and transient overexpression of GF-BET 
constructs increases the expression of said luciferase.  
 For BRD4, transcription could be severely inhibited by targeting either the BD1 
or the BD2 (figure 4.7A). A similar trend was shown by BRD3 (figure 4.7B). BRD2 
showed a significantly greater impact from BD1 inhibition, although targeting the BD2 
did reduce the expression of the luciferase (figure 4.7C). Finally, BRDT showed a strong 
response to BD1 and double-mutant inhibition, but again presented a smaller albeit 
measurable response with the BD2 (figure 4.7D). In some cases targeting a single BD 
has a greater impact on transcription than targeting both with the LV/LV double-
mutant. This could indicate that inhibiting either the BD1 or BD2 is sufficient for 
reducing transcription, while mutating both BDs may reduce the effective inhibitor 
dose (by halving the compound : L/V BD ratio).  
In contrast with the FRAP assay on chromatin binding, these results show the 
BD1 and BD2 to be equally important to transcription for BRD4 and BRD3. In contrast, 
in the case of BRD2 and BRDT, the BD1 is still pre-eminent but the BD2 does now play 




Figure 4.7. Importance of individual BET BDs to the transcription of NF-B signalling genes. 
Normalised luminescence of lysate from HEK293T cells transfected with GFP-labelled BET constructs and a NF-B-
RE/luc2P reporter plasmid, and treated with 1 µM compound and/or 0.01% DMSO. Basal luciferase expression (with 
GFP plasmid) subtracted as background. Signal normalised to each construct’s DMSO control. Results are mean and 
standard error of six technical replicates spread over two independent experiments. Statistical significance 




Table 4.2. Importance of each BET BD to NF-B-mediated transcription 
Percentage inhibition of NF-B-mediated transcription binding by 9-ME-1 treatment (200 nM for BRD4, 
BRD3 and BRDT; 40 nM for BRD2), calculated with regard to the impact of 9-ME-1 on each BET proteins 
LV/LV construct. Note: LV/LV construct may retain some activity even after 9-ME-1 treatment. Colour 
scale: 0% = white, 100% = dark green. Note: all inhibition values below 15% were not statistically 
significant (p>0.05). 9-ET-1 results omitted for clarity. 
9-ME-1 inhibition (%)
L/V BD WT BD1 BD2 Both
BRD4 -14 142 139 100
BRD3 43 72 72 100
BRD2 -6 123 61 100
BRDT -13 105 51 100
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4.5 – Effects of 9-ME-1 on WT Cell-viability: 
We have shown through both biochemical/biophysical and cellular assays that 
our bumped compounds have little activity against WT BET bromodomains, and our off-
target screening has only uncovered one notable off-target (MT1). As such, we 
hypothesised that our bumped compounds should show little to no impact on the 
phenotype of WT cells, as these cells will lack any L/V-mutated BET proteins. To test this 
hypothesis, the viability of BET-sensitive cell-lines was measured at increasing 
concentrations of 9-ME-1, using Promega’s ATP-measuring CellTiter-Glo assay [187]. 
This assay had already been optimised for suspension cell-lines, specifically BET-
sensitive AML-derived MV4-11 and HL-60 [91], by Dr Kwok-Ho Chan [188]. In order to 
test adherent cell-lines, for example BET-sensitive, LAC-derived A549 and H23 [94], this 
assay had to be re-optimised to work with much lower cell densities.  
 
Figure 4.8. Cell viability assay LAC optimisation. 
Luminescence of A549 cells mixed with Promega CellTiter-Glo reagent, after being seeded over a range of 
densities, treated with 0.05% DMSO and/or 50 µM (+)-JQ1 and incubated for 24, 48 or 72 hours. Assay 
quality (assay window and Z’) calculated for each condition. 
To discover the optimal assay conditions for adherent cell-lines, A549 cells were 
seeded in 384-well assay plates over a range of cell-densities and treated with either 
DMSO or 50 µM (+)-JQ1 for 24, 48 or 72 hours. Increasing the cell number showed a 
clear increase in signal, saturating at 1000 – 10,000 cells depending on incubation time. 
Longer incubation times also in general produced larger assay windows and Z’ values, 
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with slightly lower optimal cell numbers (figure 4.8). These experiments revealed the 
optimal conditions for this assay to be ~2000 cells with a 72 hour incubation time, giving 
a 10-20-fold assay window and Z’ values of ~0.7 [171]. 
 
 
Figure 4.9. Impact of 9-ME-1 on WT cell-viability 
Viability of BET-sensitive cells: adherent, LAC-derived A549 & H23; suspension, AML-derived MV4-11 & 
HL-60. Cell viability determined via Promega CellTiter-Glo measurement of ATP-levels. 
 
Titrating 9-ME-1 against BET-sensitive cells showed it to be inactive, when 
compared to active and inactive JQ1 compounds (figure 4.9). While (+)-JQ1 shows a 
strong reduction in cell viability and IC50 values of 600 to 100 nM 9-ME-1 acts more like 
the inactive (-)-JQ1, and shows no impact below 1 µM. This clearly shows 9-ME-1 to be 
A) relatively inactive against WT BET proteins in cells, and B) to not have any 





4.6 – Effects of 9-ME-1 on WT Cell Colony formation: 
 As an alternative to the cell-viability assay discussed previously a colony-
formation assay was developed. These assays involve seeding small numbers of cells, 
which are treated with compound for long timescales (~1 week) before being fixed and 
stained. The readout of this assay is the number of colonies left after staining, and the 
degree to which small-molecules reduce this. These such assays require adherent cell-
lines, and was hence carried out with A549 cells. Initial testing, wherein a range of cell-
densities was incubated for 7 days and fixed/stained with 0.01% crystal-violet in 25% 
MeOH for 1 hour did leave visible cells, but colony counting was not possible and 
washing the cells with H2O displaced large amounts of cells (figure 4.10A).  This fixing 
problem was solved by separating the fixing and staining processes, and fixing the cells 
with 100% MeOH at 4°C, which showed no displacement despite multiple H2O washes 




Figure 4.10. A549 colony-formation assay optimisation. 
A) 6-well plates seeded with A549 cells (number indicated) and grown for 1 week. Cells then fixed at 
room temperature with 25% MeOH and stained with 0.01% crystal-violet. Dotted circle shows area 
where cells removed during attempted second wash with water. B) 6-well plates seeded with A549 cells 
and grown to 100% confluence before being fixed at 4°C with indicated cell-fixing solution, and stained 
with 0.1% crystal violet. 
 Following this optimisation, the effect of 9-ME-1 on WT A549 cells was 
measured (figure 4.11) (figure S4.2). While the presence of 1 µM (+)-JQ1 killed 
essentially all cells, 1 µM 9-ME-1 reduced colony numbers by only ~10% on average – 
showing similar results to the cell-viability experiments and confirming that 9-ME-1 
does not inhibit WT BET bromodomains, or other unknown off-targets, at the doses 




Figure 4.11. Effects of 9-ME-1 on WT A549 colony formation. 
6-well plates seeded with 2000 A549 cells, treated with 1 µM compound and/or 0.01% DMSO and 
incubated for 8 days before being fixed with 100% MeOH and stained with 0.1% crystal-violet. Assay 
carried out with two biological replicates, each with two technical replicates. Statistical significance 
(compared to DMSO treatment) determined with two-tailed t tests: ns P>0.05; * P≤0.05; ** P ≤0.01; *** 
P≤0.001; **** P<0.0001.  
A dose-response experiment was then performed, to get an idea of what sort 
of 9-ME-1 dose would have a strong impact on any L/V-mutated A549 cells while 
avoiding any significant WT effects (figure S4.3). (+)-JQ1 was shown to be fully-lethal at 
1 µM, partially lethal at 100 nM and have no impact at lower doses. 9-ME-1, 
meanwhile, was shown to have no impact until dosed at 10 µM.  Although it is possible 
that (+)-JQ1 might be more potent against WT cells than 9-ME-1 would be against L/V 
cells, together this data suggests that a dose between 100 nM and 1 µM would likely 
give full L/V lethality alongside little impact on WT.  
In order to better perform colony-formation dose-response experiments the 
decision was taken to move into a 96-well format and to bypass the counting of 
colonies. A549 were seeded in 96-well plates, treated with a gradient of compound 
doses and grown until DMSO-treated wells were fully confluent before fixing and 
156 
 
staining. The potent inhibitor and PROTAC, (+)-JQ1 and MZ1, here used as positive 
controls, showed inhibition of colony-formation from 400 nM to 1 µM, while (-)JQ1 
showed high confluence growth even at 10 µM. As expected, 9-ME-1 showed no 
inhibition at 3 µM, but with a noticeable reduction in signal (though not visible 
confluence) at 10 µM (figure 4.13).  
 
Figure 4.13. 96-well A549 colony-formation assay 
96-well plate seeded with A549 cells, treated with compound and/or 1% DMSO and incubated for 1 
week before being fixed with 100% MeOH and stained with 0.1% crystal-violet.  
 
 The dose-response, 96-well colony-formation assay developed above is a 
valuable complement to the CellTiter-Glo assay, for assessing cell viability and the 
cytotoxicity of compounds. The colony-formation assay is not easily quantifiable, 
requires adherent cells and may be difficult to transfer to a 384-well plate. 
Additionally, the quality of any specific assay run will be strongly affected by the 
growth-rate of the cells and exactly how long they are incubated with compounds. On 
the other hand, this assay is easier to run for extended periods of time, allowing one to 
study cell-viability over short time periods (2-3 days) with CellTiter-Glo and longer 
periods (1+ week) with the colony-formation assay. Additionally, as the colony-
formation assay works by direct visualisation of cells it is less vulnerable to assay 
interference and false negatives/positives than the ATP/luminescence measuring 
CellTiter-Glo assay. This assay has since been used in other projects, such as the 




4.7 – Attempts to Answer Other Biological Questions: 
 The previously described FRAP and luciferase assays were very successful in 
allowing us to probe BET bromodomain function with the bump-&-hole system. While 
performing these experiments, however, several similar experiments were tried and 
failed. These assays attempted to look into the importance of BET BD1s and BD2s to 
gene expression and overall cell-viability, relying on GFP-BET overexpression and, in 
some cases, siRNA of endogenous proteins. These experiments were inconclusive and 
thus highlight the need to, ultimately, produce model cell-lines with the L/V mutation 
incorporated into endogenous BET genes that will be expressed and regulated 
appropriately, while eliminating the need to knock-out/down WT genes. Although this 
work failed to answer biological questions a great deal was learnt from these 
experiments that should inform future experiments, hence their description within this 
thesis. 
The BRD4 / NF-B luciferase assay, as originally developed by Dr Kwok-Ho 
Chan, was quite different from the final version. It was performed in A549 cells (more 
biologically relevant, and in line with literature [95]) instead of HEK293T, used siRNA to 
suppress endogenous WT BRD4 expression and featured TNF- induction, looking at 
the differing increase in luciferase expression between different constructs (figure 
4.14).  
The transient overexpression of BRD4 was generally unable to rescue the 
luciferase signal following siRNA knock-down of the endogenous protein, but an 
increase in signal was observed by Dr Chan in one experiment where the siRNA was 
also shown to have had no impact on the endogenous protein (for unknown reasons) 
(figure 4.14A). This suggested that, going forward, siRNA knock-down of endogenous 




Figure 4.14. Development of luciferase assay. 
A) Luciferase experiments run by Dr Kwok-Ho Chan, looking for an increase in luciferase signal upon 
GFP-BRD4 (L) overexpression. Experiment run with siRNA (targeting 5’ UTR and hence not effecting 
exogenous protein) that was mildly effective shows a decrease in luciferase induction with BRD4 
overexpression. Experiment run with 3’ UTR targeting siRNA, that was not effective, shows a noticeable 
increase in induction with BRD4. B) Replicate experiment, where BRD4 overexpression again reduced 
luciferase induction, and where 9-ME-1 had a very weak and non-selective impact. C) Data from B, 
without induction normalisation, showing that without TNF- induction BRD4 overexpression strongly 





Even following the removal of the siRNA step no clear ‘rescue’ was observed 
with BRD4, and no meaningful impact was seen with 9-ME-1 treatment (figure 4.14B). 
Overexpression of GFP alone consistently led to a much higher increase in luciferase 
expression upon TNF- induction (figure 4.14b). Analysis of the uninduced samples 
revealed that this was not because the signal with TNF- induction was higher for GFP 
compared to GFP-BRD4, but instead a result of the uninduced signal, being 
substantially lower for the GFP control than with the GFP-BRD4 constructs (figure 
4.14C). This led to the decision to remove the TNF- induction step, which allowed for 
the observation of strong increases in luciferase expression from GFP-BRD4 WT and 
L/V mutants, with the attendant L/V-selective decrease in signal from bumped 
compounds. As the removal of TNF- led to a large decrease in signal it became 
difficult to work with A549 cells, which consistently produced lower luminescence than 
the HEK293T. 
 As we had previously utilised transient overexpression of mutant GFP-BET 
constructs to study chromatin binding and transcription it was hoped a similar assay 
could be developed to investigate the importance of BD1s/BD2s to the viability of BET-
dependent cells. As such, BET-dependent A549 cells were transfected with GFP-BET 
constructs and their viability measured through the CellTiter-Glo assay (figure 4.15). 
The first experiment ran showed some promise: BRD4 overexpression did not increase 
the viability of the cells, but 9-ME-1 was shown to reduce their viability when paired 
with the LV/LV BRD4 double mutant, suggesting that both bromodomains need to be 









Figure 4.15. Attempts to study cell-viability through BET overexpression. 
A) CellTiter-Glo signal produced by A549 cells following GFP or GFP-BRD4 (L) overexpression and 
treatment with DMSO or 9-ME-1. B) Repeat of A, but including overexpression of GFP-BRD3 and GFP-
BRD2 constructs. C) BRD4 (L) assay repeated again, but with addition of BRD4 UTR targeting siRNA 
(which does not affect exogenous protein). D) BRD4 (L) experiment repeated but with gradient of (+)-
JQ1 and 9-ME-1 doses.  
Unfortunately, this result could not be recreated in later experiments with 
BRD4 and other BET proteins, nor was any strong or consistent increase in cell-viability 
recorded as a result of BET overexpression (figure 4.15B). Attempts to knock-down the 
endogenous BRD4 through siRNA, using a protocol developed by Dr Kwok-Ho Chan, 
merely increased the experimental variance (figure 4.15C). Finally, a dose-response 
experiment was carried out, with cells transfected in a 6-well plate then re-seeded in 
384-well assay plates, and no BRD4 construct was shown to alter the dose-response 
curve of 9-ME-1 or (+)-JQ1 (figure 4.15D).  
 
4.8 – Discussion: 
 The FRAP assay was chosen to confirm L/V-selective bromodomain inhibition in 
cells as it was a technique that could be used to confirm mutant functionality (chapter 
2), show target engagement (validate the system) and measure the importance of each 
BD to chromatin binding (utilise the system for a biological question). The FRAP assay 
is a powerful way to observe the displacement of full-length BET proteins from 
chromatin in cells, but it does suffer from low throughput and is not optimised for 
dose-response experiments. FRAP also requires the expression of exogenous GFP-
labelled protein, though this is less of a drawback in this context, as testing L/V mutant 
BET proteins would require such exogenous expression anyway.  One other issue is the 
need to treat cells with an HDAC inhibitor to ensure a usable assay window. This issue, 
however, is not FRAP-specific and would likely apply to any assay seeking to monitor 
displacement of overexpressed BET proteins from chromatin. The assay-window 
problem had previously been solved in the course of assay optimisation by previous 
members of the group while obtaining data for [159]. This was achieved by bleaching 
an area much larger than the area in which fluorescence was measured. Unfortunately 
changes in the hardware available prevented this option from being reused. Lowering 
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the expression of the GFP-BET protein may have increased the assay window, but may 
leave the transfected nuclei too dim for the FRAP assay to function. Finally, former lab 
member Lars van Beurden observed that running the assay at lower temperatures 
increased the assay window, but also greatly increased variance. Replacing the GFP tag 
with a brighter fluorophore (such as Clover and its derivatives [190]) may allow for 
further optimisation of the FRAP assay. A brighter tag could allow for FRAP assays to 
be carried out in cells expressing a much lower (and closer to endogenous) level of 
tagged BET protein. Reducing the levels of tagged protein will both improve the signal 
to noise by re-balancing the BET:ac-chromatin ratio to near-WT, and generate more 
realistic dose-response relationships.  
 Chromatin immunoprecipitation, with massively parallel DNA sequencing (ChIP-
Seq) is another means of monitoring the interaction of BET proteins to chromatin, that 
could be employed in the future to complement the FRAP assay [191, 192]. An 
advantage of ChIP-Seq is the ability to monitor the recruitment of BET proteins to, and 
their displacement from, multiple specific gene loci or epigenetic marks. This 
additional data is not, however, required for this project as the focus was on the 
displacement of BET proteins from chromatin in general. Additional ChIP-Seq 
experiments could be worthwhile in the case of BRD4 and BRD3, as it would be 
interesting to dissect to what extent BD1 versus BD2 blockade might displace BET 
proteins from different gene loci / epigenetic marks.  
One highly unexpected outcome of the FRAP work was the observation of GFP-
BRD2 aggregation in response to inhibition. Such distributions of nuclear proteins are 
often observed in response to DNA damage and repair, however a recent study 
suggested that BRD2 is not involved in any such process [193]. Such aggregation could 
be due to the addition of the GFP-tag, issues with the specific BRD2 construct used or 
the high cellular concentration of the overexpressed protein. As mentioned in chapter 
2, this aggregation of GFP-BRD2 may be connected to the unusually severe impact the 
L/V mutation has on GFP-BRD2 LV/LV’s ability to bind chromatin. Aggregation of GFP-
labelled bromodomains in response to inhibition has been observed previously, and 
developed into an assay to measure inhibitor potency [194]. Gacias et al., in their 
publication of the BD2-selective inhibitor Olinone, also observed this aggregation (or 
“punctate distribution”) of GFP-BRD2 [128]. As this redistribution was observed with a 
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pan-selective BET inhibitor, but not the BD2-selective Olinone they put forth that the 
BD2 of BRD2 is important for its subcellular localisation. With the bump-&-hole system 
we are able to interrogate this phenomenon much more selectively, and have shown 
that GFP-BRD2 aggregation requires inhibition of both BDs – showing how the bump-
&-hole system can be a much more effective means for investigating biology than 
current BET inhibitors. Further investigation is warranted to determine if this 
phenomenon is simply an artefact specific to GFP-BRD2 constructs, or actually 
represents how endogenous BRD2 is localised and functions within the cell nucleus. 
 There is currently constant progress in the development of novel in-cell target 
engagement assays, which could be used to confirm L/V-selective BET inhibition of the 
bumped compounds (but would not be useful for studying chromatin binding). The 
cellular thermal shift assay (CETSA) is a commonly used means of measuring target 
engagement in cells, and the ability of ligands to thermally stabilise proteins, without 
the need for much specialised reagents or equipment. Attempts were made to 
implement this assay for the project, utilising cell-lines developed by Dr Kwok-Ho Chan 
that used the Flip-in system to stably transfect U2OS cells with tetracycline-controlled, 
GFP-labelled BRD4 constructs. As the endogenous WT BRD4 and the exogenous, GFP-
Labelled proteins could be monitored simultaneously by western blot this assay had 
the potential to show the selective engagement of L/V BRD4 in preference to WT BRD4 
in the same system (as opposed to testing the two separately and comparing the 
results). The tetracycline-induced expression of GFP-BRD4 proteins was confirmed 
(figure S4.5A), and protocols for western-blotting of BRD4 have already been 
extensively developed in-house [132, 188]. However, no clear thermostabilisation 
could be observed, both in an unselective fashion with (+)-JQ1 and in a selective 
fashion with 9-ME-1 (figure S4.5B-C). A dose-response CETSA assay has been utilised 
on the BET proteins [85], but no such assay was successfully developed for this project.  
 Finally, some plate-based cellular target engagement assays have been 
developed that aim to translate the plate-based biochemical assays discussed earlier 
(chapter 3) from a purified, buffer-based context to a lysate or cellular environment. 
The most successful so far is the NanoBRET assay [195], in which a fluorescent probe 
(or covalently-labelled histone peptide) excites a NanoLuc luciferase recruited to the 
target protein, unless displaced by test compounds. As this assay requires the 
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transfection of a NanoLuc-tagged target protein it should be possible to alter the 
expression vector to express L/V mutants of the target BET proteins.  
 
4.9 – Conclusions: 
 Using the cellular FRAP assay our bumped compounds were shown to be able 
to selectively displace L/V BET proteins from chromatin, and through varying the exact 
dose it was possible to find the concentration range in which this was optimal. The 
bump-&-hole system was further validated, as 9-ME-1 was shown not to effect the cell 
viability or colony-formation of WT BET-dependent cell-lines expressing no L/V 
mutants. 
 The bump-&-hole system was then utilised to answer biological questions 
regarding how the BET proteins, and their tandem BDs, work, on a molecular level, to 
bind acetylated chromatin and induce transcription of downstream genes. Through the 
FRAP assay it was shown that, for all BET proteins, the BD1 was most important to 
chromatin binding. Excitingly though, the importance of the BD1 varied between BET 
proteins, from being the sole driver of chromatin binding in BRDT to almost parity with 
BD2 in BRD3. Utilising a luciferase reporter-gene assay, the bump-&-hole system was 
then applied to investigate transcription of NF-B-RE controlled genes. Although it is 
difficult to identify how exactly a given BD contributes to transcription (and not just 
chromatin binding), several BD2s appeared to play a greater role in transcription than 
could be explained by their importance to chromatin binding.  
Further experiments, using overexpressed GFP-BET proteins to investigate cell-
viability were attempted without success, outlining the limits of what could be 























5.1 – Introduction: 
 The ultimate goal of the BET bump-&-hole system is to chemically interrogate 
the function and importance of the BET proteins/BDs, both in healthy biological 
systems and during disease. Although we have been able to investigate BET protein 
function in cells by transient expression of L/V BET constructs such experiments are 
not sophisticated enough to properly investigate the BET proteins. Further 
experiments require mutant BET proteins to be expressed at a level similar to their WT 
counterparts, and for their expression to be regulated and vary appropriately.  
 The first attempt to develop such a system, performed by Dr Kwok-Ho Chan, 
used the Flp-in and T-Rex systems to stably transfect U2OS cells with tetracycline-
dependent GFP-BET constructs, while knocking-down endogenous genes with siRNA 
(figure S5.1A-B) [6, 159]. The tetracycline dose was optimised to equalise GFP-BRD4 
(long) expression with that of the endogenous gene, but unfortunately the exogenous 
gene (even when WT) could not restore the expression of BRD4-regulated genes 
following siRNA treatment (figure S5.1C). This is due to the GFP-BRD4 expression being 
broadly comparable to the endogenous gene, but not actually regulated in the same 
manner. In addition this Flp-in system only allows for a single isoform to be expressed, 
but BRD4 has multiple splice variants with differing functions [46, 47]. In addition the 
BRD4 siRNA was ‘leaky’ and allowed for some endogenous expression. Pleasingly, ET 
was still shown to be active and L/V-selective in altering the expression of BRD4-
regulated genes (figure S5.1D). Given these results it was clear that the ideal model 
cell-line would contain the L/V mutations knocked-into endogenous BET genes, both 
ensuring proper regulation and splicing, while removing the endogenous WT genes. 
Given the different gene-editing tools currently in use the best way to resolve these 
issues is to use the CRISPR/Cas9 gene-editing system. 
The CRISPR/Cas9 system, now used for gene editing, evolved as an anti-
viral/phage component of the adaptive immune systems in bacteria and archaea [196]. 
In infected prokaryotes, viral DNA is recognised and inserted into CRISPR arrays within 
the host genome. This vDNA is modified and transcribed into gRNA strands, which bind 
the Cas9 nuclease and direct it to cleave and inactivate matching vDNA. The CRISPR 
system appears to exist in ~45% of bacteria and ~85% of archaea species, and there is 
some evidence that it has been adapted for use in DNA repair and gene regulation. 
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Some viruses and phages have evolved to counteract the CRISPR system, either 
through random mutation of PAM sites or the expression of CRISPR-inhibiting proteins 
[196].  
  From 2013 onwards, the CRISPR/Cas9 system has been repurposed for 
deliberate gene-editing [197-199], gradually replacing the older and less practical zinc-
finger nucleases and TALENS systems [200-203]. In this context, target cells are 
transfected to express a nuclease (typically Cas9), which will recognise PAM sites 
within DNA (“NGG” for Cas9) and gRNA strands [204-206]. gRNAs consist of 2 RNA 
strands: crRNA possesses homology for the target DNA sequence (which must be 
within ~20bp of a PAM site), and tracrRNA which forms a hairpin loop with the crRNA 
to form an active complex and direct Cas9 to the target DNA. The Cas9 nuclease will 
then generate a double-strand break at the target sequence, which is generally 
repaired through either non-homologous end joining (NHEJ) or homology-directed 
repair (HDR) (figure 5.1.) [204-206]. In NHEJ the broken strands are directly 
reconnected, but with the generation of random indel mutations. These random indels 
can often lead to the knock-out of all or part of the target gene, for which the 
CRISPR/Cas9 system is frequently utilised [204-206]. HDR instead repairs the DNA 
break using a homologous donor DNA template (typically a sister chromatid). When a 
DNA template is also introduced into the target cell a sequence of desired DNA, 
containing insertions, deletions or mutations, can be intentionally knocked-into the 
target gene. These knock-ins can be used to introduce novel genes or regulatory units, 
create reporter genes, introduce tags onto endogenous proteins or introduce small 
mutations [204-206]. The need for an additional component (DNA template), and the 
overall dominance of NHEJ-mediated DNA repair, results in knock-outs being far more 




Figure 5.1. CRISPR/Cas9 mediated gene editing. 
The Cas9 nuclease binds to a gRNA with homology to target DNA, and to a PAM site in the target DNA. 
Following cleavage the double-strand break can be repaired via NHEJ, which can create random indel 
mutations, or by HDR using a donor DNA template. The random mutations from NHEJ can create knock-
out mutants, while the right donor DNA template used in HDR can be used to create knock-in mutants.  
In CRISPR/Cas9 experiments the Cas9 nuclease, gRNA and (if performing a 
knock-in) DNA template must be introduced into the target cell. The gRNA strand may 
consist of 2 separate strands (tracrRNA and crRNA) that later interact, or a single 
strand combining the 2. Transfection of cells with plasmids can be used to introduce all 
3 components, with the transcription of gRNA strands, transcription and translation of 
a Cas9 gene and containing the DNA template. Instead of a plasmid containing a Cas9 
gene some protocols rely on transfection of a Cas9 mRNA which can then be 
immediately translated [207]. Several cell-lines have also been developed that stably 
express a permanently integrated Cas9 gene, and hence require transfection of only 
gRNA and DNA template [208, 209]. The DNA template can also be introduced as a 
single or double-stranded DNA molecule instead of being contained within a larger 
plasmid. The exact transfection protocol varies with target cell-line and nature of 
CRISPR components, with cation-lipid transfection reagents, electroporation, 
microinjection and viral transfection used in the literature [205].  
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5.2 –Design of CRISPR Knock-In System: 
 The first CRISPR knock-ins designed for the BET bump-&-hole system were 
designed by Dr Kwok-Ho Chan and aimed to knock-in the L/V mutation onto the BD1 
and BD2 of BRD4 in A549 cells (figure 5.2A-B). The decision of which cell-line to focus 
on is not a simple one. Creating L/V mutants of otherwise normal human cell-lines 
would better allow for an accurate investigation into the function of the BET proteins, 
however focusing on cell-lines derived from cancers in which the BET proteins are 
validated targets will help understand the role of BET proteins in disease and their 
potential as therapeutic targets. Here A549 cancer cells were selected so as to sooner 
generate clinically relevant data.  
 A549 is a hypotriploid cell-line, meaning it may have elevated copy numbers for 
the BET genes [210]. Increased copy numbers will both complicate the generation of 
homozygous knock-ins, and potentially complicate the analysis of later experiments 
into knock-in/knock-out detection and genetic characterisation. One published A549 
karyotype shows 2 copies of chromosomes 6 (BRD2), 9 (BRD3) and 19 (BRD4) and 1 
copy of chromosome 1 (BRDT), but 13 abnormal chromosomes generated by 
translocation of chromosome regions. The abundance of abnormal chromosomes 
complicates estimations of gene copy numbers. The CanSAR database [211] gives 
elevated copy numbers for all BET-encoding chromosomes except chromosome 6. 
However the same database shows that only BRD3 is triploid, while the other BET 
genes are diploid. The Harmonizome database shows no BET gene to have an 
increased or decreased copy number [212]. Finally, the CellMiner NCI-60 Analysis Tool 
suggests BRD4, BRD3 and BRDT are diploid while giving no data on BRD2 [213]. Based 
on the above sources (specifics in table S5.1) it was decided to assume that A549 cells 
possess 2 copies of the BRD4 gene. It must be noted, however, that A549 cells have 
displayed cytogenic instability [210] and the BRD4 copy number of the specific A549 
cell-line in our possession was not experimentally confirmed. 
The full DNA sequence for the BRD4 gene (including introns) was obtained from 
the NCBI (NC_000019.10 reference GRCh38.p12 primary assembly), and the exons that 
form the long BRD4 isoform were identified (reference sequences NM_058243.2 / 
NP_490597.1 [214]). The codons encoding for L94 and L387 were identified and the 
requisite DNA changes for the L/V mutation were determined. To aid with later 
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analysis of potential KI clones a novel restriction site was introduced into each BD, 
using silent mutations when this fell into an exon region. Based on DNA sequence, 
commercial availability and activity in relevant buffers restriction sites for enzymes 
BamHI and ApaL1 were introduced into BD1 and BD2, respectively. Next, two PAM 
sites (sense and antisense) were identified, to allow for Cas9 binding. To minimise off-
target double-strand breakage it was decided to utilise the S. pyogenes Cas9 D10A 
nickase mutant, which uses a PAM site with sequence “NGG”. By reducing off-target 
activity this nickase mutant should reduce toxicity and increase the reliability of results 
obtained using any knocked-in cells [215, 216]. As the nickase will only cleave one 
strand of DNA a pair (sense/antisense) of PAM sites and gRNAs are required. The 20 
nucleotides up-sequence of each PAM site was used to form the target-binding crRNA 
component of the gRNAs. To prevent repeated cleavage of knocked-in DNA the L/V 
knock-in was also engineered to remove the PAM sites through the introduction of 
silent mutations in the donor DNA sequence. In some cases a single mutation could be 
used for two KI elements (i.e. the L/V mutation also destroying a PAM site). To this 
donor DNA 500bp stretches of sequence before and after the L/V knock-in were added 
as homology arms for HDR. Finally, a set of primers were synthesised for later PCR-
based assays and sequencing (figure 5.2C) (table S5.2). Both Fwd and Rev primers were 
generated, with 1 pair located at the outer edges of the homology arms/insert (inner) 
and 1 pair just outside the homology arms/insert (outer). The last primer was 
developed to be selective for knocked-in DNA sequences, exploiting the sequence 





Figure 5.2. BRD4 L/V knock-in design 
Design of BRD4 L/V knock-in reagents targeting BRD4 BD1 (A) and BD2 (B). Sense and anti-sense 
reference DNA sequence shown, alongside donor DNA template (orange) and protein sequence. L94 
codon highlighted in blue. PAM sites and gRNA regions highlighted in green. Introduced restrictions sites 
shown in red. ~500bp homology arms on DNA template omitted for clarity. C) Design of primers for KI 
testing and sequencing.  
 
The original knock-in protocol, developed by Dr Kwok-Ho Chan, utilised 
transfection of multiple plasmid vectors. A pX335 plasmid encoded a Cas9 D10A 
nickase gene and the gRNA, while a pBABE vector had the knock-in DNA templates 
encoded in its sequence. Plasmids were transfected into cells using Lipofectamine LTX 
(Thermo), and transfected cells were later selected for using treatment.  
  The design of CRISPR reagents for BRD2, BRD3 and BRDT knock-ins was begun 
by myself. These designs were not completed as it was anticipated that, following 
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BRD4 knock-ins, better ways of designing reagents may be realised. DNA templates 
and gRNA sequences were based on NCBI chromosome sequences (table S5.3) (figure 
5.3). The codon responsible for the critical leucine residue was mutated to encode a 
valine. To develop novel restriction sites a semi-computational approach was utilised. 
The website tool re site finder [217] can be given a DNA sequence, and will check 
several commercial catalogues for restriction sites either already present in the given 
sequence or that can be introduced through silent mutations. Re site finder was given 
the DNA sequence adjacent to the L/V mutation and generated many potential 
restrictions sites that required 3 or less mutations. Priority was given to restriction 
enzymes that were either already used in the AC lab, or readily available. Enzymes with 
specific restrictions sites were preferred over those with variable sites (i.e. enzyme AleI 
with site ‘GACNNNNNGTC’). Finally to simplify later identification of knock-ins, 
enzymes with medium to high activity in the buffers of high-fidelity DNA polymerases 
Phusion and Q5 were preferred (table 5.1). Various PAM sites were identified around 
the L/V and restriction site mutations. The ideal PAM sites would be those that can be 
deleted through a silent mutation and are 40-70 bp apart and close to the introduced 
mutations. In addition, PAM sites could only be exploited if their relevant crRNA (20 bp 
up-sequence) did not possess significant potential off-targets in the genome, as off-
target cleavage is a serious concern with the CRISPR/Cas9 system [218, 219], which can 





Figure 5.3. Non-BRD4 CRISPR designs 
Design of L/V knock-in DNA templates for all non-BRD4 BDs (orange), based on reference gDNA 
sequences. Encoded protein sequence included, and target leucine codon/residue highlighted in blue. 




Table 5.1. CRISPR knock-in L/V mutations and novel restriction sites. 
DNA sequence for WT leucine codons, and intended valine mutants. Restriction enzyme for which novel 
restriction site is introduced. WT DNA sequence, and mutations creating novel restriction site. Values of 
enzyme activity in PCR buffers is from New England Biolabs [223]. +++ - 100%, ++ - 50%, + - 25%. Total 
sequence changes required for L/V mutation and novel restriction site numbered. 
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5.3 – Optimisation of RNP Transfections 
 While an abundance of CRISPR work has been carried out with the kind of 
plasmid-based systems described above that majority of contemporary work is now 
performed using so-called ‘RNP transfections’, wherein purified Cas9 proteins are pre-
incubated with gRNAs (and in the case of knock-ins template DNA) and these 
ribonucleoprotein (RNP) complexes are directly transfected into cells (figure 5.4) [224-
226]. This new system has various advantages over the traditional plasmid-based 
transfection. Target cells are no longer required to produce the Cas9 nuclease or gRNA 
strands; the chance of cells not being transfected with all necessary plasmids (or not 
expressing all components at the same time) are greatly reduced; the Cas9 nuclease is 
rapidly cleared from the cells which greatly limits off-target mutagenesis and 
cytotoxicity [226]. One notable disadvantage of the system is that, without the 
presence of a plasmid expressing a selection marker (i.e. puromycin resistance) it can 
be more difficult to select for transfected cells and hence identify successful knock-ins.  
A number of short experiments were planned, attempting to knock-in the BRD4 
L/V mutations into A549 cells, with the aim of confirming the suitability of RNP-based 
knock-ins, determine the optimal protocol and compare the results to the plasmid-
based system. It was hoped that the knock-in efficiency of different protocols could be 
compared using gDNA extracted from non-sorted transfected cells (a mix of 
untransfected cells and hetero/homozygous knock-outs/ins) using two PCR-based 
assays. Fully evaluating the efficacy of each protocol would require single-cell sorting 
of the resulting populations and one-by-one screening for the presence of the knock-in 





Figure 5.4. Comparison of plasmid and RNP-based knock-ins. 
Plasmids method: plasmid containing template DNA and plasmid encoding single gRNA and Cas9 gene 
transfected into nucleus. gRNA and Cas9 are expressed, combine and use template DNA for knock-in. 
RNP method: separate crRNA and tracrRNA are combined, then combined with purified Cas9 protein. 
RNP complex and ssDNA template are transfected into nucleus, where they work to perform knock-in. 
 The two knock-in detection assays, developed by Dr Kwok-Ho Chan rely on PCR 
amplification of the BRD4 BD1/BD2 regions of extracted gDNA (figure S5.2). In the 
original ‘cleavage’ assay an ~1100 bp region of the genome, encompassing the knock-
in insert, is amplified before undergoing an overnight digestion with a restriction 
enzyme. As the L/V knock-ins contain engineered restriction sites (BamHI for BRD4 
BD1, ApaLI for BD2) cleavage of the PCR product will only be observed with successful 
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knock-ins. This assay is quantitative, and theoretically allows for estimations of the 
knock-in efficiency of different protocols (by analysing the gDNA of mixed cell 
populations) and can discriminate between hetero and homozygous knock-ins (when 
analysing FACS-sorted cells). Preliminary experiments validated the assay (figure 
S5.3A), although the ‘knock-in’ signal from a population of unsorted cells was almost 
undetectable. An alternate ‘amplification’ assay foregoes the restriction step and 
instead aims to amplify the knock-in region through a knock-in specific primer. By 
utilising the various knock-in mutations it is hoped that a primer can be specific 
enough to only amplify DNA when the knock-in is present. This assay should be able to 
generate a strong signal even when the knock-in rate is very low, but this assay will not 
be quantitative. Again, preliminary experiments validated the assay (figure S5.3B), but 
did raise the possibility of false-positives arising from interactions with leftover 
template DNA in the cells. Another serious concern was just how selective the primers 
could be, and how low a false-positive rate was acceptable given the anticipated low 
knock-in efficiency.  
BRD4 BD1 L/V knock-ins were attempted with the RNP protocol and a range of 
transfection reagents: RNAiMAX (Thermo), CRISPRMAX (Thermo), jetCRISPR (Polyplus) 
and TransIT-X2 (Mirus), with cells transfected by Dr Kwok-Ho Chan with the plasmid-
based protocol used for comparison. Knock-in efficiency was first analysed using the 
amplification assay, with mixed results (figure 5.5). The expectation was that the WT 
primer would generate a strong ~500 bp band for all samples, while the L/V primer 
would produce a fainter but visible band for any sample with a successful knock-in (i.e. 
the plasmids transfection, hopefully the RNP transfections but not the WT cells). 
Instead the results were far less clear as the L/V primer produced a band with WT cells 
and the amount of DNA loaded onto the gel varied greatly between samples. It was 
necessary to look not at the intensity of the ‘L/V band’ in isolation, but to compare it to 
the intensity of the bands produced by WT-specific primers (calculating the LV/WT 
ratio) in order to control for varying levels of gDNA. This, pleasingly, saw that all RNP 
transfections were more effective than the plasmid protocol, with TransIT-X2 being 
clearly the most effective. The reliability of the data is questionable however, as the 
L/V-specific primer still generated a strong band with WT gDNA (although this sample 




Figure 5.5. CRISPR RNP Test 1 
A549 cells were transfected with RNP complexes for BRD4 BD1 L/V knock-in, using transfection reagents 
RNAiMAX (rMAX), CRISPRMAX (cMAX), jetCRISPR (jetC) TransIT-X2 (X2), or by Dr Kwok-Ho Chan using a 
plasmid-based protocol (KI Plasmid). Genomic DNA was extracted, and the BRD4 BD1 region amplified 
with either WT or L/V-specific primers. A) PCR products were ran on a 1% agarose gel alongside 
Generuler 1kbp PLUS size ladder (Thermo) and visualised with SYBR safe. B) Intensities of ~700 bp bands 
were quantified in Image Studio Lite (Licor). LV/WT ratio = intensity of expected product band with L/V 
primer / intensity with WT primer.  
 The transfections were repeated for both BRD4 BD1 and BD2 knock-ins, and 
gDNA of higher quality was extracted. Additionally, following the manufacturer’s 
protocol, the PLUS reagent was used alongside the CRISPRMAX transfection reagent. 
Both the BD1 and BD2 datasets indicated that TransIT-X2 was again the superior 
transfection reagent, and both showed CRISPRMAX (with PLUS reagent) to also be 
effective (figure 5.6). Both datasets also show RNAiMAX (not designed specifically for 
RNP transfection) as the worst transfection reagent. Strangely, the BD1 assay again 
showed knock-in signal for the WT cells (again, the lowest of all samples) and 
suggested that the plasmid-protocol was actually superior to RNP transfection. The 
BD2 assay meanwhile again indicated the superiority of TransIT-X2 and CRISPRMAX, 
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but failed to generate any signal with the WT primer with the WT and plasmid-
transfected samples – again calling the reliability of the assay into question.  
 
 
Figure 5.6. CRISPR RNP Test 2. 
A549 cells were transfected with RNP complexes for BRD4 BD1 and BD2 L/V knock-in, using transfection 
reagents RNAiMAX (rMAX), CRISPRMAX with PLUS reagent (cMAX+), jetCRISPR (jetC) TransIT-X2 (X2), or 
by Dr Kwok-Ho Chan using a plasmid-based protocol (KI Plasmid). Genomic DNA was extracted, and the 
BRD4 BD1 region amplified with either WT or L/V-specific primers. A) PCR products were ran on a 1% 
agarose gel alongside Generuler 1kbp PLUS size ladder (Thermo) and visualised with SYBR safe. B) 
Intensities of ~700 bp bands were quantified in Image Studio Lite (Licor). LV/WT ratio = intensity of 
expected product band with L/V primer / intensity with WT primer. 
 The cleavage assay was then run on the BD1 samples, in the hopes it would 
prove more reliable and quantitative. Here a strong ~1100 bp ‘uncut’ band was 
expected from all samples, while successful knock-ins would produce a very faint ~500 
bp ‘cut’ band. The best KI method would show a greater proportion of ‘cut’ PCR 
product. Again the results were highly mixed, with all samples showing a range of 
bands in addition to the expected ~1100 bp PCR product and the ~500 bp cleaved 
fragment (figure 5.7). This assay also, like the amplification assay, indicated the 
presence of knock-ins with WT cells, and actually suggested that the WT cells 
possessed a greater proportion of knock-ins than the RNAiMAX or TransIT-X2 





Figure 5.7. CRISPR RNP Test 3. 
A549 cells were transfected with RNP complexes for BRD4 BD1 and BD2 L/V knock-in, using transfection 
reagents RNAiMAX (rMAX), CRISPRMAX (cMAX), jetCRISPR (jetC) TransIT-X2 (X2), or by Dr Kwok-Ho Chan 
using a plasmid-based protocol (KI Plasmid). Genomic DNA was extracted, and the BRD4 BD1 region 
amplified, then digested overnight with BamHI. A) PCR products (and knock-in template) were ran on a 
1% agarose gel alongside Generuler 1kbp PLUS size ladder (Thermo) and visualised with SYBR safe. B) 
Intensities of ‘cut’ ~500 bp bands and ‘uncut’ ~1100 bp bands quantified in Image Studio Lite (Licor). +/- 
ratio = intensity of 500 bp band with BamHI / intensity without BamHI. Cleave % = intensity of ‘cut’ 
bands as a percentage of the ‘uncut’ ~1100 bp bands. 
 The RNP transfections could have been replicated, and modifications to the 
protocols for each assay could have been made to increase their reliability. Higher-
fidelity DNA polymerase enzymes could have reduced the false negative/positive rate, 
while PCR clean-up kits could remove many of the unwanted bands. The main 
optimisation step would likely be the tweaking of the PCR protocol, to both remove 
unwanted bands and to improve the accuracy of the WT and L/V-specific primers. This 
may have required the use of different PCR cycles for WT versus L/V primers (and BD1 
vs BD2 primers), which would make the assays much less practical. 
 Repetition and optimisation of the RNP transfections and knock-in assays was 
not carried out, and the decision was taken to progress to a genuine knock-in attempt. 
Identifying the best transfection protocol, and maximising the knock-in efficiency 
would greatly aid in designing a protocol for obtaining knocked-in cells, but it was not 
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clear if that could actually be done. Even with improvements to PCR cycles it was not 
clear if any reliable and meaningful data would be obtained while analysing mixed, 
unsorted populations of cells following a transfection, and the cleavage and 
amplification assays may only be reliable or sensitive enough when utilised on sorted 
cells wherein each sample would contain only WT cells or only knocked-in cells. 
Optimisation of the knock-in strategy would have to be done in an incremental 
fashion, with multiple approaches done in tandem, with the protocol that generated 
the most (or any) knocked-in cells used for knocking-in the L/V mutation on the next 
bromodomain. 
 
5.4 – Knock-In Attempt – BRD4 BD1 L/V: 
 The first proper attempt to knock-in an L/V mutation was carried out on A549 
cells and aimed to introduce the L94V mutation into the BD1 of BRD4. It was planned 
to later attempt the BD2 knock-in on both WT and BD1 L/V cells, so as to acquire all 
three BRD4 L/V cell-lines (LV/WT, WT/LV and LV/LV). Low-passage number A549 cells 
were revived from an aliquot in cryostorage and grown-up in a 6-well plate. Once at 
60% confluency the CRISPR transfection was performed. Due to the additional length 
of the plasmid-based system and the slow growth of the revived cells only RNP-based 
knock-ins were attempted. Specifically the knock-in was attempted using the TransIT-
X2 and the CRISPRMAX (with PLUS reagent) transfection reagents, given their slight 
superiority in the (albeit unreliable) optimisation experiments.  
 Following transfection the cells were then given 3 days to grow in the incubator 
before being sorted. This allowed for new cells to replace those killed by the 
transfection (or resulting CRISPR activity) and for any RNP complexes to be cleared 
from the cells. The cells were not left to grow any longer, in case any L/V mutant cells 
that were generated were then out-competed by WT cells and made harder to identify 
later. The two populations of cells were then sorted by the School of Life Science Flow 
Cytometry and Cell Sorting Facility. From each population three 96-well plates were 
seeded, each well containing a single clone, giving potentially 576 distinct clones to 
analyse. Clones were hereafter referred to by their location post-sort, for example CM 
2D7 refers to the CRISPRMAX-transfected clone sorted into well D7 of plate 2.  
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 In the hope of reducing the number of clones requiring testing through PCR-
based assays a triage was attempted using the 96-well colony-formation assay 
described in chapter 4. As cells started to reach confluence each of the six 96-well 
plates was passaged and 3 new plates seeded. Of these 3 plates 1 was handled 
normally, and its cells used for later experiments. The other 2 plates were treated with 
either DMSO or 2 µM 9-ME-1 for 1 week, and then fixed and stained to look at cell 
growth and cytotoxicity. It was hoped that, if BRD4 BD1 activity is essential for A549 
cells, only successfully knocked-in cells would show a response to 9-ME-1. The cells 
grown in DMSO could also be used to confirm that the cells were still viable. Of course, 
given the lack of the BD1 mutant cell-lines the assumptions this assay rested on could 
not be confirmed in advance, nor was it known whether or not it would identify 
heterozygous knock-ins. As such it was felt that this experiment may not work, but if it 
was successful it would greatly reduce the amount of PCR work required later.  
 The assay was carried out as planned, revealing the difficulty on performing 
such an experiment on so many 96-well plates without the use of specialised 
hardware. The multiple pipetting steps were complicated by the need to replace tips 
between wells, to prevent cross-contamination; and efficient trypsinisation and 
passage of A549 cells proved difficult and likely inconsistent. The results of the assay 
were somewhat mixed. Checking each well with the light microscope suggests about 
50% of the clones survived the cell sorting process and went on to grow and divide, 
while the colony-formation assay shows far fewer clones growing in the DMSO-treated 
plates. Pleasingly, there were several clones that seemed to grow quite well in DMSO 
and were significantly perturbed by 9-ME-1 treatment (some examples in figure 5.8). 
Additionally, after scanning the stained plates 1% SDS was used to extract the dye from 
the cells, allowing for measurement of absorbance at 595 nm and a more quantitative 
analysis. This dye extraction also highlighted some clones that visually appeared 
unaffected by 9-ME-1 but accumulated significantly less crystal violet. Due to doubts 
about the assay’s reliability it was decided to take a larger number of clones forward 
for later analysis. By collecting any clone to show any degree of 9-ME-1 sensitivity 
(either visually or by A595 measurement) two 24-well plates were filled with 48 clones. 
Meanwhile the 96-well plates were frozen and stored at -80°C, with the hope that 




Figure 5.8. Colony-Formation Assay on CRISPR Clones. 
CRISPR-transfected and FACS-sorted A549 cells seeded in 96-well plates, treated with 0.02% DMSO or 2 
µM 9-ME-1 and incubated for 7 days, fixed with 100% MeOH and stained with 0.1% crystal-violet. A) 
Clones showing apparent 9-ME-1 sensitivity, identified by visual analysis of stained cells or A595 
measurement of wells following dye extraction with 1% SDS. B) A clone showing no such 9-ME- 
sensitivity. C) A595 values for the above clones. 
 
 The 48 clones were grown up in 24-well and later 12-well plates, and their 
gDNA extracted using the Qiagen DNeasy blood & tissue kit. As the L/V-specific PCR 
primer amplification assay was seen as unreliable the knock-in could be directly 
confirmed through PCR amplification of the BD1 region and either BamHI digestion of 
the knocked-in restriction site, or DNA sequencing of the PCR product directly. As DNA 
sequencing is obviously highly dependent on the minimisation of PCR-associated errors 
in DNA sequence it was decided to switch from Taq polymerase to a high fidelity 
enzyme. The QF polymerase would be ideal, but BamHI is not active in its reaction 
buffer, which would complicate the restriction assay. The Phusion polymerase also 
possesses high fidelity while allowing for BamHI activity. A trial PCR amplification and 
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clean-up (NEB Monarch kit) was performed on two samples, to ensure later samples 
would be of high enough quality for DNA sequencing (figure 5.9A).  For both samples 
the major PCR product was of the correct length, and little PCR product was lost in the 
clean-up (figure 5.9B). In the gel electrophoresis there were no visible impurities in the 
raw PCR product, and hence no improvement in the ‘clean’ samples. Meanwhile UV 
nanodrop analysis of the samples showed that the cleaned samples were of much 
higher quality. The A260/A280 ratio was much improved by the clean-up protocol. The 
removal of proteins and other impurities has greatly lowered the apparent DNA 
concentration (~135 to ~10 ng/µl) while the gel electrophoresis shows no actual 
reduction in DNA content. 
 The two purified PCR products were then submitted for DNA sequencing, using 
the ‘Fwd Inner’ primer (~80 bp from start of PCR product, ~450 bp from knock-in 
mutations). The sequencing reactions were successful, and the provided sample was 
both abundant and pure enough to generate reads with reliable coverage of the 
knock-in region. Neither clone tested was shown to be successfully knocked-in (hetero 
or homozygous), but the results did show that PCR-amplification of the clone gDNA, 
and using DNA sequencing to test for the knock-in, was a practical way to test the 
remaining 45 clones (figure 5.9C-D). For discussing subsequent sequencing results it 
was decided to refer to individual nucleotides/basepairs not by their absolute position 
within the reference gDNA sequence, but by their position relative to the critical L/V 
mutation (C59726G for BRD4 BD1). Both samples did show an unintended, off-target 
mutation (G to T, at position +49) which was originally thought to be a PCR error but 




Figure 5.9. Validation of BRD4 BD1 PCR, Clean-Up and DNA Sequencing. 
BRD4 BD1 region amplified from gDNA by PCR (Phusion polymerase), and resulting reaction mixture 
purified. A) Nanodrop analysis of raw PCR mixture and purified product. B) 10 µl of raw PCR product and 
purified product run on a 1% agarose gel alongside Generuler 1kbp PLUS size ladder and visualised with 
SYBR safe. C) DNA sequence of original WT gDNA and purified PCR products. Blue = WT, orange = non 
knock-in mutations. Location and nature of desired knock-in mutations are given. D) Portion of 







The PCR and sequencing protocol was applied to all 44 remaining clones (2 of 
the 48 selected clones failed to grow) (figure 5.10). Of the 46 clones that underwent 
sequencing 6 failed to generate any reads (figure 5.11A) (discussed later), 2 appeared 
to contain heterozygous knock-outs and the remaining 36 showed no sign of any 
knock-in. The 35 clones showing no knock-in were disposed of, and the 8 clones with 
potential knock-outs were frozen and stored at -80°C for later investigation. The G/T 
mutation at position +49 was seen in all PCR products, showing it to be a SNP and not 







Figure 5.10. CRISPR Sequencing Screen. 
DNA sequence of PCR products derived from A549 clones targeted for BRD4 BD1 L/V knock-in, 
compared to WT reference sequence (NC_000019.10) in blue. Nucleotides are numbered relative to the 
key L/V C59726G mutation. Location and nature of knock-in mutations given. Key knock-in nucleotides 
that were not mutated are highlighted in blue. Divergences from WT sequence are highlighted in 
orange. Clones CM 1B8 and 3E1 failed to grow after being transferred to 48-well plate, prior to gDNA 
extraction and PCR. Clones X2 1C4, 1C6, 2E4, 3D6, 3F9 and 2B10 did not produce any PCR product with 




5.5 – Knock-Out Characterisation: 
 Potential heterozygous BRD4 BD1 knock-outs were identified in clones CM 2D7 
and CM 1F4. They were first identified by a sudden breakdown in the coherence of the 
reads at positions +39 and +32, respectively, and overlapping signals at many positions 
(figure 5.11C).  A look at the chromatogram for CM 2D7 showed that some stretches of 
the WT sequence were still identifiable, like the 2 Cs at positions +39 and +40 and 6 Cs 
from positions +83 to +88. The PCR products of these clones was sequenced using the 
Rev Inner primer, which generated reads suggesting the potential knock-outs CM 2D7 
and 1F4 terminated at positions +42 (2D7) +66 (1F4), giving knock-outs with length 4 
and 35 bp, respectively (figure 5.11D). The PCR products were ran on a 1% agar gel, 
and no clear difference in size is visible (figure 5.11B). Very faint ~1000 bp bands are 
visible for clone 1F4, but these are likely from an adjacent size-marker. The knock-outs 
are contained entirely within the intron sequences. 
 If the BRD4 gene is triploid in A549 cells then, strictly, the term ‘heterozygous’ 
cannot be used as it refers to diploid systems. As the triploid nature of BRD4 is not 
certain, and lacking any better term, the term ‘heterozygous’ will still be used. But, it 
must be noted that ‘heterozgous’ knock-out clones may in fact only have 1 (or 2) of 3 




Figure 5.11. Genetic characterisation of potential knock-outs. 
A) Gel electrophoresis of BRD4 BD1 PCR products from WT A549 cells and potential KO clones ran 
alongside GeneRuler 100bp Plus DNA Ladder (Thermo) and visualised with SYBR safe. B) Gel 
electrophoresis of BRD4 BD1 PCR products from WT A549 cells and potential heterozygous KO clones 
run alongside Generuler 1kbp Plus DNA ladder (Thermo) and visualised with SYBR safe. C) Portion of 
sequencing chromatograms, centred on beginning of suspected heterozygous knock-out, displayed in 
SnapGene Viewer. D) DNA sequence of PCR products derived from potential KO clones, compared to WT 
reference sequence (NC_000019.10) in blue. Nucleotides are numbered relative to the key L/V C59726G 
mutation. Location and nature of knock-in mutations given. Key knock-in nucleotides that were not 
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mutated are highlighted in blue. Divergences from WT sequence are highlighted in orange. Sequencing 
performed with BRD4 exon2 Fwd inner primer. 
To investigate the significance (if any) of these potential knock-outs the viability 
of the clones was assessed using the CellTiter-glo and 96-well colony-formation assays 
(figure S5.4). The colony-formation assay, ran on all potential KOs, showed all clones to 
have reduced viability (figure 5.12A). Clones X2 2E4, X2 3F9 and CM 2D7 showed some 
visible cell growth during the assay, while the remaining clones showed no visible 
colonies. Meanwhile the CellTiter-glo assay, ran only on the CM 2D7 clone, showed no 
drop in cell viability for the potential KO (figure 5.12B). The pronounced difference in 
the growth of clone CM 2D7 between the two assays could be due to a technical error 
when seeding the colony-formation assay, or suggest a loss in cell adherence. 
 
Figure 5.12. Viability of Potential BRD4 BD1 Knock-Outs 
A) Absorbance at 595 nm of A549 cells stained with crystal violet dye (7 days’ growth), and dye 
extraction in 1% SDS. B) Luminescence of A549 cells measured via Celltiter-Glo assay (3 days’ growth.) 
The remaining 6 clones (X2 1C4, 1C6, 2E4, 3D6, 3F9 and 2B10) failed to 
generate any reads at all, and were later shown to have generated no PCR product, 
due to either serious problems with the gDNA extraction or hinting at sequence 
changes so widespread that the annealing sites of one or both PCR primers were 
deleted (such as an extensive and homozygous knock-out). Unfortunately there was 
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insufficient time to further investigate these clones and determine the exact cause of 
the lack of sequence reads.  
 
5.6 – Discussion: 
 One early step that could have aided this knock-in attempt would be ensuring 
that the starting population of A549 cells was clonal. As A549 cells often display 
cytogenic instability the cells utilised in CRISPR transfection was likely polyclonal. This 
would add layer of variability to later experiments, which may account for some odd 
results. Different populations within our A549 cell-line may grow at different rates, 
complicating the passaging of the many clones that were sorted post-transfection. 
When the colony-formation assay was repurposed to screen for 9-ME-1 sensitivity (a 
potential marker of L/V knock-in) differences in the copy number or expression of 
BRD4 (or other proteins) make it unlikely that (excluding knock-ins) all A549 cells are 
equally sensitive to the 9-ME-1 dose. This could also explain why, when characterising 
the viability of potential BRD4 knock-outs, different clones showed different growth-
rates. Before future knock-in attempts a monoclonal population should be established. 
This can be done through cell-sorting, as was done post CRISPR transfection, or even 
by extensive dilution of a polyclonal population and seeding into a multi-well plate.  
Both the optimisation of the knock-in transfection and the detection of 
knocked-in clones is limited by the assays involved in knock-in detection. The 
amplification assay, using WT and L/V-specific PCR primers, did not give the clear and 
reliable binary response hoped for, and the occasional lack of bands generated by WT 
primers casts doubt on its results. It is difficult to tell how ‘selective’ a given primer is, 
and given that our knock-in templates were not designed for such an assay we may not 
be able to generate very selective primers from the small changes in DNA sequence 
introduced. New knock-in templates, with additional silent mutations may allow for 
much more selective primers. Another potential optimisation is to alter the annealing 
temperature used, which should reduce ‘off-target’ amplification. This optimisation 
could be quite complex, especially if the WT and L/V-selective primers possess 
differing optimal annealing temperatures. The cleavage assay, utilising the introduced 
restriction site, should be more reliable and quantitative but does rely on a sufficiently 
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high knock-in efficiency. Using the cleavage assay on unsorted cells may not be 
realistic, although some techniques discussed below may help with this. If new KI 
templates are designed then it might be worthwhile to remove an endogenous 
restriction site, rather than introducing a novel one. One could then run a 3-part assay: 
non-selective PCR amplification, cleavage, and a second round of PCR using primers 
selective for uncleaved PCR products. The second round of amplification should then 
boost the sensitivity of the assay.  
 Instead of our in-house developed PCR-based assays for KI detection the 
SURVEYOR nuclease assay, from the literature [227, 228], could be used instead. In this 
assay the target locus (in this case BRD4 BD1/BD2) is amplified from gDNA using PCR. 
This PCR product will (hopefully) contain a mixture of homozygous ‘WT’ and ‘KI’ DNA 
duplexes, but through denaturation and re-annealing any KI duplexes can be converted 
into partially mismatched heterozygous WT/KI duplexes. This mismatched DNA will 
then be selectively cleaved by nucleases such as CEL II and T7 endonuclease I, 
producing additional, smaller bands following gel electrophoresis [227-229]. 
Quantification of gel bands can then be used to calculate an estimated of the 
proportion of gDNA containing a modification. The SURVEYOR assay has been used 
often in the literature when discussing CRISPR-mediated gene editing [197, 199, 207]. 
The SURVEYOR assay in many ways acts like our existing cleavage assay, which has 
provided mixed results, but it does remove the need to introduce a new restriction site 
during the knock-in. Its main advantage is that, as the WT and KI DNA duplexes are re-
annealed the final percentage of DNA that is cleaved by the nuclease should 
theoretically be double the percentage that was originally knocked-in, doubling the 
sensitivity of the assay [227]. The SURVEYOR assay is hence very effective for 
measuring knock-out efficiency, but it may be far less suited for knock-ins. Unlike our 
cleavage assay the SURVEYOR assay measures all changes to DNA sequence – including 
KOs and off-target mutations [227], and hence the majority of ‘gene-modification’ 
signal we observe may not be due to knock-ins. Comparing the strengths of different 
assays (table 5.2) the SURVEYOR assay may not be as accurate as the cleavage assay 
when determining if individual clones possess knock-ins, but it can be used to 





Table 5.2. Comparison of knock-in detection assays. 
 Knock-in detection could also be carried out by progressing from PCR and gel-
electrophoresis to Southern blots [230]. In such experiments PCR products from BD 
sequences would be transferred to into membranes where they can be tested with 
hybridisation probes. This could be used alongside the cleavage assay, where the use 
of probes could increase sensitivity and clarify results otherwise complicated by 
unwanted DNA bands (as in figure 5.7).  Protocols for assessing CRISPR knock-out and 
knock-in efficiencies using next generation sequencing are also being developed. One 
such protocol [231] can be performed on an unsorted population of cells and is highly 
sensitive.  
 Outside of CRISPR-based gene-editing, the literature features many examples 
of assays developed to detect specific single-nucleotide polymorphisms (SNPs) (too 
many to describe here) which could be repurposed to detect our desired knock-ins 
[232]. In the Invader assay [233] two oligonucleotides with partially overlapping 
homology for the SNP form a three-part structure with the sample DNA strand, which 
can be cleaved by the Flap endonuclease (FEN). One of the overlapping 
oligonucleotides possesses both a fluorophore and complementary quencher label, 
hence cleavage by FEN will generate a fluorescence signal. If the SNP is not present in 
the sample DNA the three-part structure is not formed properly, is not cleaved by FEN 
and the fluorophore is unable to generate any signal. Another assay, TaqMan [234, 
235], works on a similar basis with a SNP-commentary oligonucleotide probe 
possessing a fluorophore/quencher pair on opposite ends of the probe. In the absence 
of the SNP this probe forms a hairpin structure, keeping the fluorophore/quencher pair 
in proximity and preventing signal. When this probe binds to a SNP-containing DNA 
sample the fluorophore and quencher will be brought apart, generating signal. These 
SNP assays may be more complex and require more expensive reagents than our PCR-
based assays, and may still face issues with selectivity and false-positives. Additionally 
Assay Sensitivity Quantitative? KI-specific? Throughput Source
Amplification High No In theory High In-house
Cleavage Low Yes Yes Mid In-house
SURVEYOR High Yes No Low Literature
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the oligonucleotide probes will need to be carefully designed and assay conditions 
optimised. The relatively high-throughput nature of these assays, and their apparent 
success in detecting very small changes in DNA sequence does mean they may be ideal 
for future knock-in detection. 
In order to maximise the chance of obtaining a heterozygous or homozygous 
BRD4 BD1 L/V knock-in almost 600 A549 cells were sorted into 6 96-well plates, to be 
grown and analysed. This proved to be too many cells to properly care for and study. 
A549 cells appear to be somewhat resistant to trypsinisation, often requiring ~7-10 
minutes instead of ~5 minutes for the other adherent cell-lines worked on in this 
project. This, combined with the 96-well format, made passaging the clones very 
difficult and inconsistent. For many reasons (polyclonal starting population, variation 
in media volume, edge-effect in plate) different clones would grow at different rates, 
needing to be passaged on different days and split to a greater extent. Additionally, 
the mere act of checking the confluence of 600 clones was impractical, and clones 
could not really be passaged at different rates. Finally, running the PCR-based KI-
detection assays on hundreds of clones would have been very difficult, time-
consuming and would require large amounts of expensive enzymes and gDNA 
extraction kits. For this reason the colony-formation assay was used to look for 9-ME-1 
sensitivity, and narrowed the population down to ~45 clones. This assay, however, was 
likely not very reliable due to the above mentioned differences in clone confluence and 
growth, and the difficulty in running said assay in such a small format and such large 
numbers. A better way to utilise 9-ME-1 to detect L/V knock-ins might be to instead 
develop a 9-ME-1-dye/fluorophore conjugate and see if it accumulates in KI versus WT 
cells 
CRISPR work by Dr Kwok-Ho Chan in a separate project suggests that obtaining 
heterozygous knock-ins can be reasonably easy, and may only require 100-200 clones. 
Hence it may help with later knock-in attempts to run much smaller, easier to manage, 
experiments with the aim of obtaining heterozygous knock-ins (figure 5.13). These 
heterozygous knock-ins can then undergo a second round of transfection and sorting 
to obtain homozygous knock-ins. One downside to this could be the risk of doubling 
the likelihood of deleterious off-target double-strand breakage during the knock-in 
process, which could be especially severe when developing double-mutants (i.e. BRD4 
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BD1 L/V, BD L/V cell-lines) which would undergo four rounds of transfection. As this 
approach would double the amount of ‘work’ done on said knock-in cells they 
accumulate other, not immediately noticeable, changes in the genome. This increased 
divergence from WT may hinder the usability of the knock-ins, as results obtained from 
them may not be of any use in understanding WT cells. Heterozygous knock-in cell-
lines may also be of use while, although bumped compounds will only be able to 
inhibit ~50% of the expressed target BET protein. Whether or not this would be 
sufficient to investigate BET protein/BD function will likely depend on the exact 
context one is studying. If the target BET gene is triploid then performing the L/V 
knock-in in only 1 of 3 genes would further limit the impact of bumped compounds, 
while generating homozygous (3 of 3 genes) in a stepwise fashion would require an 
additional round of transfection.  
 
Figure 5.13. Different methods to generate knock-in clones. 
Four different, potentially usable, clones can be generated through CRISPR, following one or two rounds 
of transfection. Target genes (e.g. BRD4) can be heterozygously or homozygously knocked-out or 




Despite not detecting any knocked-in clones several knock-out clones may have 
been generated. Two clones are believed to possess short heterozygous knock-outs 
within an intron sequence in the BD1 region of BRD4, while 6 clones may have much 
more widespread, homozygous knock-outs. Western blot analysis of BRD4 levels could 
identify whether these potential knock-outs have prevented BRD4 expression, or 
potentially lead to the expression of truncated isoforms lacking the BD1. Due to the 
pre-eminence of NHEJ-mediated DNA repair it is expected to generate substantially 
more KO than KI clones following a CRISPR experiment, and the appearance of these 
potential KO clones can be taken as evidence that the gRNAs used and RNP 
transfections are functional.  
 One potential strategy, moving forwards, is to create heterozygous knock-
out/knock-in cell-lines, instead of the much more difficult homozygous knock-in (figure 
5.13). If knock-outs are generated that abolish BD function, but do not affect cell 
viability (will be dependent on specific BD and cell-line) then the other, still WT, allele 
could be targeted for a L/V knock-in. If cells are able to survive with only one functional 
allele of a the BET protein in question then such a system should be a viable way to 
study said protein and its associated phenotypes with bumped compounds like 9-ME-
1. Some knock-outs will remove or frameshift the entire BET gene, while others may 
only remove small stretches of the gene sequence and make relatively minor changes 
to the final protein sequence. In such cases site-directed mutagenesis could be used to 
recreate the effects of the knock-out on the protein level and produce protein 
constructs for characterisation. The effects of a knock-out on BD function could then 
be assessed by peptide ITC titrations on single-BD constructs, or FRAP experiments 
with full-length, GFP-tagged constructs.  
The use of RNP transfections, as opposed to transfecting cells with plasmids 
expressing Cas9 and containing KI template DNA, is believed to have many advantages 
but does have one serious downside. Plasmid-based transfections allows for the use of 
FACS to select for successfully transfected cells, as one can use plasmids that also 
express GFP proteins. In order to allow for FACS-enrichment of transfected cells IDT 
has recently developed fluorophore-labelled gRNAs. By attaching the ATTO-550 dye to 
the long, invariable tracrRNA FACS can be used to select for cells that have been 
successfully transfected with RNP complexes [236]. This approach may be somewhat 
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limited if a sizable proportion of the fluorescent RNA is not packaged into full RNP 
complexes, but is still transfected into cells. These cells would then still be selected for 
but would not have any chance of being knocked-in. The ATTO-550 dye has been 
confirmed to be compatible with the FACS equipment used in the School of Life 
Sciences. By enriching for transfected cells it may become possible to use the PCR 
cleavage assay to quantify the overall knock-in efficiency of a given transfection 
protocol, while without said enrichment the efficiency is too low for detection without 
single-cell sorting. If said overall efficiency can be measured, without single-cell 
sorting, then optimisation of transfection protocols will be much easier. Fluorescent 
gRNAs can also be used to measure simple transfection efficiency, perhaps by 
transfecting cells in a microscope dish and later imaging them for ATTO-550 and a 
DAPI-style nuclear stain [236].  
One other change to our knock-in strategy that would allow for fluorescent 
selection of knocked-in cells would be to switch from a (relatively) subtle L/V knock-in 
onto endogenous BET proteins and instead knock-in a full-length, L/V-mutated GFP-
BET construct (like those used in FRAP assays), either on top of endogenous BET genes 
or into other regions of the genome. This would allow for selection of knocked-in cells, 
as opposed to transfected cells with the fluorescent gRNA strategy. The reason this 
strategy has not been employed is the presence of multiple, potentially conflicting, 
BRD4 isoforms. Yet BRD2 and BRD3 do not possess such divergent isoforms and hence 
this strategy could be employed to more easily produce BRD2/3 mutant cell-lines. 
Depending on where these constructs are knocked-in there could still be issues with 
proper regulation of expression and silencing of endogenous genes; while depending 
on the promoters used one may only need to knock-in a single copy of the construct, 
further simplifying the process.  
 Several approaches have been trialled in the literature that seek to boost HDR-
mediated DNA repair and knock-in efficiencies, which could be adapted for future 
bump-&-hole knock-ins. Attempts have been made to boost knock-in efficiencies by 
inhibiting NHEJ processes with small-molecules, thus increasing the utilisation of HDR 
by targeted cells. An inhibitor of DNA ligase IV, Src7, increased the efficiency of HDR-
mediated gene editing at 4 gene loci in several cell-lines (including A549) from 2 to 19-
fold [237]. In a later paper cytochalasin, an inhibitor of actin polymerisation, aided the 
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generation of knock-in mice embryos [238]. Similar results have also been seen with 
the B3-adronergic receptor agonist L755507 and the natural product resveratrol [239, 
240]. Use of these inhibitors have not become particularly widespread due to the often 
small improvements in knock-in efficiency and concerns over toxicity [239, 241].  
Small-molecules, and other tools, can also improve KI-efficiency by interfering 
with the cell-cycle (figure 5.14). NHEJ dominates DNA repair from the G1 to the G2 
phase, while HDR-mediated NDA repair occurs only in the S and G2 phases (alongside 
NHEJ), as only at this stage can sister chromatids be used as repair templates [242]. As 
such perturbation of the cell-cycle, or temporally control of the CRISPR-process may 
increase knock-in efficiency. A combination of small-molecule cell-cycle 
synchronisation and well-timed CRISPR RNP nucleofection increased the efficiency of 
HDR-mediated DNA repair from ~10% to ~33% [243]. By fusing Cas9 and the N-
terminal region of Geminin one lab created a ‘Cas9-hGem(1/110)’ construct that would 
be ubiquitinated and degraded during the G1 phase of the cell-cycle, and limit gene-
editing activity to the less NHEJ-dominated S, G2 and M phases. This process almost 
doubled the efficiency of HDR in HEK293T cells, albeit from an unusually low baseline 
of ~0.5% [244]. Finally, a recent paper has shown that HDR efficiencies can be 
increased 2-10-fold in HEK293 cells through ‘cold shocking’ cells at 32°C for 24-48 h 
after transfection [245]. An accumulation of cells at G2 and M phases was an early 
explanation for this effect, but this has not yet been confirmed, while the 
thermodynamic stabilisation of DNA recombination intermediaries is another likely 
factor. Crucially, several of these studies [239, 243, 245] that showed increases in HDR 
efficiencies also observed a plateau at ~33%, suggesting this may be an absolute limit 
(without more extensive perturbation of biology). Another point to consider is that the 
above referenced works typically report on HDR efficiency, or the percentage of DNA 
repair mediated by HDR, and not a parameter more directly relevant to this work (i.e. 
percentage of transfected cells shown to possess a desired KI). The use of A549 cells 
stably transfected to express the nickase enzyme would simplify subsequent knock-ins, 
but would require a significant up-front investment of resources, would not help with 
knock-ins in other cell-lines and may perturb natural cellular functions. Said stably 
transfected nickase gene could potentially be placed under the control of certain 
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promoters and regulatory elements that maximise Cas9 levels during the S phase of 
the cell-cycle, when HDR occurs. 
 
 
Figure 5.14. Exploitation and perturbation of the cell-cycle to boost knock-in efficiency. 
G1 – growth. S – DNA replication. G2 – preparation for division. M – mitosis. 
  
In addition to the above CRISPR knock-on optimisations there have also been 
advances in the overall methodology used to generate KIs, combining multiple changes 
in protocol and reagents. By switching from short ssODN to long ssDNA knock-in 
templates the Easi-CRISPR system increased knock-in efficiency from ~10% to ~50% 
and simplified template design [241]. The Easi-CRISPR system is limited with regards to 
insert size (~1.5 kbp limit), but this should still be suitable for our purposes. In the Tild-
CRISPR system PCR amplification or enzyme cutting is used to generate dsDNA 
templates with ~800 bp homology arms, which are delivered into cells alongside gRNA 
and Cas9 mRNA [246]. Compared to a standard homologous recombination DNA 
template Tild-CRISPR increased overall knock-in efficiency 10-20-fold, while avoiding 
the insert size and financial cost of Easi-CRISPR templates. Finally, the PITCH system 
attempts to optimise gene editing by utilising MMEJ instead of HDR [247]. Double-
strand DNA breaks can be repaired with MMEJ when short (~20 bp) microhomologies 
are present up-and down-stream of the break site, and this occurs in the M and S 
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phases of the cell-cycle. This system generated knock-in efficiencies of 60-85% in 
HEK293T cells and zebrafish embryos, and also allows for easy template design. 
Our sequencing reads, derived from the gDNA extracted from transfected A549 
cells, consistently showed several single base-pairs differing from the database-derived 
gDNA sequences we used for designing primers and templates. The most notable 
example was a T at position +49 instead of a G, and there were several more. A few 
isolated examples could be explained as errors introduced during PCR, and may be 
removed by the use of an even higher fidelity enzyme. However, the consistency at 
which these were observed suggests they are not errors, but simply examples of the 
A549 genome differing from those used to make database sequences. As far as can be 
discerned, these SNPs should not affect the BRD4 BD1 L/V knock-in, as they do not 
alter the PAM sites or regions targeted by gRNAs, and the large homology arms used in 
CRISPR can tolerate several mismatches. SNPs could be an issue when working with 
other BDs or in other cell-lines, where they may alter PAM sites and gRNA sites. 
Additionally, if these SNPs impact on protein sequence, splicing or other regulatory 
systems it would be ideal to not alter them in the course of the L/V knock-in, as we 
want to minimise sequence changes. In the future CRISPR knock-ins should be 
designed based on DNA sequences derived from A549 cells (or other intended targets), 













5.7 – Conclusions: 
 The development of cell-lines bearing the L/V mutation on endogenous, 
properly expressed BET proteins is key to the future use of the BET bump-&-hole 
system. This is likely best done through the CRISPR/Cas9 system, which we plan to 
utilise in an RNP-transfection method with the Cas9 D10A mutant nickase enzyme. 
Preliminary results suggest that both the plasmid and RNP-based transfections do 
generate knock-ins, and some optimisation may be possible but this is severely limited 
by our inability to reliably detect knock-ins within unsorted populations of cells. An 
attempt was made to knock-in the L/V mutation onto BRD4 BD1 in A549 cells, which 
appears to have been unsuccessful. This work has however taught many lessons on the 
practical aspects of CRISPR-mediated knock-ins, which in addition to advances in the 
literature and commercial CRISPR products should improve future attempts. In 
addition several clones were identified as potential hetero-/homo-zygous BRD4 or 
BRD4 BD1 knock-outs. This both suggests that our current CRISPR knock-in system is 


































6.1 – Implications for Bump-&-Hole Systems 
 After several years of developing, optimising and implementing the BET bump-
&-hole system we believe some of our observations can be applied to bump-&-hole 
research in general (not just to BET bromodomains).  These observations may aid in 
the design of similar systems with regards to other families of structurally conservative 
and therapeutically significant proteins. 
The most fundamental component of any bump-&-hole system is the mutation 
utilised for selective inhibition of the preferred target.  As any reliable investigation 
into the biology of the protein(s) of interest requires a functional mutant it is 
imperative to properly characterise any mutants developed, and to focus only on those 
that seem likely to function in cells or in vivo. Fortunately, we see a reasonable 
correlation in the ranking of mutants between low-level functionality assays with 
purified constructs (i.e. BLI / ITC) and higher-level cellular experiments 
(FRAP/luciferase), suggesting that functional mutants should be identifiable at early 
stages. Unfortunately, it is very difficult to know exactly how ‘functional’ a mutant 
needs to be to ensure viable mutant cell-lines or animal-models, and this will likely 
depend on the exact role of any target protein. Additionally, we do see some variance 
in the impact of mutations across different experiments, as the L/A mutants show a 
~10-fold drop in affinity for peptides (ITC), a ~3-fold decrease in chromatin binding 
(FRAP) but an almost complete collapse of downstream gene expression induction (NF-
B luciferase assay). Researchers ought to focus on mutations that are as subtle and 
structurally conservative as possible (figure 6.1). The L/A mutation can be argued to 
not be too severe from a structural standpoint, but has since been shown to be 
suboptimal, and our preferred L/V mutation represents the loss of only a single heavy 
atom. Even the leucine/isoleucine L/I mutation could have been used, if the L/V 
mutation proved unusable, as without the loss of any heavy atoms it did allow for 
selectivity, albeit limited. Once an acceptable functional mutant has been 
characterised selective bumped compounds can then be assessed, and any limits on 
potential selectivity as a result of the necessary mutation must simply be accepted. 
Other bump-&-hole projects outside of our work, like those in kinases or 
PKMTs, do utilise much more disruptive mutations (i.e. I/A, Y/A). This is likely the result 
of different proteins being potentially much more or much less tolerant of mutations, 
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in an essentially random fashion. Alternatively, this could be an indicator that PPIs are 
quite sensitive to mutations, while enzymatic catalytic sites are fairly tolerant of any 
mutations that don’t directly affect catalytic residues.  
 
Figure 6.1. The supremacy of more conservative mutations and smaller bumps. 
More severe mutations lead to a loss in mutant functionality, while larger and more flexible bumps tend 
towards a loss in compound potency. 
Just as a subtle mutation is key, it seems that appropriately minor chemical 
modifications are likely the best way to generate the best mutant-selective inhibitors 
(figure 6.1). The BET bromodomain bump-&-hole system has progressed from a L/A 
mutant and a 2-carbon, ethyl bumped ligand to a L/V mutation paired with a 1-carbon, 
methyl bumped ligand (with additional methoxy-shift modification). Although larger 
bumps might be considered to offer enhanced selectivity they possess three severe 
drawbacks. The most obvious is the potential loss of affinity to the mutant, if the bump 
is too large or does not fit optimally into the created cavity. The second drawback, 
which has shown to be more severe in our SAR work, is that longer carbon chains will 
possess greater rotational flexibility, which is likely to seriously impair 
affinity/selectivity for mutants. Our 4-carbon, propyl-bumped compound was one of 
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the least potent and selective compounds trialled. The 4-carbon alkyl-bump, bearing a 
rigid double-bond, was much more effective, though notably still worse than the 2-
carbon ethyl bump. The utilisation of double C=C bonds (as just discussed) or even the 
incorporation of 3-carbon rings into bumps could be beneficial, if they are possible 
synthetically. Thirdly, larger bumps can significantly alter the DMPK properties (LogP, 
membrane permeability and CLint) of an inhibitor scaffold, which is not desirable for 
cellular investigations.  Larger bumps (especially those possessing rings) will increase 
the hydrophobicity of the compound (as seen with the propyl bump) and potentially 
alter cell-membrane permeability and metabolic degradation by microsomes.  
 Through our SAR we have also revealed insights into other ways of modifying 
scaffold compounds to generate superior bumped inhibitors. Moving  the methoxy 
group from the 8’ to the 9’ position on the scaffold (relatively distant from the bump 
and mutation) was quite beneficial and was present in two of the best compounds (9-
ME and 9-ET), showing the value in trialling a range of modifications seemingly 
irrelevant to the target mutation. The strong impacts of the different alternate side-
group modifications show that the flexibility of the part of the ligand the steric bump is 
derivatized from can be very important to affinity and selectivity. The residual WT 
binding of compounds like ET is best explained by the rotation of the methyl-ester 
side-group into a conformation that reduces the WT steric clash, and attempts to 
prevent this through amide side-group : protein hydrogen bonds had a strong impact 
on WT binding, producing several of the least WT-potent compounds tested. 
Rotational freedom of the bump site may also explain why the compounds targeting 
the W/F and W/H mutants (with modified chlorophenol rings) displayed low 
selectivity. Ideally, compounds would feature the bump coming off a part of the 
scaffold that is both rigid, yet correctly oriented to ensure any bump added is able to 
fit into the mutant cavity out of a suitably fixed vector. 
For the bulk of this project the focus has been on the mutation and compound 
aspects of the bump-&-hole system, though the means by which the mutation is 
implemented into a model biological system is also key to its use in answering 
biological questions. Transient overexpression of GFP-BRD4 constructs was successful 
for investigating the importance of the BD1s and BD2s to chromatin binding and 
transcription, but attempts to utilise this to study the importance of BET BDs to cell 
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viability failed. These attempts showed that for more advanced experiments the 
mutant BET proteins must be stably expressed by model cell-lines, and the 
endogenous WT proteins must be suppressed or removed. Originally this was intended 
to be done by using the Flip-in system to stably integrate a tetracycline-dependent 
GFP-BRD4 gene into U2OS cells, while using siRNA to knock-down the WT gene [159]. 
Some results obtained with this system were promising, but the inability to properly 
regulate or splice the L/V BRD4 gene left it unable to fully rescue the expression of 
BRD4-dependent genes following knock-down of the WT gene. In order to both ensure 
that mutant BET genes are perfectly regulated and spliced, and completely remove 
endogenous WT expression, it was clear that the CRISPR/Cas9 system had to be used 
to knock-in the L/V mutation onto BET genes. This work has not yet been successful, 
but is likely the only way to use the bump-&-hole system to answer more detailed 
biological questions, like what BET proteins are needed for the proliferation of 

















6.2 – BET Protein Function Model: 
Using the FRAP assay the importance of each BET proteins’ BD1 and BD2 to 
chromatin binding was quantified. This work showed the BD1 to be the most 
important to chromatin binding, and that the BD2 had no role in chromatin binding for 
BRD2 and BRDT and little role in BRD4. In recent years several papers have been 
published showing evidence for interactions between BET bromodomains and 
acetylated non-histone peptides (figure 6.2). BRD4 BD2 has been shown to bind Twist 
and the RelA subunit of NF-B (both when acetylated) [90, 95], BRD2 BD2 is believed 
to interact with acetylated STAT3 [112] and BRD3 BD1 has been shown to bind di-
acetylated GATA1 [248]. The lack of chromatin binding displayed by these 
bromodomains was surprising, and it was decided to investigate their importance to 
transcription – a key cellular function of BET proteins. Work with a NF-B luciferase 
assay showed that, with regards to NF-B signalling, the BD2 of BRD4 is equally 
essential to transcription as its BD1. Additionally, the BD2 of BRD2 and BRDT were 
shown to play a role in transcription despite no observable chromatin binding. These 
findings collectively show that, although they do not bind chromatin, these BD2s and 




Figure 6.2. BET bromodomain : non-histone protein interactions. 
Structures of BET bromodomains in complex with acetylated non-histone protein peptides, with 
acetylated lysine residues highlighted. PDB codes: BRD2 BD2 / STAT3 (5U5S), BRD3 BD1 / GATA1 (2L5E), 
BRD4 BD2 NF-B (2LSP), BRD4 BD2 / Twist (2MJV). 
Taking these observations and the literature we discussed we believe we have 
provided strong evidence for a new model for BET protein function. Older models 
often feature BET proteins binding acetylated chromatin through both the BD1 and the 
BD2 (sometimes the same pattern of Kac marks, sometimes with the BD1/BD2 binding 
different marks or different histone tails), while additional domains (e.g. ETD, CTD, 
atypical kinase) work to activate RNA POL II and initiate the elongation phase of 
transcription and up-regulate the expression of downstream genes (figure 6.3A) [47, 
249]. One issue with these models is that, given the abundance of acetylated 
chromatin and gene promoters, these BET proteins would be very non-selective and 
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would affect a large number of downstream genes. Thus, they would represent a very 
‘blunt’ tool for regulating cellular processes. Selectivity could be acquired through the 
BD1/BD2 recognising different Kac combinations, but evidence for this at the peptide 
level is mixed, and the BD2s we now know play little role in chromatin recognition. In 
this new model (best explained by [90]) the BD2 binds acetylated NHPs, like NF-B and 
Twist, which then direct the complex to specific enhancers/promoters and hence to 
more specialised sets of downstream genes (figure 6.3B). Hence the expression of 
downstream genes can be regulated through: chromatin acetylation, BET expression, 
NHP expression and NHP acetylation. This BD2:NHP interaction may only matter for a 
narrow subset of BET-regulated genes, but given our data it is likely to be important in 
at least some circumstances. Interestingly, although BRD3 is also shown to bind an 






Figure 6.3. A revised model for BET protein function 
Schematic representation of BET protein mode of action, using BRD4 as an example. In older BET protein 
models (A) both the BD1 and BD2 bind acetylated histone tails, directing additional domains to recruit 
and activate additional protein complexes, such as P-TEFb, which induce transcription. In the new model 
(B) BRD4 BD1 binds to acetylated histone tails. BD2 binds (in some cases) to acetylated non-histone 
proteins such as NF-B, which themselves recognise and bind specific regulatory DNA sequences such as 






This model has several therapeutic implications. Firstly, regarding the 
displacement of BET proteins from chromatin, inhibition of BD1s alone is sufficient for 
the displacement of all BET proteins save BRD3. Conversely, BD2 inhibitors will displace 
only BRD3 (and perhaps BRD4 less so), which could explain differing cellular and 
(potentially) therapeutic impacts of pan-selective, BD1-selective and BD2-selective BET 
inhibitors. Full BRD3 displacement, meanwhile, requires inhibition of both BDs. 
Taking a broader view, one can theorise that pan-BET inhibition, or BD1-
selective inhibition will, generally, displace a given BET protein from chromatin and 
thus disturb the expression of all downstream genes. This mass perturbation will lead 
to a number of cellular and therapeutic effects, both positive and negative. BD2-
selective inhibition meanwhile, will disrupt only BD2:ac-NHP interactions and hence 
only alter the expression of a narrower range of downstream genes (figure 6.4). This 
suggests that BD2-selective inhibition may be more successful in a clinical setting, as 
there is a chance that positive impacts (e.g. reduced cancer proliferation) may be 
maintained while negative on-target toxicity may be avoided (although the opposite is 
just as possible). Further experiments with said inhibitors will be needed to confirm 
this, as it is not clear what effects are dependent on BD2:ac-NHP interactions. This 
theory may explain the relative clinical success of BD2-selective RVX-208 (the only BET 
inhibitor to reach phase three clinical trials to date) [111], which has also been shown 
to alter the expression of far fewer genes than pan-selective (+)-JQ1 [116]. A growing 
awareness of this possibility may explain the recent development of BD2-selective 
inhibitors by AbbVie (ABBV-744) [120] and GSK (GSK268 and GSK340) [121]. ABBV7-
744 has been shown to be less effective against a number of non-AML cell-lines [119], 
which this theory would explain as due to BET-regulated oncogenes relevant to these 




Figure 6.4. Possible therapeutic implications of pan-BET/BD1 inhibition vs BD2-selective inhibition. 
BD1 or pan-selective BET inhibitors (such as (+)-JQ1) will displace BET proteins from chromatin, 
disturbing all downstream genes and producing many positive and negative therapeutic effects. In 
contrast, BD2-selective inhibitors (such as RVX-208) will, mostly, not displace BET proteins from 
chromatin, and only disturb genes dependent on BD2:ac-NHP interactions. Hence BD2-selective 
inhibitors will generate a more limited therapeutic impact but potentially bear improved safety profiles. 
 
6.3 – Future Development & Applications of BET Bump-&-Hole System: 
 The optimised BET bromodomain bump-&-hole system has been used in 2 
cellular assays (FRAP and NF-B luciferase) to study the BET proteins. Both of these 
assays have utilised transient overexpression of WT and L/V BET protein constructs, 
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and hence have been fairly easy to run. Transient construct overexpression has its 
limits, and could not be used to study the importance of BET BDs to cell viability, but 
there is likely several more experiments that could be run in such a fashion. Suitable 
overexpression assays will require one of two properties. The FRAP assays works very 
well as what is measured (GFP fluorescence and recovery) is directly generated by the 
overexpressed constructs. The luciferase assay meanwhile, uses a measurement that is 
affected by endogenous BET (and other) proteins. This measurement, however, is 
clearly increased by BET overexpression and hence its inhibition by bumped 
compounds can be assessed. As future bump-&-hole experiments relying on BET 
overexpression will need these properties options are limited. Luciferase gene reporter 
assays, looking at genes/signalling other than NF-B, should be simple enough to 
develop. One problem with these assays is that comparisons are difficult to make 
between BET proteins, and are best used to compare the BD1s and BD2s.  
 Other, comparably straightforward, uses of the bump-&-hole system could be 
experiments to compare the importance of the BD1 and BD2 to the HAT and PK 
activity of BRD4. BRD4’s HAT activity was shown with purified recombinant protein and 
transient overexpression [54], and it should be possible to replicate this work with L/V 
constructs. The atypical kinase activity of BRD4 was also assessed with purified protein 
and transient expression, and these experiments have already been performed with 
(deletion) mutant constructs [52]. As NMC is fundamentally caused by BRD4/3-NUT 
fusion proteins aspects of this disease can be studied through transient expression of 
BRD4/3-NUT constructs [64, 76, 250, 251]. These transient expression experiments can 
be repeated with L/V mutant constructs and 9-ME-1 treatments to better understand 
the role of different BET BDs in this disease. For example, such experiments with L/V-
mutant BRD4/3-NUT constructs could determine the viability of treating NMC with 
BD1 or BD2-selecive BET inhibitors. As treatment of NMC requires displacement of 
BRD4/3-NUT from chromatin our FRAP experiments suggest that BRD4-NUT complexes 
could be treated with BD1-selective inhibitors, while BRD3-NUT would require both 
BD1 and BD2 blockade for effective displacement. 
Many biological questions will not be answerable through the use of transient 
overexpression of mutant BET proteins, and will require the use of the CRISPR/Cas9 
technology to create cell-lines expressing properly-regulated and spliced mutant BET 
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proteins from the same endogenous locus as the parental gene, with no remaining WT 
protein. Performing such knock-ins are possible with current technology, but as seen in 
chapter 5 it is a difficult and time-consuming process. The ideal mutant cell-line will 
have simply a small knock-in creating a few small changes in DNA sequence, but these 
knock-ins will be very difficult to detect. Alternatively one could knock-in a gene 
cassette expressing a full-length mutant BET protein, alongside a GFP or other easily 
identifiable tag; but this mutant gene will not be regulated or spliced appropriately and 
the endogenous WT gene will need to be dealt with. Hopefully, advances in 
CRISPR/Cas9 technology and optimisation of knock-in methodology will allow for 
generation of cell-lines containing L/V mutants of different BET BDs. These cell-lines, 
and the 9-ME-1 probe, can then be used by the Alessio Ciulli lab, sent to collaborators 
or distributed via third parties (such as Tocris [252], chemicalprobes.org [253] and cell-
line databases [254] or other commercial vendors).  
 Once successfully implemented into a variety of cells the bump-&-hole system 
can be used to answer a number of pressing biological questions. The most immediate 
efforts should likely focus on, essentially, replicating observations previously made 
with BET inhibitors in a BD-specific fashion. Combining the mutant cell-lines with 
cytotoxicity/cell-viability assays like CellTiter-glo can be used to determine the BET BDs 
that are the best targets for different cancers. For example, cell-lines with BRD4 
mutated may be more vulnerable to 9-ME-1 treatment, while experiments with ABBV-
744 suggest several cancer types will not be affected by 9-ME-1 if only BD2s are 
mutated [119]. Such experiments can also be used to address the suspicion that the 
anti-cancer effects of BET inhibitors is reliant on the inhibition of multiple BET proteins.  
 Other advantageous effects of BET inhibition can be tested in a similar fashion. 
Implementing the L/V mutation into PBMC cells would allow for recreating GSK’s 
cytokine release assay in a BD-specific fashion, and identify the BET proteins/BDs that 
are suitable targets for BET-based inflammation suppression. This would not be 
applicable to the similar whole-blood assay used in conjunction.  In a similar fashion, 
mutant HepG2 cells can be used to determine which BET proteins/BDs are necessary 
for the ApoA1 up-regulation observed by GSK [99] and Resverlogix [100]. This would 
aid the development of BET inhibitors for cardiovascular indications.  
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 This general approach could also be utilised for investigating and dissecting the 
unwanted effects of BET inhibition. BET inhibition has been shown to result in the up-
regulation of BET proteins, limiting the efficacy of BET inhibitors against cancers. The 
exact fashion in which this occurs has not been determined, i.e. does inhibition of any 
one protein up-regulate all BET proteins, or just that specific protein; or is all up-
regulation caused only be inhibition of one or two specific BET proteins? Recent data 
suggests that induced BET protein degradation and pan-inhibition leads to feedback 
upregulation of BRD2 specifically [255]. By tracking the expression of BET proteins in 
mutant cell-lines treated with 9-ME-1 this feedback system could be properly 
characterised. Perhaps the major on-target toxicity of BET inhibitors is 
thrombocytopenia, the depletion of platelets. The inhibition of which BET proteins/BDs 
contributes to thrombocytopenia could be addressed using one recent method, 
however this would require the insertion of the L/V mutation into an entire animal 
(rat) and is likely impractical [107]. Addressing this question would ideally rely on a 
cell-line based assay for measuring, or predicting, platelet depletion, meaning only one 
cell-line would need to be mutated. Additionally, most assays for measuring 
thrombocytopenia are diagnostic [256-258], and hence use patient sera, and focus on 
heparin-induced thrombocytopenia. It is possible that a single cell-line based 
thrombocytopenia assay could be developed using megakaryocyte cells [259], and the 
measurement of platelet production or certain biomarkers. Finally, it may be that one 
or more pharmaceutical companies has developed such an assay, for use in developing 
BET inhibitors, and has not yet disclosed it. 
 Following these experiments more advanced techniques could be paired with 
the bump-&-hole system. Over the years many papers have paired proteomic and 
transcriptomic techniques to measure changes in gene expression brought about by 
BET inhibitors [77, 116, 260, 261]. These have identified many downstream genes, and 
suggested many broader biological processes regulated by the BET proteins. 
Performing these experiments with mutant cell-lines and 9-ME-1 will allow 
identification of downstream genes on a protein and BD-specific level. This will help 
show to what extent differing BET proteins are involved in different biological 




















 The aim of this work was to advance an existing, promising but unoptimised, 
bump-&-hole system for engineering allele-selective inhibition of specific BET 
bromodomains, and take it up to a stage where it can be applied to investigate the 
roles of individual BET proteins and their individual bromodomains.  
 The original L/A mutation, which allowed for selective inhibition but had 
reduced function, was replaced with an L/V mutation. The L/V mutation was 
thoroughly characterised biophysically, structurally and functionally in cells. In vitro, 
the introduced mutation was shown to have little to no impact on the stability, 
structure and affinity of recombinant BET BD proteins for acetylated histone peptides. 
Full-length L/V BET proteins were then tested in cells and shown to be able to bind 
chromatin and drive the transcription of downstream genes, to a much better extent 
than L/A BET proteins (figure 7.1).  
 While the original bump-&-hole system utilised an ethyl-bumped compound, 
ET, the switch to a new mutation required a fresh round of compound evaluation. By 
testing an expanded range of bumps and other chemical modifications, and purifying 
the active 2R,3S enantiomer, improved mutant-selective inhibitors were developed. 
The bumped compound that emerged as best-in-class, 9-ME-1 showed increased 
overall selectivity and strong DMPK properties, albeit not being quite as potent against 




Figure 7.1. Optimisation of BET bromodomain ‘bump-&-hole’ system. 
The optimised L/V | 9-ME-1 bump-&-hole system was validated in cells and 
used to investigate the importance of individual BET BDs to the BET proteins’ ability to 
bind chromatin and drive the transcription of NF-B-regulated genes. These 
experiments showed that chromatin recognition and binding is primarily driven by the 
BD1s of the BET proteins, with the BD2s played a less prominent role to varying 
degrees depending on the family member. Specifically, in the case of BRD2 and BRDT 
the BD2 was found to play no observable role in chromatin binding, and BRD4 BD2 
played a very small role too. In contrast BRD3 was seen to rely on both BDs to achieve 
full chromatin recognition. Experiments on transcription, meanwhile, showed that for 
at least some downstream genes the BD2s still play a role in transcription. These 
results, combined with recent observations from the literature, were used as evidence 
for a new model of BET protein function. In this model the BET BD2s do not necessarily 
bind acetylated chromatin and, for certain downstream genes, they act through 
binding acetylated NHPs, which direct the BET protein and associated transcription 




Figure 7.2. A model for BET protein function 
Schematic representation of BET protein mode of action, using BRD4 as an example. BRD4 BD1 binds to 
acetylated histone tails. BD2 binds (in some cases) to acetylated non-histone proteins such as NF-B, 
which themselves recognise and bind specific regulatory DNA sequences such as NF-B-REs. Additional 
BRD4 domains bind, recruit and activate additional protein complexes, such as p-TEFb, which induce 
transcription.  
Finally, it was recognised that to enable more sophisticated investigations into 
BET protein biology would require the introduction of the L/V mutation into 
endogenous BET genes in WT cell-lines. A method for inserting said mutation through 
the CRISPR/Cas9 gene editing system was developed, and an attempt was made to 
knock-in the L/V mutation onto BRD4 BD1 in A549 cells. This attempt has so far not 
been shown to be successful, but many lessons have been learnt that will aid in future, 











 The highest priority, regarding future development and use of the BET bump-&-
hole system, is the generation of L/V-mutant cell-lines as was attempted in chapter 5. 
The generation of apparent BRD4 KO cells suggests that existing gRNAs are suitable for 
targeting BRD4 BD1. Hence the focus should be on maximising the percentage of cells 
(following transfection) that have been correctly knocked-in, and optimising their 
detection. The use of fluorophore-labelled gRNA strands will allow for selection of 
transfected cells through FACS, which should greatly reduce the number of clones that 
must be screened to find successful knock-ins. If improved assays for detecting knock-
ins can be developed, perhaps taking inspiration from research into SNP genotyping, 
then it will also become easier to optimise transfection conditions, to improve both 
the transfection efficiency and the knock-in efficiency. The decision may also be taken, 
following validation and characterisation of the apparent BRD4 KOs, on the value of 
generating heterozygous KO/KI cell-lines. With so much research being conducted on 
CRISPR/Cas9 gene editing there is also a reasonable likelihood that in the near future 
advances will be made in how CRISPR-mediated knock-ins are conducted, that may aid 
our own efforts in this direction.  
Following generation of BRD4 L/V KI cell-lines (A549 LV/WT, WT/LV and LV/LV) 
the first step (following genetic validation of said knock-in) should be assessing the 
viability of said cell-lines and determining whether the effects of the L/V mutation on 
BRD4 has affected the cells in a more general fashion. This could be quite easily down 
through the use of the CellTiter-Glo and crystal-violet colony-formation assays, as was 
done for the potential KO cell-lines in chapter 5. These same assays could then be used 
to measure the vulnerability of these cell-lines to 9-ME-1 (or other bumped 
compound) treatment. Such experiments would show which (if any) BRD4 BDs are 
important to A549 cell-viability, for example is BRD4 BD1 inhibition sufficient to kill 
A549, or are inhibiting both BRD4 BDs necessary, or do multiple BET proteins need to 
be targeted? The next step would be to utilise proteomic and transcriptomic 
techniques, such as RNAseq and TBT-labelled LC-MS/MS to determine which 
downstream genes are up or down-regulated by BRD4 inhibition versus (+)-JQ1 pan-
BET inhibition. Comparisons could also be made to datasets utilising BRD4 knock-out 





Figure 7.3. Future experiments with L/V knocked-in cells. 
A) The L/V mutation (red) should be knocked-into WT cells (blue), and successful knock-ins identified 
and cultivated. B) Assays such as CellTiter-Glo and colony-formation measurement can be used to (left) 
determine if the L/V mutation reduces the viability of knock-in cells, and (right) determine which BDs are 
necessary for cell proliferation. C) Transcriptomic and proteomics can determine which genes are 
regulated by specific BET proteins and/or BDs. 
 Through our intensive SAR work we have settled on 9-ME-1 as the ‘best’ 
bumped compound, but additional chemistry could be done to produce an even better 
L/V-selective inhibitor. The introduction of small carbon cycles, such as cyclopropane, 
into bumps may boost L/V affinity by limiting the freedom of the bump and the 
corresponding entropic penalty to binding. Furthermore, it may reduce WT binding by 
removing the ability of the bump to twist into an orientation that relieves the steric 
clash. The use of double C=C bonds has been trialled with the AL bump, which can be 
used to modulate rotational freedom, but also reduces the length of the bump. 
Further use of C=C double bonds may help produce improved bumped compounds. 
One final bump modification to test is the use bioisosteres. Replacing the methyl bump 
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of 9-ME with a CF3 group may be a way of fine-tuning the size of the bump, as the 
resulting bump would occupy a slightly larger space than a simple methyl group. This 
modification will also effect the electronic properties of the compound, which could 
have a differential impact on binding affinity between WT and L/V BDs. Such 
modifications could also alter DMPK properties and van der Waals interactions with 
the L/V cavity.  
 Many BET inhibitors are based on the basic benzodiazepine core but use 
structural variations such as amide side-groups, thiophene instead of methoxy-phenol 
rings and even alternate Kac mimics. Bumped analogues of these alternate scaffolds 
could be trialled as L/V-selective inhibitors. Recently a super-potent PROTAC 
compound was developed, using an oxazepine inhibitor that acted as a (+)-JQ1 mimic 
[262]. These compounds could also be modified to contain our L/V-selective bumps, 
and their enhanced affinity and hydrophobicity may be lead to bumped compounds 
with improved selectivity or cellular potency.  
 
Scheme 7.1. Potential Future Bumped Compounds. 
Chemical structure of 9-ME and potential future bumped compounds utilising new cyclic or fluoride-
containing bumps, alternate scaffolds or linked to functional groups. L/V-selective modifications within 





9-ME-1 could also be modified to produce a set of functional derivatives, for 
use in protein pulldowns or labelling. 9-ME could be modified to develop L/V-selective 
analogues of the previously discussed Bio-JQ1 [86], photo-cross-linkers [87, 88] and 
click-reactive probes [89]. These compounds could then be used to pulldown or modify 
specific BET proteins, in advanced chemical genetics studies to investigate their protein 
binding partners or genome localisation.  
 
 In this thesis a system has been developed allowing for highly-selective 
chemical inhibition of the BET bromodomains – a protein family of great interest to 
epigenetics and a range of clinical indications. This system has already been used to 
better understand how these proteins function on an immediate, molecular level and 
with further work and the development of mutant cell-lines we will be in a position to 
answer a great number of questions on the BET proteins. This knowledge could then 























Chapter 8  










8.1 – Plasmids  
Single BET bromodomain constructs (WT, L/V and L/A) were encoded in pNIC28-Bsa4 
(KanR) plasmids. Constructs are as follows: BRD2 BD1 (K71-K176), BRD2 BD2 (G344-
D455), BRD3 BD1 (P24-E144), BRD3 BD2 (G306- P416), BRD4 BD1 (N44-E168), BRD4 
BD2 (K333-E460), BRDT BD1 (N21-E137) and BRDT BD2 (S257-M361). Uniprot 
accession numbers: BRD2 – P25440; BRD3 – Q15059; BRD4 – O60885; BRDT - Q58F21. 
WT DNA and protein sequences can be found in [32] and details of the site-directed-
mutation can be found in table 8.1. Single BET BD constructs possess an N-terminal 
His6-tag and TEV protease cleavage site. WT plasmids were provided by the Oxford 
Structural Genomics Consortium. L/A mutants created by Terrence Kwan and Enrique 
Lin-Shiao, L/V mutants created by Dr Kwok-Ho Chan and Teresa Cardote. These 
plasmids were used for purification of single-bromodomain constructs from 
transformed E. coli cells, for use in assays and X-ray crystallography. 
Full-length BET proteins (WT, L/V and L/A) with N-terminal eGFP-tag were encoded in 
pcDNA5 FRT/TO (AmpR) plasmids (pcDNA6.2 for BRDT). Constructs are as follows: 
BRD2 (M1-G801), BRD3 (M1-E726), BRD4 (M1-F1362) and BRDT (M1-D951). The GFP-
BRDT construct also contained a C-terminal V5 tag. Details of site-directed-mutation 
can be found in table 8.1. pcDNA5 FRT/TO-GFP vector, and BRD2 (NM_001113182.2 
[263]) and BRD3 cDNA (NM_007371.3 [264]) clones were provided by Dr Mark Peggie 
(DSTT, University of Dundee). BRD4 cDNA (NM_058243.2 [214]) was provided by the 
Oxford Structural Genomics Consortium, contained within a pEGFP-C1 plasmid. BET 
proteins were then cloned into pcDNA5 FRT/TO-GFP plasmid. WT GFP-BRDT plasmids 
purchased from Addgene (65381), originally produced by the Kyle Miller lab [193] 
using BRDT cDNA (NM_001242806.2 [265]).  Cloning and site-directed-mutagenesis 
performed by Annica Pschibul (BRD4 L/A), Teresa Cardote (BRD4 L/V), Lars van 
Beurden (BRD3 L/V) and Andrew Runcie (BRD2 and BRDT L/V). These plasmids were 
used for expression in mammalian cells, primarily for FRAP & luciferase assays, but 
could also be used for CETSA or western blots (using BET & GFP antibodies). 
The NF-B-RE luciferase reporter was encoded in a pBABE plasmids, following cloning 
from a pGL4.32 vector. This reporter consists of one Luc2P gene, with C-terminal PEST 
tag, controlled by a miniP promoter and 5 copies of an NF-B response element. This 
plasmids was acquired from Dr Mark Peggie (DSTT, University of Dundee). This plasmid 
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was used for expression in mammalian cells for the NF-B luciferase assay. BRD4 (and 
to a lesser extent other BET proteins) required for NF-B signalling. Expression can be 
induced with TNF- treatment, but this is not always necessary/advisable (i.e. 
HEK293T cells). 
 
Single point mutations were introduced using QuickChange II Site directed 
Mutagenesis Kit (Agilent). Primers were designed following the recommendations from 
the manufacturer. The polymerase chain reaction (PCR) was performed on a 2720 
Thermal Cycler (Applied Biosystems®). Upon digestion of the parental DNA strands by 
DpnI restriction enzyme, the PCR product was transformed into competent E. coli 
DH5α cells and grown on lysogeny broth (LB) agar plates containing corresponding 
selection antibiotics at 37°C for 16h. Single colonies were then picked from the agar 
plates and grown for 12h in 10 mL of LB medium containing selection antibiotics. 
Extracted and purified plasmid DNA were then sequenced to confirm the presence of 
the desired mutation. 
 








Bromodomain WT Leucine codon L/A codon L/V codon
BRD2 BD1 CTG GCG GTG
BRD2 BD2 CTG GCG GTG
BRD3 BD1 CTG GCG GTG
BRD3 BD2 CTG CTG GTG
BRD4 BD1 CTC GCC GTC
BRD4 BD2 CTA GCA GTA
BRDT BD1 TTG GCG GTG
BRDT BD2 CTC GCC GTC
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8.2 – Protein Expression & Purification 
BL21 (DE3) E. coli cells were transformed with bromodomain-expressing pNIC plasmids 
using heat shock. Cell cultures were grown at 37°C and 200 rpm in LB media with 50 
µg/ml kanamycin. A starter culture was incubated until saturation, then diluted 100-
fold in fresh media and grown until reaching an optical density of 2.0 (OD600). The 
temperature of the culture was decreased to 18°C, and protein production                                                                                 
was induced overnight with 0.4 mM IPTG.  Cells were harvested the next day by 
centrifugation (4500 g for 20 minutes at 4°C, swing-out JS-4.2 rotor on a Beckman J6-
MC centrifuge) and stored as pellets at -20°C.  
Cell pellets were resuspended in lysis buffer (50 mM HEPES, 500 mM NaCl, 10 mM 
imidazole & 2 mM 2-mercaptoethanol pH7.5) and treated with one complete protease 
inhibitor (Roche) tablet.  Cells were lysed using a Stanstead pressure cell homogenizer 
and the lysate centrifuged at 50 000 g for 1 hour at 4°C (fixed-angle JA-25.50 rotor in 
Beckman Avanti J-25 centrifuge) and the supernatant transferred and passed through 
a 0.45 µm filter.  
The lysate was purified using metal ion affinity chromatography, with a His Trap 5 ml 
Ni sepharose column (GE Healthcare) on an AKTApure™ system (GE Healthcare). The 
column was washed with 30 ml of lysis buffer, and the protein was eluted using 30 ml 
of elution buffer (50 mM HEPES, 500 mM NaCl, 250 mM imidazole and 2 mM 2-
mercaptoethanol at pH 7.5). The Ni column elution was concentrated to 2 ml using a 
Vivaspin 20, 10 000 MWCO (Sartorius) before further purification using size exclusion 
chromatography. Concentrated Ni column elution was passed through a Superdex 75 
16/60 Hiload column (GE healthcare) on an AKTApure™ system, using gel filtration 
buffer (20 mM HEPES, 150 mM NaCl and 1 mM DTT at pH 7.5). Desired fractions were 
pooled, concentrated and aliquoted before being flash frozen and stored at -80°C. 
 
8.3 – Differential Scanning Fluorimetry (DSF / Thermal Shift) 
DSF experiments were performed on a BioRad CFXconnect machine, using clear 96-
well plates. Protein constructs were tested at 6 µM, with 2.5X SYPRO orange 
(Invitrogen), in 40 µl of buffer (10 mM HEPES, 100 mM NaCl, pH7.5). Samples 
underwent a heat cycle from 20°C to 95°C, heated at a rate of 1°C every minute. Plates 
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were read at 1 minute intervals. Each sample was tested in triplicate. Data was 
analysed as recommended by Niesen et al. [169], using GraphPad Prism 6 and the 
SGC’s DSF Analysis 3.02 spreadsheet.  
DSF can be used to screen inhibitors. This follows the same protocol but with the 
addition of ~1 µM compound and associated DMSO. 
 
8.4 – BioLayer Interferometry (BLI) 
All BLI experiments were carried out on a OctetRed 384 instrument (ForteBio), at 25°C 
and in 20 mM HEPES, 150 mM NaCl pH7.5 buffer. A histone peptide library, possessing 
both single and multiple lysine acetylation marks, was obtained from Alta Bioscience 
Ltd. Peptides were 20 residues long and were biotinylated on the C-terminal (with 
aminohexanoic linker).  Streptavidin-coated BLI tips (ForteBio) were loaded in 100 µl 5 
µM peptide (or 10 µg/ml biocytin) over 10 minutes. For the assay bromodomain 
constructs were kept at 20 µM in 100 µl buffer in black 384-well plates, agitated at 
1000 rpm. Each assay involved exposing peptide-loaded BLI tips to buffer for 120 s to 
determine baseline signal, 240 s in protein to measure association and finally 120 s in 
buffer to measure dissociation.  Raw data was then analysed using the ForteBio 
software, to account for background signal and non-specific binding. 
 
8.5 – Isothermal Titration Calorimetry (ITC) 
ITC titrations were performed on an ITC200 instrument (MicroCal™, GE Healthcare). 
Proteins, peptides and compounds were all dissolved in ITC buffer (20 mM HEPES, 100 
mM NaCl, pH7.5), with protein samples buffer-exchanged through dialysis using D-
tubes (Millipore). Each ITC titrations consisted of 20 titrations: 1 initial injection of 0.4 
µl over 0.8 s, followed by 19 injections of 2 µl over 4 s, at 2 minute intervals. Data was 
analysed using the Microcal LLC ITC200 Origin data analysis software, using a single 
binding site model, to determine binding values such as Kd and enthalpy of binding.  
Peptide titrations were carried out at 15°C, with 2 mM of acetylated histone peptide 
titrated against 50-150 µM bromodomain. Ligand titrations were performed at 30°C, 
with 250 µM active ligand titrated against 25 µM bromodomains, with a final DMSO 
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concentration of 2.5%.  Reverse ligand titrations were also performed at 30°C, with 
150 µM protein titrated against 15 µM ligand. 
 
8.6 – X-ray Crystallography 
Purified BRD2 BD2 L/V (8 mg/ml) was combined with 2-4 mM compound to form a 
protein:ligand complex. This complex was mixed with precipitant solution at a 2:1 ratio 
in a sitting-drop vapour diffusion format. A variety of crystallisation conditions were 
used, with the majority using 0.1 M Tris, pH 7-9, 45-60% pentaerythiol propoxylate 
(5/4 PO/OH) with or without 0.2 M imidazole. Crystals appeared within hours and 
were fully grown after 2-3 days. 
Diffraction data were collected either in-house with a Rigaku M007H5 X-ray generator, 
with Varimax Cu-VH5 optics and a Saturn 944HG+ CCD using a wavelength of 1.5418 Å; 
or Diamond Light Source beamline I04-1 using a Pilatus 6M-F detector at a wavelength 
of 0.92819 Å and at a temperature of 100K.  
Indexing and integration of reflections was performed either with XDS (with the 
XDSGUI interface) [266]or MOSFLM [267], and scaling and merging with AIMLESS [268] 
in CCP4i [269]. To solve the phase problem the molecular replacement method was 
used with the programs MOLREP [270] and Phaser [271], using search models derived 
from the coordinates of BRD2 BD2 WT (PDB 2DVV). The initial model was refined 
iteratively using PHENIX [272, 273] and COOT [274]. Ligand structures and restraints 
were generated using eLBOW [275], REEL [276] and PRODRG [277]. The MOLPROBITY 
[278] server was used to validate the geometry and steric clashes in the structures. The 
structure models have been deposited in the protein data bank (PDB) and data 
collection and refinement statistics are presented below. Figures were generated using 
PyMOL [279].  
I generated crystals, processed data and refined structures for AL, ET-Am1, ME and 9-
ME co-crystal structures. Dr Kwok-Ho Chan did the same for the apo structure and the 
ET, 9-ET, ME-Am1, 9-ME-Am1 and AL-tBu co-crystal structures. All in-house data 
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1.95) 
31.85  - 
1.60 (1.657  
- 1.60) 
32.00 - 1.60 

















































Redundancy 5.7 (5.7) 17.1 (15.3) 15.3 (14.6) 8.6 (7.8) 4.3 (4.2) 10.3 (7.2) 
       
Refinement       
Resolution 
(Å) 
19.50  - 





40.10  - 
2.40 (2.486  
- 2.40) 
44.04  - 
1.95 (2.02  - 
1.95) 
31.85  - 
1.60 (1.657  
- 1.60) 
32 .00 - 
















Unique no. of 
reflections 

































No. atoms       
Protein 991 922 893 3613 918 948 
Ligand/ion  31 40 31 128 40 41 
Water 237 203 57 559 212 219 
B factors       
Average 13.3 12.9 43.2 19.3 16.7 11.8 
Protein 10.1 10.4 43.3 18.4 14.3 8.9 
Ligand/ion 16.9 11.0 37.9 15.4 15.8 15.4 
Water 26.0 24.9 44.4 25.9 27.6 24.0 
R.m.s. 
deviations 
      
Bond lengths 
(Å) 
0.005 0.007 0.011 0.009 0.007 0.009 
Bond angles 
(°) 
1.03 1.05 1.19 1.04 1.08 1.06 





Structure ME-Am1 ET-Am1 AL-Am1 9-ME-Am1 AL-tBu 




     
Space group P 21 21 2 P 21 21 2 P 21 21 2 P 21 21 2 P 21 21 2 
Cell 
dimensions 
     













, ,   (°) 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 
Resolution (Å) 
35.98  - 1.40 
(1.45  - 1.40) 
42.05  - 1.75 
(1.813  - 
1.75) 
25.41  - 1.85 
(1.916  - 
1.85) 
35.92  - 1.40 
(1.45  - 1.40) 
14.31  - 1.20 













I/sigma(I) 15.07 (4.57) 7.72 (6.60) 9.64 (3.00) 21.35 (7.92) 9.10 (3.25) 
CC1/2 0.998 (0.955) 0.992 (0.99) 0.997 (0.776) 0.999 (0.982) 0.994 (0.781) 
Completeness 
(%) 
99.77 (97.92) 99.66 (99.92) 95.19 (95.67) 98.72 (93.14) 99.19 (99.29) 
Redundancy 9.6 (4.8) 3.9 (4.0) 3.9 (3.9) 7.5 (3.7) 5.8 (5.8) 
      
Refinement      
Resolution (Å) 
35.98  - 1.40 
(1.45  - 1.40) 
42.05  - 1.75 
(1.813  - 
1.75) 
25.41  - 1.85 
(1.916  - 
1.85) 
35.92  - 1.40 
(1.45  - 1.40) 
14.31  - 1.20 










Unique no. of 
reflections 























No. atoms      
Protein 931 909 1818 932 939 
Ligand/ion 41 42 66 41 45 
Water 218 185 196 229 218 
B factors      
Average 12.7 14.3 26.5 14.3 14.2 
Protein 9.7 12.2 25.9 11.1 11.2 
Ligand/ion 11.5 14.8 26.3 13.6 18.1 
Water 26.0 24.7 32.0 27.5 26.2 
R.m.s. 
deviations 
     
Bond lengths 
(Å) 
0.006 0.006 0.014 0.011 0.019 
Bond angles 
(°) 
1.68 1.01 1.52 1.15 1.75 






8.7 – AlphaLISA Assays 
AlphaLISA assays were carried out in 384-well, light-grey Alphaplates (PerkinElmer), 
with an assay volume of 25 µl. To prepare each assay each component was diluted in 
AlphaLISA buffer (50 mM HEPES, 100 mM NaCl, 0.1% BSA, 0.02% CHAPS, pH7.5) to 5x 
its intended final concentration, and added at a volume of 5 µl, using a 12-channel 
Matrix P125 multi-channel pipette (Thermo). His-tagged protein, biotinylated 
probe/peptide and test compounds were added to the well, and incubated for 1 hour 
at room temperature. Then, in low-light conditions, acceptor beads were added and 
incubated for 1 hour, then donor beads were added and incubated for 1 hour. Alpha 
signal was measured in a Pherastar FS, using the AlphaLISA module. Dose-response 
curves were generated in Prism 6 (Graphpad), using the ‘log(inhibitor) vs response – 
variable slope equation’.   
Unless stated otherwise, the acceptor beads used were anti-His6 antibody-conjugated 
AlphaLISA acceptor beads (PerkinElmer) and streptavidin-coated Alphascreen donor 
beads (PerkinElmer), at a final concentration of 10 µg/ml. For the original, failed 
biotinylated-peptide displacement assay the final concentrations used were 200 nM 
BRD, 200 nM biotinylated H4 K(5,8)ac and 0.1% DMSO. For the successful, Bio-JQ1 
assay final concentrations were 100 nM BRD, 5 nM Bio-JQ1 and 1% DMSO. For the SAR 
screen bromodomains and Bio-JQ1 were pre-mixed, aliquoted and stored at -80°C. 
 
8.8 – DMPK 
Compounds were prepared in-house and sent to the Kevin Read lab (DDU) for 
measurement of plasma half-life, intrinsic clearance and PAMPA permeability. Material 
requirements for these assays (combined) was 100µl of 10 mM compound in DMSO. 
Plasma Half-life: 
 50 µM test compound incubated in mouse BALB/c plasma (pre-warmed to 37°C 
and buffered to pH7.4 in ratio of 70:30 plasma:buffer). At 0, 30, 60, 120 and 180 
minutes a 50 µl aliquot of incubation mixture were removed and mixed with 200 µl 
acetonitrile, containing 50 ng/ml Donepezil as the internal standard, to stop the 
reaction. The samples were centrifuged to sediment any precipitated protein and the 
microplates sealed prior to UPLC-MS/MS analysis using a Quattro Premier XE (Waters 
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Corporation). XLfit (IDBS) was used to calculate the exponential decay and hence the 
rate constant (K) using the ratio of the peak areas of the test compound to the internal 
standard at each time point. The half-life was calculated for each test compound using 
the formula: t1/2 = 0.693/K.  
Intrinsic Clearance: 
 0.5 µM test compound was incubated with BALB/c female CD1 mouse liver 
microsomes (Xenotech LLC TM; 0.5 mg/ml 50 mM potassium phosphate buffer, pH7.4) 
and the reaction started with addition of excess NADPH (8 mg/ml 50 mM potassium 
phosphate buffer, pH7.4). At 0, 3, 6, 9, 15 and 30 minutes a 50 µl aliquot of the 
incubation mixture was removed and mixed with 100 µl acetonitrile to stop the 
reaction. Internal standard was added to all samples, which were centrifuged to 
sediment precipitated protein and the microplates were then sealed prior to UPLC 
MS/MS analysis using a Quattro Premier XE. XLfit was used to calculate the 
exponential decay and hence the rate constant (K), based on the ratio of the peak 
areas of test compound to internal standard at each time point. The rate of intrinsic 
clearance (CLint) was then calculated using the following formula: 
 CLint (ml/min/g liver) = K * V * microsomal protein yield 
Where V (ml/mg protein) is the incubation volume/mg protein added, and microsomal 
protein yield is taken as 52.5 mg protein/g liver. Verapamil (0.5 µM) was used as a 
positive control to confirm assay performance.  
PAMPA: 
 PAMPA assays were performed using a 96-well pre-coated BD Gentest™ 
PAMPA plate (BD Biosciences). Each well was divided into two chambers; donor and 
acceptor, separated by a lipid-oil-lipid tri-layer constructed in a porous filter.  The 
effective permeability, Pe, of the compound was measured at pH 7.4.  Stock solutions 
(5 mM) of the compound were prepared in DMSO.   The compound was then further 
diluted to 10 µM in phosphate buffered saline at pH 7.4. The final DMSO concentration 
did not exceed 5% v/v. The compound dissolved in phosphate buffered saline was then 
added to the donor side of the membrane and phosphate buffered saline without 
compound was added to the acceptor side.  The PAMPA plate was left at room 
temperature for 5 h.  After which time, an aliquot (100 µl) was then removed from 
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both acceptor and donor compartments and mixed with acetonitrile (80 µl) containing 
an internal standard.  The samples were centrifuged (10 min, 5⁰C, 3270 g) to sediment 
precipitated protein and sealed prior to UPLC-MS/MS analysis using a Quattro Premier 
XE. Pe was calculated as shown in the below equation: 
Pe (nm/sec) =     107     x     - In [1 - CA (t) / Cequi])  /  (A * [1/VD + 1/VA] * t) 
Where: 
CA(t)    = peak area of compound present in acceptor well at time t = 18000 sec 
Cequi    = [CD(t) * VD + CA(t) * VA] / (VD + VA) 
A          = filter area  
VD        = donor well volume  
VA        = acceptor well volume  
t           = incubation time  
CD(t)    = peak area of compound present in donor well at time t = 18000 sec 
Recovery of compound from donor and acceptor wells was calculated and data was 
only accepted when recovery exceeded 70 %.  
 
8.9 – Off-Target Screening (companies) 
Off-target screening was carried out by a number of organisations, who were provided 
with compounds in the form of 100% DMSO solutions. 
BROMOscan experiments were performed by DiscoveRX (San Diego, California, USA), 
requiring 60 µl of 10 mM MZ-20 (for KdELECT assay) and 70 µl of 1 mM 9-ME-1 (for 
bromoMAX screen).  
The kinase screen was carried out within the School of Life Sciences, at the MRC PPU 
International Centre for Kinase Profiling. 9-ME-1 was submitted for the Express Screen 
panel, which required 200 µl of 1 mM compound. 
A broad-spectrum screen of transporters, ion channels and receptors was performed 
at Eurofins CEREP (Bois-l'Évêque, France). 9-ME-1 was tested against the Express 




8.10 – Tissue Culture 
Human U2OS, HEK293T, HL-60 A549 and H23 cell lines were obtained from ATCC and 
MV4;11 cell line was obtained from DSMZ. U2OS, HEK293T, A549 & H23 were kept in 
DMEM medium (Gibco) supplemented with 10% FBS (Gibco), 1% L-glutamate (Gibco) 
and 100 U/ml penicillin and streptomycin. MV4-11 and HL-60 were kept in RPMI 
medium (Gibco) supplemented with 10% FBS, 1% L-glutamate (Gibco) and 100 U/ml 
penicillin and streptomycin. Cells were kept in an incubator at 37°C, 5% CO2. All cell 
lines were tested for mycoplasma contamination every month using MycoAlert 
Mycoplasma detection kit (Lonza). 








Suspension Suspension Adherent Adherent 
BET-
dependent? 
No No Yes Yes Yes Yes 














Table 8.4 Cancer cell-Line characteristics. 
8.11 – Fluorescence Recovery after Photobleaching (FRAP) 
FRAP experiments were performed in human osteosarcoma U2OS cells transfected 
with pcDNA5 FRT/TO plasmids encoding wild-type and mutant GFP chimeras of BET 
proteins (pcDNA6 for GFP-BRDT). Cells were seeded into glass-bottom, 35x10 mm 
dishes (WillCo) at ~200 000 cells in 2 ml media per dish ~66 h before FRAP. Cells were 
transfected using 3 µl FuGENE HD (Promega) and 1 µg of plasmid DNA ~42 h before 
FRAP. Eighteen hours before the FRAP assay cells were treated with test compounds 
and SAHA (Sigma-Aldrich) to a final concentration of 2 µM SAHA 0.03% DMSO. 
FRAP experiments were carried out on a Deltavision Elite imaging system (GE 
Healthcare) running Resolve 3D (SoftWoRx) kept at 37°C and using a FITC filter set (488 
nm excitation, 525 nm emission). Cells were imaged using a 60X objective lens 
(Olympus), with an exposure time of 0.05s and using 2x2 binning to give a 512x512 
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pixel image. Cells were excluded for FRAP experiments if they displayed aberrant 
morphology and signs of cell-death. Cells providing a signal of <1000 fluorescence units 
were excluded as they were too close to the background signal for photobleaching 
(requiring reduction to ~50% fluorescence) to be observed. Cells fluorescing over 3500 
units were also excluded due to the risk of detector saturation.  
Cells were photobleached using a quantifiable laser module (QLM), set to a 
wavelength of 488 nm and 100% power, for 0.5s, covering an area with a 0.5 µm 
radius. For each cell 5 images were captured pre-bleach (over 5 s) and 32 post-bleach, 
using a CoolSNAP HQ camera (Photometrics). Post-bleach imaging was usually spread 
over 60s and distributed to best measure a t½ of ~2 s, although this was altered in 
some cases. FRAP experiments were analysed in SoftWorx (GE Healthcare) using the 
PK analysis function, set to analyse a bleach event with 0.5 µm2 radius. Calculated t½ 
values were extracted and analysed in Prism 6 (GraphPad). Each experiment was run 
twice on separate days, with ~20 cells tested on each day. 
 
8.12 – Cell Viability Assays 
Cell-viability, and the impact of our compounds, was measured using the CellTiter-Glo 
assay (Promega). Slightly different protocols were utilised for AML-derived suspension 
cell-lines (MV4-11 & HL-60) and LAC-derived adherent cell-lines (A549 & H23). 
For suspension cells, test compounds were serially diluted in a sterile, white, clear-
bottomed 384-well cell-culture microplate (Greiner Bio-one), at 2X concentration and 
a volume of 25µl. Cell suspension was then added, with 25 µl at 2X concentration. Both 
cells and compounds were diluted in RPMI medium. After 48 h incubation 25 µl of 
CellTiter-Glo reagent was added to each well. Following 15 minute incubation the 
luminescence signal was read on a Pherastar FS. The final concentration of assay 
components are as follows: 3x105 cells/ml, 0.05% DMSO, 5 µM and below compound. 
Adherent cell-lines were first seeded into the microplate, at 3000 cells in 25 µl. The 
next day 25 µl of 2X concentration, serially diluted test compounds were added. Both 
cells and compounds were diluted in DMEM medium. Following a 72 h incubation 25 µl 
of CellTiter-Glo reagent was added to each well. Following a 30 minute incubation the 
236 
 
luminescence signal was read on a Pherastar FS. The final concentration of assay 
components are as follows: 0.05% DMSO, 5 µM and below compound. 
Data was processed and dose-response curves generated using Prism 6 (Graphpad). 
For the failed GFP-BET overexpression experiments A549 cells were seeded in 96-well 
plates with 40000 cells in 100 µl. Cells were transfected the next day, using a scaled-
down version of the transfection mixture used in luciferase assays. Compounds were 
again added at 2X concentration in 100 µl. For luminescence measurement 100 µl of 
reagent was added per well.  
 
8.13 – Colony Formation Assays 
For colony formation assays A549 cells were seeded in 6-well plates at a volume of 2 
ml. For qualitative assays 2x104 cells were seeded, while quantitative assays utilised 
2x103 cells. The next day the media was replaced with DMEM containing 1 µM 
compound and/or 0.1% DMSO (unless stated otherwise). Plates were then incubated 
for 7-14 days, until the desired confluence (in general or within colonies) was obtained. 
Qualitative assays took 7-9 days, while quantitative assays required 10-14 days.  
Following incubation, media was removed and cells washed with 1 ml H2O. Cells were 
fixed with 1 ml 100%, ice-cold MeOH, incubated for 30 minutes at 4°C. Cells were then 
stained with 500 µl 0.1% crystal-violet dye (in MeOH), with a 30 minute room-
temperature incubation.  Cells were then washed three times with H2O and left to dry 
overnight.  
For 96-well dose-response colony formation assays, 1000 A549 cells were seeded per 
well in 90 µl DMEM. The next day cells were treated with 10 µl 10x test compound in 
DMEM. Following 7-10 days incubation cells were fixed and stained as with 6-well 
plates, but with volumes of 50 µl. 
Dried plates were scanned in an Epson Perfection V800 scanner, with a resolution of 
1200 dpi and in 16-bit grayscale and 48-bit colour form. Colonies were counted 
manually from computer images. 
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For some assays, crystal-violet dye was later extracted by 1% SDS over 3 hours, and the 
absorbance at 595 nm measured in a Pherastar FS.  
 
8.14 – Luciferase Assays 
Luciferase experiments were performed in human HEK293T cells seeded in a 24-well 
plate at 1x105 cells in 500 µl media, and transfected with pcDNA5 FRT/TO plasmids 
encoding WT and mutant GFP-BRD4 chimeras, and pBABE NF-B-RE/luc2P reporter 
plasmid. Cells were transfected using Lipofectamine™ LTX (Invitrogen) with PLUS™ 
reagent, with each well receiving 0.5 µg of each plasmid, 2.5 µl LTX and 0.5 µl PLUS 
reagent in 100 µl OPTIMEM. Cells were treated overnight with 1 µM test compound 
and 0.02% DMSO. After treatment cells were washed with PBS, lysed with passive lysis 
buffer (Promega) and stored at -20°C. 
Luciferase activity was measured suing the Promega luciferase assay. In a black low-
volume 384-well microplate (Corning) 3 µl of clarified lysate was mixed with 15 µl 
luciferase assay reagent and after 15 minutes luminescence was measured in a 
Pherastar FS. Each experiment was run twice, on separate days, with each experiment 
containing 3 technical replicates. 
 
8.15 – Cell Extract Thermal Shift Assay (CETSA) 
U2OS FLP-IN cells, containing tetracycline-inducible GFP-BRD4 WT/WT and LV/LV, 
were cultured in 10 cm dishes. Unless stated otherwise, cells were treated with 0.1 
µg/ml tetracycline, giving protein levels equivalent to the endogenous WT BRD4 (long). 
Cells were trypsinised, washed with PBS and lysed through repeated (4x) liquid-
nitrogen freeze/thaw cycles. Before the fourth freeze the protein content of each 
lysate was quantified through the BCA assay (Thermo) and aliquoted, before being 
stored at -80°C.  
For the compound assay, lysate was diluted in PBS to 3 mg/ml protein, and incubated 
for 1 hour with 1 µM compound / 0.01% DMSO.  Aliquots of treated and untreated 
lysates were then heated for 5 minutes from 35 to 60°C, on a CFXconnect (BioRad). 
Heated lysates were then clarified by centrifugation at 17 000g for 10 minutes at 4°C, 
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before undergoing SDS-PAGE on a NuPAGE 3-7% tris-acetate gel (30 mg protein per 
well). 
Bands were transferred from the gel to PVDF membrane in a 4°C, overnight transfer 
(BioRad Mini Trans-Blot) using TBST buffer (TBS buffer with 0.1% Tween-20) with 10% 
MeOH, and blocked for 1 hour at room temperature with 3.5% BSA in TBST. Blotting 
with the primary antibody was done either overnight at 4°C, or for 1 hour at room 
temperature, and secondary antibody blotting was done at 4°C for 1 hour. BRD4 was 
blotted for using an Abcam αBRD4 128874 rabbit antibody, at 1:1000, then a Licor 
αrabbit cw800 antibody at 1:10000. GFP was blotted for with a Chromatek αGFP 3H9 
rat antibody at 1:1000, followed by a Licor 800cw αrat antibody at 1:10000. Bands 
were visualised using a Licor Odyssey Sa imaging system, and images were processed 
and band intensity measured using Licor Image Studio v5.2.5. Band intensities were 
normalised relative to those heated to the lowest temperature.  
 
8.16 – CRISPR/Cas9 BRD4 BD1 L/V Knock-In 
RNP Transfection: 
The Cas9 nickase (Alt-R® S.p. Cas9 D10A Nickase V3) and the large, invariable, nickase-
binding gRNA strand (Alt-R® CRISPR-Cas9 tracrRNA) were ordered from Integrated DNA 
Technologies (IDT). The short, variable, DNA-binding gRNA strands (Alt-R® CRISPR-Cas9 
crRNA) and the knock-in template DNA were custom-ordered from IDT.  
Cells were transfected at ~50% confluence. The following protocol is for a 10 cm dish, 
and can be scaled down for 6-well plates. First, 4 µl of 100 µM long, invariable gRNA, 
and 20 µl of 10 µM of each short, custom gRNA was diluted in 320 µl duplex buffer, 
heated to 95°C and slowly cooled to room temperature. The nickase (61x stock) was 
diluted to 1x in optimem, with 6.6 µl 61x stock in 400 µl media. Next 330 µl of the RNA 
mix was mixed with 330 µl of 1X nickase, and incubated at rt for 10 minutes.  Template 
DNA was diluted with 10.5 µl 10 µM stock to 300 nM in duplex buffer. Next 535 µl of 
RNP and 270 µl of DNA was diluted in 1200 µl media, and incubated for 10 minutes. 
Meanwhile, 250 µl of diluted transfection reagent was prepared, with 25 µl of reagent 
(25 µl of PLUS reagent), and incubated for 10 minutes. The final transfection mixture 
was formed from 750 µl of the RNP/DNA solution combined with 250 µl of dilute 
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transfection reagent, incubated at rt for 15 minutes. Cells were washed with PBS and 
given fresh media, before being treated drop-by-drop with 1ml of the final transfection 
solution.  
Cell Sorting: 
4 days after transfection the cells underwent single-cell sorting. Cells were washed, 
trypsinised, centrifuged and re-suspended in 3 ml DMEM with 1% FBS, at 2-5x106 
cells/ml. Cells were sorted onto 96-well plates, which the day before had been coated 
with 1% gelatin and filled with 150 µl of conditioned media (50% DMEM with 10% FBS, 
40% used media (filtered), 10% FBS) before being incubated overnight at 37°C. After 
the addition of single cells the plates were centrifuged at 50xg for 1 minute, before 
being incubated at 37°C for 2 weeks.  
Colony-Formation Assay: 
The colony-formation assay was begun once a large number of clones had formed 
large, and densely confluent colonies. Cells were drained and detached with 50 µl 
trypsin (inactivated with 150 µl DMEM). For each 96-well plate containing sorted cells, 
3 new 96-well plates were seeded. Two plates were seeded with 70 µl dissociated 
cells, and one was seeded with 50 µl cells. The plates with 50 µl of cell solution were 
used for continued growth and passaging of cells, and had 150 µl DMEM added. The 
plates with 70 µl cells were used to test for 9-ME-1 sensitivity, and the next day were 
treated with 140 µl of media containing 0.04% DMSO or 3 µM 9-ME-1. After 1 week 
DMSO-treated cells began to reach confluence, and so the cells were fixed with 100% 
MeOH for 1 hour at 4°C and stained with 0.1% crystal-violet for 1 hour at room 
temperature. Cells were then washed with H2O and dried overnight, before being 
scanned in an Epson Perfection V800 scanner, with a resolution of 1200 dpi and in 16-
bit grayscale and 48-bit colour form. Later, crystal-violet dye was extracted by 1% SDS 
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Chapter 2 Supplementary Figures 
 
 
Figure S2.1. Characterisation of L/G and L/I Mutant Bromodomains. 
Unpublished data from Dr Michael Zengerle and Enrique Lin-Shiao. A) DSF-measured melting 
temperature of WT, L/I and L/G BRD2 BD1 bromodomain constructs. B) ITC titrations of tetra-acetylated 
H4 K(5,8,12,16)ac peptide into BRD2 BD1 bromodomain constructs, at 15°C. C) Results of ITC titrations 
of ET compound into WT and L/I BET bromodomain constructs. 
 
 
Figure S2.2. BET Bromodomain Sequence alignment 
Sequence alignment of the eight human BET bromodomains, with positions of α–helices and associated 
loops. Conserved residues highlighted in green, with mutated leucine in red. Conserved residues making 





Figure S2.3. BET bromodomain construct purification. 




Figure S2.4. Full BET bromodomain histone peptide binding profiles. 
Binding profiles of WT and L/V BET bromodomain constructs for acetylated histone peptides, derived 
from the BLI screen. Average response of two negative controls (biocytin-loaded tips) subtracted, to 
account for any non-specific binding. Responses color-coded to maximum and minimum response of 





Figure S2.5. Sample BLI curves. 
Streptavidin-labelled BLI tips were loaded with biocytin or biotinylated histone peptides, and then 






Figure S2.6. Crystallographic analysis of ZA loop during binding 
Aligned X-ray crystal structures of BRD2 BD2 L/A apo (green) (4QEU) and bound to ET (brown) (4QEW), 
as well as BRD2 BD2 WT bound to an acetylated H4 peptide (blue) (2E3K). Bound peptide not shown. 





Figure S2.7. BRD2 BD2 mutant alternate crystal packing. 
A) Coot screenshot of a BRD2 BD2 apo structure, and MTZ map, for L/V (left) and L/A (right) mutants. 
Valine/alanine residues are circled in red. Crystal contacts (electron density map lacking fitted atoms) 
are observed interacting with the ZA loop from clearly different orientations. B) BRD BD2 L/V apo 
structure and MTZ map, with L/A structure superimposed. A potential steric clash, between the L/A BD’s 












Figure S2.8. FRAP theory and impact of chromatin binding. 
A) In group of free GFP-BET, bleached and unbleached protein can move freely in and out of bleach spot, 
leading to rapid recovery. B) When GFP-BET is mainly bound to immobile chromatin protein cannot 





Figure S2.9. Example FRAP datasets. 
Nuclei of U2OS cells transiently overexpressing GFP-BRD4 (L) and treated with 2 µM SAHA, 0.03% DMSO 
and 1 µM (+)-JQ1. Nuclei are bleached with laser at 0s (red circle) and imaged while the fluorescence 
recovers. Cells shown are representative of population from B. B) Fluorescence recovery plots for ~20 





Figure S2.10. GFP cellular localisation. 
U2OS cells transfected with monomeric GFP and treated with 2 µM SAHA and 0.03% DMSO. Visually 




















Chapter 3 Supplementary Figures 
 
 
Scheme S3.1 Bumped compounds. 









Table S3.1. AlphaLISA biotinylated-peptide titrations 




Table S3.2. AlphaLISA Bio-JQ1 titrations.  




Figure S3.1. Bio-JQ1 AlphaLISA assay accurately ranks inhibitors and can detect fragment binding. 
A) AlphaLISA titrations of BET inhibitors against Bio-JQ1 and BRD2 BD2 WT. B) AlphaLISA titrations of (+)-
JQ1 and fragment F-2 (acetaminophen) against Bio-JQ1 and BRD2 BD2 WT. C) Results of previous 
titrations. D) Chemical structure of fragment F-2 (acetaminophen). 
 
 
Table S3.3. AlphaLISA bumped compound screen results. 




Table S3.4. Previously-obtained ITC data 
pKd values for bumped compounds against select WT and L/V BET bromodomains. “-“denotes no visible 
binding. Data by Dr Michael Zengerle. 
 
 
Table S3.5. ITC bumped-compound screen results. 
A) Kd and pKd values from ITC titrations of bumped compounds into WT and L/V BET bromodomain 
constructs. 
B) Replicated ITC titrations of 9-ME and 9-ET into WT and L/V BET bromodomain constructs. * denotes 
mean WT and L/V Kd values, and resulting selectivity. 
Compound
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Figure S3.2 Only the 2R,3S enantiomer binds BET bromodomains. 
A) Part of the chemical structure of the 2R,3S enantiomer of 9-ME, with relevant atoms and bonds 
numbered and highlighted. B) X-ray co-crystal structure of BRD2 BD2 L/V in complex with 9-ME, with 






Figure S3.3. Ligand omit maps from bumped compound co-crystal structures. 
Electron density maps observed in X-ray crystal structures of BRD2 BD2 L/V in complex with bumped 
ligands (bromodomain omitted for clarity). The unbiased Fo-Fc omit map (grey mesh) is shown 




Figure S3.4. Separation of 9-ME enantiomers. 










Figure S3.5. 9-ME-1 ITC titrations. 







Chapter 4 Supplementary Figures 
 
 
Figure S4.1. Preliminary FRAP data. 
Recovery times of GFP-labelled BRD4 (L) constructs following 0.5 s laser bleach event, at 0.01% DMSO, 
treated with 1 µM I-BET762 or ET. Each bar is mean ± SE of ~50 U2OS cells tested over two separate 
experiments. Statistical significance (compared to each construct’s DMSO treatment) determined with 
two-tailed t tests: ns P>0.05; * P≤0.05; ** P ≤0.01; *** P≤0.001; **** P<0.0001. Experiment performed 
by Lars van Beurden. 
 
 
Scheme S4.1. SAHA 








Table S4.1. Detailed FRAP results. 
Average t½ values of GFP-BET constructs transiently overexpressed in U2OS cells, following 0.5s laser 
bleach, at 0.03% DMSO and/or 9-ME-1. 9-ME-1 dose is 200 nM or 40 nM (denoted by ‘9-ME-1 *’). 
Values are mean of ~40 cells, over 2 separate experiments. GFP-BRD2 LV/LV aggregated when treated 





Figure S4.2.  9-ME-1 assessment in A549 colony-formation assay. 
6-well plates seeded with 2000 A549 cells, treated with 1 µM compound and/or 0.01% DMSO and 




Figure S4.3. Dose-response A549 colony-formation assay. 
6-well plates seeded with 20000 A549 cells, treated with compound and/or 0.1% DMSO and incubated 









Figure S4.4. PROTAC assessment with colony-formation assay. 
From [189]. A) 96-well plate seeded with A549 cells, treated with compound and/or 1% DMSO and 
incubated for 1 week before being fixed with 100% MeOH and stained with 0.1% crystal-violet. B) 
Crystal-violet dye extracted with 1% SDS, and absorbance measured at 595 nm. C) Viability of BET-
sensitive MV4-11 and 22RV cells, determined via Promega CellTiter-Glo, following 72 h incubation with 




Figure S4.5. CETSA assay for assessing cellular target engagement of BET inhibitors. 
A) U20S Flp-In cells, stably expressing GFP-BRD4 (L) WT in response to tetracycline treatment, were 
treated with a gradient of tetracycline doses, and the expression of the GFP-BRD4 (L) was observed 
through αBRD4 and αGFP western-blotting. Cells treated with 0.3 µg/ml tetracycline failed to express 
any protein, likely due to experimental error with the treatment. B) Thermal-gradient CETSA curve of 
GFP-BRD4 (L) WT, expressed from cells in A with 0.1 µg/ml tetracycline, treated with 0.01% DMSO and 1 
µM (+)-JQ1. C) Thermal-gradient CETSA curve of GFP-BRD4 (L) WT/WT and LV/LV, expressed from cells 
in A with 0.1 µg/ml tetracycline, treated with 0.01% DMSO and 1 µM 9-ME-1. 
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Table S5.1 Reported BET Copy Number in A549. 
CellMiner reported no cell-number for BRD2 in A549. 
 
 
Table S5.2 Primers for analysing BRD4 knock-ins. 
Red nucleotides in KI-specific primers are complementary to KI sequence but not WT. 
 
 
Source Measurement BRD4 BRD3 BRD2 BRDT
CellMiner Gene No. 1.7 2.0 N/A 1.6
Gene No. 2.0 3.0 2.0 2.0
Chromosome 19 9 6 1
Ch. No. 3.5 3.0 2.0 2.5
CanSAR

















Figure S5.1. Implementation of bump-&-hole system through Flp-in system 
A) Original plan for implementing L/V mutation into cell lines. Mutant BET proteins introduced through 
stable transfection of Tet-induced GFP-BET constructs, while endogenous WT gene knocked-down by 
RNAi (targeting non-coding region not found in GFP-BET construct).B) Integration of GFP-BET constructs 
using the Flp-in T-Rex system. U2OS cells stably transfected with pFRT/lacZeo and pCDNA6 T/R vectors, 
randomly integrating FRT site and Tet repressor into genome. Transfection with FRT-recombinase 
encoding pOG44 vector and GFP-BET encoding pcDNA5 FRT/TO vector leads to FRT-targeting 
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recombination event, integrating GFP-BET construct under CMV/Tet-operator control into genome. Tet 
repressor protein will inhibit GFP-BET expression, unless inhibited by Tetracycline. C) qPCR-measured 
expression of BRD4-regulated genes in Flp-in U2OS cells stably transfected with tetracycline-dependent 
GFP-BRD4 WT/WT, following treatment with negative siRNA, BRD4 siRNA and a combination of BRD4 
siRNA and 0.1 µg/ml tetracycline. D) qPCR-measured expression of BRD4-regulated genes in Flp-in U2OS 
cells stably transfected with tetracycline-dependent GFP-BRD4 WT/WT and LV/LV, following treatment 









BRD4 BRD3 BRD2 BRDT
gDNA NC_000019.10 NC_000009.12 NC_000006.12 NC_000001.11
mRNA NM_058243.2 NM_007371.3 NM_001113182.1 NM_001242806.2




Figure S5.3. PCR Assays for Knock-In Detection. 
Starting with extracted gDNA from cells that are either WT or contain L/V knock-in (orange), 
bromodomain region amplified via PCR reaction. L/V-agnostic PCR will amplify region from all cells, but 
restriction enzyme will only digest this DNA if it contains the knocked-in restriction site (red line). 
Alternatively, a primer specific for the knocked-in sequence (utilising L/V mutation and/or restriction 






Figure S5.3. Preliminary testing of knock-in detection assays. 
A) PCR was used to amplify BRD4 BD1 and BD2 regions from WT A549 gDNA, BRD4 BD1 and BD2 KI 
templates and gDNA extracted from A549 cells transfected with plasmids targeting BRD4 BDs for knock-
in. To test for presence of restriction site PCR products were then treated with restriction enzymes 
BamHI (for BD1) and ApaLI (for BD2). Final products ran on 1% agar gel, alongside Generuler 1kb PLUS 
size marker (Thermo). All work by Dr Kwok-Ho Chan. B) A549 cells were transfected with plasmids to 
generate BRD4 BD1 and BD2 L/V knock-ins. Genomic DNA was extracted from these and WT cells, and 
the BRD4 BD1 and BD2 regions amplified with either WT or specific primers. As a control WT gDNA was 
also incubated with knock-in DNA template before PCR. PCR products ran on 1% agar gel, alongside 




Figure S5.4. Effects of potential knock-out colony-formation. 
WT A549 cells, and potential BRD4 BD1 knock-outs, seeded over a range of cell densities and incubated 
for 7 days, fixed with 100% MeOH and stained with 0.1% crystal-violet. 
 
